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Summary 
 
Over the past decade, organocatalytic synthetic procedures have 
emerged as an essential part of triazole chemistry. In order to avoid 
various obstacles of metal catalyzed synthesis of triazoles in biological 
systems, various organocatalyzed syntheses were developed. 
This thesis is dedicated to the exploration of various triazolization 
strategies towards functionalized 1,2,3-triazole moieties and studies 
of their activities against cancer cell as well as viral cell lines. These 
triazolization strategies rely on inexpensive and readily available 
starting materials. 
In chapter 1 a brief summary of previously discovered organocatalyzed 
methodologies towards functionalized 1,2,3-triazoles as well as their 
biological study and the synthesis of biologically active molecules 
containing triazole as a core unit has been presented concisely. The 
goals and objectives of this thesis are also elaborated in this chapter. 
Chapter 2 describes a three-component reaction of readily available 
starting materials such as enolizable ketones, primary amines, and 
para-nitrophenyl azide leading to trisubstituted triazoles. This newly 
developed methodology has been used to functionalize various 
natural compounds and to synthesize various multifunctional building 
blocks. 
Chapter 3 is dedicated to the formation of NH-1,2,3-triazoles from 
readily available starting materials such as enolizable ketones, 
ammonium acetate, and para-nitro phenyl azide. The utility of the 
reaction has further demonstrated by direct conversion of compounds 
containing enolizable keto groups to the corresponding triazole 
heterocycles. 
Chapter 4 elucidates a highly efficient and regiospecific Zn(OAc)2-
mediated synthesis of propargyl functionalized triazole derivatives in 
a single step from ketones and propargyl amine. This methodology has 
given access to a special type of triazoles which are not possible to 
synthesize by other means. Furthermore, we have discussed the 
functionalization of propargyl triazoles with azides via click reaction to 
form an unique type of N-C linked bis-triazoles. 
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Chapter 5 represents an unprecedented Rh(II)-catalyzed selective 
decomposition of bis(1,2,3-triazoles) followed by [3 + 2]-
intramolecular annulation reaction which leads to the formation of 
3,4-fused indoles. Extension of this protocol to heterocycles leads to 
interesting polyfused 1,2,3-triazole derivatives. 
In chapter 6 a series of newly functionalized artemisinin derivatives 
has been prepared using an organocatalytic multicomponent reaction 
in order to study their activity in viral cell lines. 
Chapter 7 deals with the development of three synthetic strategies to 
access 1,4-disubstituted, 1,5-disubstituted, and fused 1,2,3-triazoles 
analogues of artemisinin with promising anticancer activity. 
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Samenvatting 
 
Het afgelopen decennium is de organokatalytische synthese  op de 
voorgrond getreden als een essentieel deel van de triazoolchemie. Om 
de obstakels te overkomen die metaal-gekatalyseerde syntheses van 
triazolen met zich meebrengen in biologische systemen, werden 
verscheidene organokatalytische methodes ontwikkeld. 
Dit thesisproject behandelt de ontwikkeling van verschillende 
strategieën voor de synthese van gefunctionaliseerde 1,2,3-triazolen 
en hun biologische activiteit tegen kanker- en virale cellijnen. De 
ontwikkelde triazoleringsmethodes zijn gebaseerd op het gebruik van 
goedkope, commerciële startmaterialen. 
In hoofdstuk 1 zal een beknopte samenvatting gegeven worden van de 
reeds ontdekte organokatalytische methodes ter vorming van 
gefunctionaliseerde 1,2,3-triazolen evenals de uitgevoerde 
biologische studies en syntheses van biologisch actieve molecules die 
een triazool bevatten als kern van de structuur. Daarnaast zullen de 
doelstellingen van deze thesis ook worden uitgewerkt in dit hoofdstuk. 
Hoofdstuk 2 beschrijft een drie-componentsreactie van beschikbare 
startmaterialen zoals enoliseerbare ketonen, primaire amines en 4-
nitrofenylazide die leiden tot trigesubstitueerde triazolen. Deze nieuw 
ontwikkelde methode werd gebruikt in de functionalisatie van 
verscheidene natuurproducten en voor de synthese van verschillende 
multifunctionele bouwstenen. 
Hoofdstuk 3 is toegewijd aan de synthese van NH-1,2,3-triazolen van 
commercieel beschikbare startmaterialen, zijnde enoliseerbare 
ketonen, ammoniumacetaat en 4-nitrofenylazide. Het nut van deze 
reactie werd verder geïllustreerd door de directe conversie van 
producten met een enoliseerbare ketongroep naar de 
overeenkomstige triazoolstructuren. 
Hoofdstuk 4 licht een zeer efficiënte en regiospecifieke Zn(OAc)2-
gemedieerde synthese toe van propargyl gefunctionaliseerde 
triazoolderivaten in één stap vanuit ketonen en propargylamine. Deze 
methode geeft toegang tot een speciaal type van triazolen die niet 
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synthetiseerbaar zijn via de gerapporteerde methodologieën. 
Bovendien wordt de functionalisatie van propargyltriazolen met azides 
via de clickchemie besproken, waardoor een uniek type van N-C 
verbonden bistriazolen kan gemaakt worden. 
Hoofdstuk 5 stelt een ongekende selectieve ontbinding voor van 
bistriazolen door een Rh(II)-gekatalyseerde [3+2]-intramoleculaire 
annuleringsreactie die leidt tot de vorming van 3,4-gefuseerde 
indolen. Het uitbreiden van dit protocol naar heterocyclische 
structuren leidt tot interessante polygefuseerde 1,2,3-
triazoolderivaten. 
In hoofdstuk 6 werd een serie van nieuwe, gefunctionaliseerde 
artemisininederivaten geproduceerd door gebruik te maken van een 
organokatalytische multicomponentsreactie, waarna hun biologische 
activiteit in virale cellijnen bestudeerd kon worden. 
In hoofdstuk 7 wordt  de ontwikkeling van drie synthetische 
procedures behandeld, waarbij 1,4-digesubstitueerde, 1,5-
digesubstitueerde en gefuseerde 1,2,3-triazoolanaloga van 
artemisinine, met veelbelovende antikankeractiviteit, toegankelijk 
gemaakt worden. 
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1. General introduction 
1.1 Overview of 1,2,3-triazoles 
Nitrogen-containing heterocycles are one of the important 
compounds found in organic chemistry as well as in the 
pharmaceutical industry. Among these, 1,2,3-triazoles have drawn 
considerable attention in the chemical community. The application of 
triazoles has emerged in each corner of pharmaceutical research 
including derivatives with anticancer, antibacterial, antiviral, and 
antifungal properties.1 In addition to the pharmaceutical applications, 
they have also been proposed for industrial applications such as 
lubricants, photo-stabilizers, and dyes.1 
Depending on the position of the substituent on the nitrogen atom, 
there are mainly two types of 1,2,3-triazoles which are 1H or 3H-1,2,3-
triazole, and 2H-1,2,3-triazole (Figure 1). 
 
 
 
Figure 1 different types of 1,2,3-triazole 
NH-triazoles exist in three thermodynamically interchangeable 
tautomeric forms 4-6. However, 14N and 15N NMR data unveil that 
tautomer 5 is present in 70-100% proportion (Figure 2).2 
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Figure 2 various tautomeric forms of NH-1,2,3-triazoles 
 
1.2 Various synthetic approaches towards the synthesis of 
functionalized 1,2,3-triazoles 
1,2,3-Triazoles are known as amide surrogates due to the high dipole 
moment and high H-bonding capabilities, and in fact have a higher 
metabolic stability than the amide bond.3 1,2,3-Triazoles were first 
synthesized by 1,3-dipolar cycloaddition reaction of azides and alkynes 
at high temperature without any selectivity, which is called the 
Huisgen cycloaddition reaction (Scheme 1).4 This reaction has not been 
applied widely in organic synthesis due to the high temperature, poor 
regioselectivity, and low chemical yield. 
Later, in 2001, Sharpless and Meldal independently introduced a 
regioselective synthesis of 1,4-disubstituted 1,2,3-triazoles via 
copper(I)-catalyzed azide-alkyne cycloaddition, which is widely known 
as the “click reaction” (Scheme 1).5 The Cu(I)-catalyzed azide-alkyne 
cycloaddition reaction has been broadly accepted in the chemical 
community due to the following reasons: a) copper accelerates the 
cycloaddition process about 108 times, b) the reaction can proceed in 
a broad range of temperatures, c) it is insensitive to water, d) the 
reaction has broad functional group tolerance, e) the compounds may 
often be purified by extraction or filtration without any column 
chromatography, and f) the reaction is insensitive to a pH range from 
4 to 12. 
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Scheme 1 synthesis of 1,2,3-triazoles via Huisgen and metal catalyzed 
cycloaddition reaction 
Soon after the discovery of the click reaction, another complementary 
discovery was achieved by the ruthenium catalyzed cycloaddition of 
alkynes and azides to exclusively form 1,5-disubstituted 1,2,3-triazoles 
(Scheme 1)6. However, high reaction temperature, low yield, and the 
use of expensive metal catalysts restricts this reaction to become 
widely applicable.  
The metal catalyzed synthesis of 1,2,3-triazoles is limited by the fact 
that toxicity of the metal catalyst hampers wider exploration in 
biological systems7. Hence an alternative strategy was required to 
avoid metal catalysts. As one possible approach, the strain promoted 
azide alkyne cycloaddition (SPAAC) reaction was developed by Bertozzi 
and co-workers (Scheme 2)8. This reaction involves the cycloaddition 
between azides and cyclooctynes, which results in the formation of 
1,2,3-triazoles without any toxic metal catalyst. This reaction gives 
access to the in vitro modification of various biomolecules. 
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Scheme 2 strain promoted azide alkyne cycloaddition (SPAAC) reaction 
In recent years, organocatalytic click reactions have received much 
attention in the chemical community due to the broad application of 
1,2,3-triazoles in various fields of chemistry. The organocatalytic 
reactions can be organized into five categories: a) enamine-mediated 
synthesis, b) iminium mediated synthesis, c) enolate-mediated 
synthesis, d) alkynes precursors, and e) activated alkenes as 
dipolarophiles. 
 
1.2.1 Enamine-mediated synthesis 
In 2008 the Ramachary group was the first to report an L-proline 
catalyzed synthesis of 1,2,3-triazoles from Hagemann’s ester (Scheme 
3).9 According to the authors, the reaction proceeds through an 
enamine intermediate 17, which is formed when Hagemann’s ester 
was treated with the proline catalyst. The resulting enamine 17 
undergoes a [3+2] cycloaddition with tosyl azide leading to the 
formation of the triazoline intermediate 18, which transforms into the 
fused tosyl triazole 19 via elimination of proline catalyst. NH-1,2,3-
triazole 20 was formed via an in situ hydrolysis by water present in the 
DMSO solvent. 
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Scheme 3 synthesis of NH-1,2,3-triazoles from Hagemann’s esters 
Interestingly, when L-proline was changed to benzylamine, the final 
product formed was an α-diazo ketone. The detailed mechanism of 
this reaction as proposed by the authors9 is shown in scheme 4 below. 
An alternative explanation is the Regitz diazo transfer to an enolate 
generated from the ester with the benzylamine base. 
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Scheme 4 synthesis of α-diazo ketone 
N-Aryl-benzotriazoles can be synthesized by a Buchwald-Hartwig-type 
of arylation of NH-benzotriazoles. The Ramachary group again 
reported an alternative synthesis based on their previous synthetic 
method to access N-aryl cyclohexadienotriazoles starting from the 
Hagemann’s esters and an azide in the presence of pyrrolidine as a 
catalyst (Scheme 5).10 The formed triazoles 28 are subsequently 
oxidized to the benzotriazoles 29 by using DDQ. 
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Scheme 5 Synthesis of N-aryl-benzotriazoles from Hagemann’s esters 
The above methodologies described by the Ramachary group have a 
serious drawback which is the narrow scope of the Hagemann’s esters 
with α,β-unsaturated keto group. 
In 2011, Wang et al. described an organocatalytic cycloaddition 
reaction of different azides and enamines derived from -carbonyl 
compounds and secondary amines affording the 1,4,5-trisubstituted 
1,2,3-triazoles (Scheme 6).11 This reaction has several advantages such 
as a) broad functional group tolerance b) regioselective product 
formation, c) high yield, d) diversity in the products. According to the 
authors, the reaction proceeds through a 1,3-dipolar cycloaddition 
reaction between the electron rich enamine 32 and an aryl azide 31, 
leading to the regioselective formation of triazoline intermediate 33. 
The triazole 34 product is formed via elimination of the amine catalyst 
from the triazoline intermediate 33. 
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Scheme 6 synthesis of 1,4,5-trisubstituted 1,2,3-triazoles from -carbonyl 
compounds 
All the previously discussed methods are restricted to activated 
carbonyl compounds. To overcome this obstacle, the groups of Wang 
and Pons-Bressy independently reported an organocatalytic reaction 
between unactivated ketones and aromatic azides to afford 1,2,3-
triazoles.12 According to Pons-Bressy, ketones and azides were heated 
at 80 C for 100h in the presence of 20 mol% catalyst to afford the 
desired triazolized product in excellent yield (Scheme 7). Interestingly, 
the reaction time can be decreased to 1h by microwave-heating 
without compromising the yield. This reaction also occurs via a similar 
enamine intermediate as discussed earlier (Scheme 6). The major 
disadvantage of this reaction is that aliphatic azides were not reactive 
enough under the reported conditions.  
 
 
Scheme 7 synthesis of 1,4,5-trisubstituted 1,2,3-triazoles from enolizable 
ketones 
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Organic solvents were employed for all the reaction methods 
described earlier, which could restrict their application in biological 
systems. In order to develop a biocompatible procedure, Wang 
discovered a proline based amphiphilic amine catalyzed synthesis of 
1,2,3-triazoles in water medium (Scheme 8).13 Due to the presence of 
the long lipophilic chain in the catalyst, the reaction occurs in the 
hydrophobic part of the catalyst. According to the authors, a tertiary 
amide was required rather than a secondary amide which indicates 
that the reaction takes place in catalytic micelles. 
 
 
Scheme 8 synthesis of 1,4,5-trisubstituted 1,2,3-triazoles from enolizable 
ketones 
Soon after that, a straightforward organocatalytic route towards the 
synthesis of 4-alkenyl-1,2,3-triazoles has been reported by the same 
group.14 The unsaturated aldehydes were heated at 50 °C with 
aromatic azides in presence of 10 mol% diethylamine and 10 mol % of 
DBU for 2h in presence of DMSO as a solvent. It has been found that 
both diethylamine and DBU were required for optimal yields. The 
reaction was found to be very general regardless of any electron 
withdrawing and electron donating groups on the unsaturated 
aldehydes or aryl azides. However, aliphatic azides gave a very low 
yield. The reaction proceeds through an enamine intermediate 38 
which undergoes DBU induced deprotonation to form dienamine 39. 
Then the cycloaddition takes place between dienamine 39 and aryl 
azide 31 to afford triazoline intermediate 40. Finally, the triazolized 
product 41 is formed via elimination of diethylamine from triazoline 
intermediate 40 (Scheme 9). 
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Scheme 9 synthesis of 4-alkenyl-1,2,3-triazoles from -unsaturated 
ketone 
Wang and co-workers developed the synthesis of 4-acyl triazoles 
starting form allyl ketones and aryl azides in the presence of a catalytic 
amount of diethylamine (Scheme 10)15. The reaction could be 
successfully implemented on allyl and aryl ketones bearing either 
electron donating or electron withdrawing groups. The electronic 
effect of substituents on the aryl ring of the azide did also not affect 
the outcome of the reaction. According to the authors, the reaction 
proceeds through an enamine intermediate 44, which reacts with aryl 
azide to furnish the intermediate 45. The intermediate 45 undergoes 
a 1,3-H shift to form the intermediate 46. After that, an intramolecular 
cyclocondensation leads to the triazolized product 47. The final 
product 48 is formed after hydrolysis and oxidation of 47.  
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Scheme 10 synthesis of acyl triazoles 
Soon after that, the group of Alves-Paixão has reported an 
organocatalytic synthesis of the arylselenyl-1,2,3-triazoles starting 
from active methylene compounds and arylselenides 50 in presence of 
catalytic amount of diethylamine (Scheme 11).16 Both β-keto ester and 
amides have been used successfully in this reaction.  
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Scheme 11 synthesis of the arylselenyl-1,2,3-triazoles from active 
methylene compounds 
Wan and co-workers in 2015 have reported an organocatalytic method 
towards the synthesis of 1,5-disubstituted 1,2,3-triazoles starting from 
enamines, primary amines and tosylhydrazine 54 in the presence of 
iodine (Scheme 12).17  
 
 
Scheme 12 synthesis of 1,5-disubstituted 1,2,3-acyl triazoles 
Soon after that, Alves and co-workers developed a pyrrolidine catalytic 
enamine-azide [3+2] cycloaddition reaction of aryl azides 31 and β-
keto sulfones 56 to afford the corresponding sulfonyl triazoles 57. The 
reaction was performed at room temperature in DMSO with 5 mol% 
of pyrrolidine (Scheme 13). This reaction is found to be applicable to a 
variety of aryl azides and β-keto aryl sulfones. 
 
 
Scheme 13 synthesis of 1,4,5-trisubstituted 1,2,3-sulfonyl triazoles 
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1.2.2 Iminium mediated synthesis 
Recently Wang et al. reported an organocatalytic method towards the 
synthesis of trisubstituted 1,2,3-triazoles (Scheme 14).18 The reaction 
was shown to be applicable to a wide range of azides such as aromatic, 
aliphatic and heteroaromatic species. The reaction was reported to 
proceed through an iminium intermediate 59. The triazoline 
intermediate 60 was formed after cycloaddition of the iminium 
intermediate 59 with the azides. The final product 62 is formed after 
hydrolysis and air oxidation of triazoline intermediate 61. 
 
Scheme 14 synthesis of ester substituted 1,2,3-triazoles 
 
1.2.3 Enolate mediated synthesis 
The enolate mediated organocatalytic synthesis of 1,2,3-triazoles was 
first demonstrated by Cui et al. in 2013 starting from propynones, 
primary amines, and tosyl azides using lithium tert-butoxide as a base 
(Scheme 15).19 According to the authors, the mechanism is initiated by 
the Michael addition of amines to propynones to form - 
unsaturated ketone 65. After that, the enolate intermediate 66 is 
formed in the presence of LiOtBu. Then, the cycloaddition of tosyl 
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azide with 66 leads to triazoline intermediate 67 which transformed to 
diazo species 68 by eliminating an amide molecule. The diazo species 
68 leads to final product 69 by spontaneous 1,5-dipolar cyclisation.19 
 
 
Scheme 15 synthesis of 1,5-disubstituted triazoles from -unsaturated 
ketone 
Soon after that, Ramachary et al. have reported an organocatalytic 
enolate mediated synthesis of 1,4-disubstituted 1,2,3-triazoles from 
enolizable aldehydes and aryl azides in the presence of 10 mol% DBU 
(Scheme 16). Both electron poor and electron rich aldehydes are found 
to give good yields in the standard reaction conditions. According to 
the authors, the enolate 71 is formed in the presence of DBU. This 
intermediate enolate 71 subsequently undergoes a [3+2] 
cycloaddition with the respective azide to form the triazoline 
intermediate 72. The final product 73 is formed after elimination of a 
water molecule (Scheme 16).20  
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Scheme 16 synthesis of 1,4-disubstituted 1,2,3-triazoles from enolizable 
aldehyde 
The first organocatalytic aerobic oxidative intermolecular azide 
zwitterionic cycloaddition was reported by Wang et al. (Scheme 17). 21 
A diverse set of activated alkenes such as α,β-unsaturated amides, 
esters, ketones, aldehydes, and nitriles were applied successfully 
under the reported reaction conditions. In addition, aliphatic and 
aromatic azides were also well tolerated under the reaction 
circumstances. According to the author, the reaction proceeded 
through a zwitterionic enolate intermediate 76, formed by the 
reaction between the α,β-unsaturated ester and DBU. Next, the 
addition of the zwitterionic enolate 76 onto the azide takes place 
which leads to the formation of intermediate 77. The intermediate 77 
generates the final product by three possible pathways. The first 
possible pathway is the generation of 4,5-dihydrotriazole 78 via an 
intramolecular SN2 reaction of 77. The second pathway involves the E2 
elimination of DBU, resulting in the formation of the intermediate 79. 
A 6π electrocyclization followed by an aerobic oxidation leads to the 
final product 75. In the final pathway, at first olefin intermediate 80 is 
formed by aerobic oxidation of 77. Then the intermediate 80 
19 
 
undergoes 6π cycloaddition leading to intermediate 81, which 
liberates DBU to furnish the final product 75 (Scheme 17).  
 
 
Scheme 17 synthesis of ester substituted 1,2,3-triazoles 
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1.2.4 Alkynes and alkyne precursors 
Although enolizable ketones and aldehydes are most commonly used 
as a starting precursor for organocatalytic synthesis, a limited number 
of reports are there where alkynes are used as a starting material for 
metal free triazole synthesis. For instance, Fokin et al. were the first to 
report a metal free organocatalytic synthesis of 1,5-disubstituted 
1,2,3-triazoles starting from alkynes and azides (Scheme 18).22 The 
reaction was carried out in the presence of 10 mol% of NMe4OH and 
tBuOK as catalyst. According to the authors, electron deficient aryl 
azides and sterically crowded azides afforded lower yields. Similarly, 
electron deficient alkynes also afforded lower yield. The mechanism is 
proposed to start with the formation of aryl acetylide 83. The 
triazenide intermediate 84 is formed after nucleophilic attack of aryl 
acetylide to azide, and undergoes a 5-endo-dig cyclization which 
results in the formation of the 1,5-disubstituted 1,2,3-triazolyl anion 
85. In the end, the final product 86 is obtained via protonation by 
tBuOH (Scheme 18). 
 
 
 
Scheme 18 Synthesis of 1,5-disubstituted 1,2,3-triazoles from alkynes 
Similarly, Lin et al.  reported 1,5-disubstituted triazoles starting from 
vinyl halides via in situ generation of alkynes in the presence of base 
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(Scheme 19).23 Here the mechanism proposed by Lin et al. is similar to 
the one previously reported by Fokin et al. 22 
 
 
Scheme 19 synthesis of 1,5-disubstituted 1,2,3-triazoles from vinyl halides 
 
1.2.5 Activated alkenes as dipolarophiles 
Paixão et al. reported an efficient method to access 1,4-disubstituted 
1,2,3-triazoles with high regioselectivity (Scheme 20).24 The reaction 
was carried out in the presence of a catalytic amount of DBU. The 
reaction proceeds through the Knoevenagel condensed product 95 
which is formed from an enolizable aldehyde 93 and malononitrile 94. 
Subsequently, deprotonation by DBU resulted in the formation of a 
vinylogous carbanion 96, which undergoes cycloaddition with the 
azide to form the intermediate 97. Finally, elimination of malononitrile 
leads to the final product 98. Despite of having  advantages such as  
low temperature and high yield, this reaction is not applicable for 
aliphatic azides. 
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Scheme 20 synthesis of 1,4-disubstituted 1,2,3-triazoles from enolizable 
ketones 
Despite the advancements in organocatalytic triazole synthesis, there 
have been no reports on the multicomponent reaction towards the 
synthesis of triazoles. For the first time, Dehaen et al. reported an 
organocatalytic reaction towards the synthesis of 1,4,5-trisubstituted 
1,2,3-triazoles starting from aldehydes, nitroalkanes and azides in one 
pot (Scheme 21).25 The reaction is carried out in the presence of p-
toluenesulfonic acid morpholine salt as a catalyst.  Thus, the 
Knoevenagel condensed product 102 was formed from aldehyde 99 
and nitroalkane 100. The condensed product 102 acts as a 
dipolarophile which undergoes regioselective Huisgen cycloaddition 
with azide 101 to form triazoline intermediate 103. The final product 
104 was formed by elimination of nitrous acid. The reaction tolerates 
aromatic, heteroaromatic, and aliphatic aldehydes. In addition, the 
reaction is applicable to aromatic as well as aliphatic azides.  
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Scheme 21 synthesis of 1,4,5-trisubstituted 1,2,3-triazoles 
 
1.3  Synthesis of bioactive triazole derivatives 
 
According to a World Health Organisation survey in 2016, HIV has 
killed more than 36 million people worldwide and approximately 39 
million people were infected by HIV.  Thus, considering the risk of HIV, 
a vast number of studies has been done. However, there are limited 
number of reports on  1,2,3-triazoles derivatives having promising 
anti-HIV activity. For instance, the most important one is the 1,2,3-
triazole derivative of tert-butyldimethylsilyl spiroamino-
oxathioledioxide or TSAO, was reported in 1995 and tested against 
different HIV cell lines. The derivative 105 was found to be most active 
derivative of this triazole derivative series with anti-HIV-1 activity (50% 
effective concentration: 0.056-0.52 pM). 26 
Cancer is also a major fatal disease which causes the second most 
number of death after cardiovascular diseases. Recently, it has been 
discovered that artemisinin derivatives also possess anticancer activity 
combined with low toxicity.  Among these, 11-aza-artemisinin and its 
derivatives were mostly studied and are known to possess various 
biological activities. However, the lack of an efficient functional handle 
for further diversification of aza-artemisinin limits its application in 
pharmaceutical chemistry. 
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Scheme 23 schematic diagram of compounds containing a triazole unit  
Over the years, triazoles have been studied for various biological 
activities, including antibacterial, antiviral, antifungal, antieleptic, anti-
alergic, antimicobacterial, anti-HIV (106), antimycobacterial (107), 
antimelanoma (108), antiplasmodial (109) and hemolysis (110) 
activities.27-35  
Tazobactum (111), which is a commercial drug, is know for antibiotic 
activity. Furthermore, there are two drugs containing a triazole moiety 
in clinical trial such as carboxyamidotriazole (112) and cefatrizine (113) 
for anticancer activity.35b 
 
 
Figure 3 Drugs containing triazole 
Because of the importance of triazole moieties, several synthetic 
strategies were discovered to access the triazole containing drug like 
molecules. In this section of the introduction we are going to present 
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only organocatalytic route towards the synthesis of drug or drug like 
molecules containing triazoles moieties. For instance, G protein-
coupled cannabinoid receptor (CB1) agonists, with the receptor 
located primarily in the central and peripheral nervous system, are 
known as potent pharmacological agents in drug development for 
various diseases such as pain, glaucoma, nausea, cancer and 
Parkinson’s disease. CB1 agonists 118 can be prepared in three steps 
via the copper-catalyzed azide-alkyne cycloaddition reaction in an 
overall yield 61% (Scheme 24).36 However, recently, the group of Wang 
has reported a metal free method to access this type of agonist in a 
single step starting form - unsaturated ester 114 and an azide 115. 
The same group has also reported a series of cannabinoid receptors 
which are synthesized in one step.37 
 
Scheme 24 synthesis of CB1 cannabinoid receptor antagonists 
Recently, an efficient organocatalytic synthesis of mGluR1 antagonist 
121 was reported by the Ramachary group starting from readily 
accessible starting materials such as enolizable ketone 119 and an 
azide 120 in a single step (Scheme 25).38 
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Scheme 25 synthesis of mGluR1 antagonist 
Ceramides are known to cause apoptosis in the mammalian system. A 
series of ceramide analogs have been prepared via click reaction, there 
by replacing the amide bond with a triazole linkage.39 An 
organocatalytic, single step approach towards triazole modified 
psychosine 124 has also been reported by Westermann in 2012 
(Scheme 26). 
 
Scheme 26 synthesis of ceramide derivative 
A two-step synthesis of the anticonvulsant drug rufinamide has been 
reported by Wang in 2015, where the first step consists of an 
organocatalytic triazole formation from an - unsaturated ester 125 
and an azide 126 in the presence of DBU as a catalyst. After an 
amidation reaction of 127, rufinamide 128 was obtained in 89% overall 
yield.40 
27 
 
 
 
Scheme 27 synthesis of rufinamide 
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Goals and objectives 
 
Considering the importance of triazoles in drug discovery, organic 
chemists are highly motivated to discover more efficient synthetic 
strategies to access complex drug like molecules bearing 1,2,3-triazole 
moiety. The research on triazole chemistry has been increased 
extensively after the discovery of regioselective 3+2 cycloaddition of 
alkynes and azides. Since then, a vast number of metal as well as 
organocatalytic methodology towards the synthesis of 1,2,3-triazoles 
has been reported. However, a general methodology is still lacking to 
access highly functionalized 1,2,3-triazoles. In the context of our 
ongoing projects concerning triazole chemistry, the main target of this 
research is to develop new methodologies towards the synthesis of 
trisubstituted 1,2,3-triazoles and their biological evaluation. 
At the initial stage of this PhD thesis, we will investigate a three-
component reaction of readily available starting materials such as 
enolizable ketones, primary amines, and para-nitrophenyl azide 
leading to trisubstituted triazoles. After successful investigation of this 
three-component reaction, we will study the scope and limitation of 
this reaction with variety of aromatic and aliphatic enolizable ketones. 
Next, we will investigate the reaction tolerance with various primary 
amines as well aromatic amine. In addition, we will investigate the 
formation of bis- and tris-1,2,3-triazoles by using this methodology. 
Furthermore, to fully exploit the versatility of this MCR, bioactive 
natural products containing functional groups such as primary amines 
and enolizable ketones will also be investigated to access novel and 
unique triazole-containing natural products.  
 
After successful investigation of multicomponent reaction towards 
trisubstituted 1,2,3-triazoles, we will focus on synthesizing NH-1,2,3-
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triazoles by replacing amine with various ammonium salt in the 
previous multicomponent reaction. After optimization of this reaction, 
we will investigate the feasibility of this reaction on various cyclic 
enolizable ketones to form 4,5-fused NH-triazoles. Furthermore, the 
regioselectivity of this reaction will be studied with unsymmetrical 
enolizable ketones.  This novel triazolization strategy will provide a 
convenient gateway to synthesize high value NH-1,2,3-triazole 
derivatives which are known to be active pharmaceutical agents, or 
potential supramolecular receptors in a single step from simple and 
readily available building blocks. 
 
 
 
Next part of this PhD study, we will elucidate a highly efficient and 
regiospecific lewis catalyst mediated synthesis of propargyl 
functionalized triazole derivatives in a single step from ketones and 
propargyl amine. After optimization of this reaction, we will explore 
the synthesis of 4,5-fused propargyl 1,2,3-triazoles starting from cyclic 
ketones. The regioselectivity of this reaction will also be investigated. 
This methodology will give access to a special type of propargyl 
substituted triazoles which are not possible to synthesize by other 
means. Furthermore, we will explore the functionalization of 
propargyl triazoles with azides via click reaction to form a unique type 
of N-C linked bis-triazoles. 
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Azavinylcarbenes derived from N-sulfonyl-1,2,3-triazoles have drawn 
considerable attention in the chemical community as a means towards 
the synthesis of various heterocycles. 1,2,3-Triazoles are known to be 
very stable heterocycles, however they can be decomposed to 
azavinylcarbenes by using appropriate substituents on the 1,2,3-
triazole ring and a transition metal catalyst. A vast number of studies 
has been done on the synthesis of various heterocyclic compounds by 
using azavinylcarbene as a key intermediate. However, there are no 
report so far on the selective decomposition of triazoles in presense 
bis-triazoles. By using appropriate substitutents on N-C linked bis 
triazoles and appropriate meta catalyst, we will investigate the 
selective decomposition of triazoles which could lead to formation of 
3,4-fused indoles.  We will also investigate the feasibility of one pot 
synthesis starting from propargyl triazoles. In this one pot reaction, we 
will react propargyl triazole with tosyl azide to form N-C linked bis 
triazoles by using copper catalyst. The N-C linked bis-triaozoles can be 
decomposed in same pot by using rhodium catalyst with out 
purification of starting materials. Furhtermore, we will also study the 
oxidation of dihydro 3,4-fused indoles to corresponding fused indoles 
by using oxidative agents. 
 
 
 
At the end of this PhD thesis, we will investigate the synthesis of 
various artemisinin derivatives of triazole. Artemisinin, which is a 
naturaly occouring 1,2,4-trioxane sesquiterpene, is well known to 
possess antimalarial activity. Recently, it has been discovered that 
artemisinin derivatives also possess anticancer as well as anti-viral 
activity with low toxicity. However, the wider application of 
artemisinin in drug discovery has been restricted due to the delicate 
structure of artemisinin. In this thesis, we will investigate the stability 
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of artemisinin in triazolization reactions. We will also explore and 
synthesize artemisinin derivatives of triazoles by using triazolization 
methodology. In addition, we will also investigate the activity of novel 
artemisinin derivatives in various cancer as well as virus strains.  
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Chapter 2 
A general metal-free route towards the synthesis of 1,2,3-
triazoles from readily available primary amines and ketones 
 
 
 
Reproduced in part with permission from [“A general metal-free route 
towards the synthesis 
of 1,2,3-triazoles from readily available primary amines and ketones” Joice 
Thomas, Sampad Jana, Jubi John, Sandra Liekens and Wim Dehaen Chem. 
Commun., 2016,52, 2885-2888] Copyright © [2016] Royal Society of 
chemistry. 
Joice Thomas carried out the experiments, analyzed the data and wrote 
manuscript, Sampad Jana carried out the experiments and analyzed the data. 
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2.1 Introduction 
In recent years, 1,2,3-triazole-containing molecules have received 
attention in diverse fields.1 Currently, the most publicized ways to 
access 1,4- and 1,5-disubstituted 1,2,3-triazoles are the Cu- and Ru-
catalyzed azide–alkyne cycloaddition reactions, respectively.2 
However, the limited access to terminal alkynes and the toxicity of the 
heavy metal catalysts hamper a wider exploration.3 Several metal-free 
methods have been developed for the regioselective synthesis of 1,4-
disubstituted 1,2,3-triazoles.4 Nevertheless, selective pathways 
towards 1,5-disubstituted triazoles are rather scarce.5 It is well 
documented that the cis-locked geometry present in 1,5-disubstituted 
triazoles could be an advantage to increase the biological activity and 
binding affinity towards several biological targets.6 Unfortunately, the 
lack of an efficient and very general synthetic route to achieve a 
diverse library of these isomers limits their applications in medicinal 
chemistry.6c More recently, significant attention has been given to the 
preparation of diversely functionalized 1,2,3-triazoles via 
organocatalysis rather than metal catalyzed routes.7,8 Unfortunately, 
the scope of these reactions is mostly limited to aromatic groups at 
the N1-position of the triazole heterocycles and extension to aliphatic 
substituents is cumbersome. Moreover, most transformations 
reported so far relied on organic azides that are mostly non-
commercial and potentially hazardous. Other major limitations are the 
low substrate scope of the other component with reactivity limited 
mostly to activated carbonyl compounds. A very general and metal-
free procedure to synthesize 1,5-disubstituted 1,2,3-triazoles is still 
lacking. Also, none of these methodologies have yet been applied to 
synthesize triazole derivatives of readily available natural products 
which could for instance facilitate structure activity relationship 
studies of bioactive/drug-like molecules. 
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Figure 4 Multicomponent reaction towards functionalized 1,2,3-triazoles. 
2.2 Result and discussion 
In 1965, Pocar et al. described the reaction of an isolated 
imine/enamine (derived from acetone and propylamine) with 4-
nitrophenyl azide (131a) which yielded 1-propyl-5-methyl-1,2,3-
triazole in moderate yield.9a Surprisingly, this report remained virtually 
unnoticed, and no further attempts were made towards the further 
development of this protocol. One of the central challenges that could 
be associated with this method is the reversibility of the 
imine/enamine formation, hampering its isolation. This led us to the 
design of a multicomponent reaction starting from an enolizable 
ketone, primary amine and 131a. We surmised that both the imine 
formation and the isomerization of enamine can be accelerated by a 
catalytic amount of an organic acid. The reaction would proceed via a 
sequence of (a) Schiff base formation, (b) tautomerisation of the 
enamine, (c) 3+2 cycloaddition reaction with 131a, and (d) 
aromatization with the loss of 4-nitroaniline (133a). Such a cascade 
process that combines multiple individual transformations in one 
operation is particularly attractive in triazole synthesis because 
isolation of the intermediate species, which may be difficult and time 
consuming especially when large collections of compounds are 
required, is avoided. Moreover, amines and ketones are inexpensive 
and abundantly present in biologically active natural products. Even 
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more alluring is that this could lead to previously inaccessible 1,5-
disubstitued 1,2,3-triazoles via a metal-free pathway. 
 
 
Entry Ratio 
129a:13
0a:131b 
Catalyst (mol%) Ar-N3 Solvent isolated 
Yield[b] 
1 1:1:1 TsOH (20) 131a toluene 80 
2 1:1:1 TsOH (20) 131b toluene 25 
3 1:1:1 TsOH (20) 131c toluene trace 
4 1:1:1 TsOH (20) 131d toluene trace 
5 1:1:1 CF3COOH (20) 131a toluene 81 
6 1:1:1 NEt3: TsOH (20) 131a toluene 83 
7 1:1:1 CH3COOH (20) 131a toluene 84 
8 1:1.2:1 CH3COOH (20) 131a toluene 86 
9 1:1.4:1 CH3COOH (20) 131a toluene 90 
10c 1:1.4:1 CH3COOH (30) 131a toluene 93 
11 1:1.4:1 CH3COOH (30) 131a toluene 90 
12 1:1.4:1 L-proline (30) 131a toluene 62 
13 1:1.4:1 Morpholine:TsOH 
(30) 
131a toluene 62 
14[d] 1:1.4:1 CH3COOH (30) 131e toluene 65 
15[e] 1:1.4:1 CH3COOH (30 131f toluene 43 
16 1:1.4:1 none 131a toluene 71 
17[f] 1:1.4:1 none 131a toluene 85 
18 1:1.4:1 CH3COOH (30) 131a CH3CN 85 
19 1:1.4:1 CH3COOH (30) 131a THF 70 
41 
 
 
Table 1 Optimization of reaction conditions for the organocatalyzed three-
component reaction of acetophenone (129a), 4-methoxybenzylamine 
(130b) and organic azides (131a-d) 
[a] Reaction conditions: except where otherwise noted, 129a is always in 
0.42 mmol amount and the molar ratio of 130a and 131a is calculated on the 
basis of this, reaction temperature is 100°C, solvent (0.4 mL, 1 molar), 4 Å 
molecular sieves (30 mg) and reaction time is 12 h. [b] isolated yield after 
column chromatography. [c] reaction performed without molecular sieves 
and reaction time is 20 h. [d] reaction time is 40 h. [e] reaction time is 56 h. 
[f] reaction time is 24 h. TsOH is p-toluenesulfonic acid. 
 
In order to validate this synthetic design, we have chosen 
acetophenone (129a), 4-methoxybenzylamine (130a) and 131a as 
model substrates. We started to investigate the optimization of 
reaction conditions by selecting acetophenone (129a) and 4-
methoxybenzylamine (130a) as the model reagents with various diazo 
transfer reagents, catalysts and solvents to form 1,5-disubstituted 
triazole 132a as summarized in Table 1. We presumed that the 
addition of 4 Å molecular sieves favors imine formation by effectively 
removing water from the carbonyl + amine imine + H2O equilibrium. 
Initial experiments were conducted via a MCR of these reagents in the 
presence of 4-nitrophenyl azide (131a) as the diazo-transfer reagent 
and 30 mol% of p-toluenesulfonic acid (TsOH) as the catalyst over 4 Å 
molecular sieves in toluene (0.4 mL, 1 molar) at 100 °C in a sealed tube 
20 1:1.4:1 CH3COOH (30) 131a ClCH2CH2C
l 
56 
21 1:1.4:1 CH3COOH (30) 131a DMSO 78 
22 1:1.4:1 CH3COOH (30) 131a DMF 67 
23 1:1.4:1 CH3COOH (30) 131a EtOH 74 
24 1:1.4:1 CH3COOH (30) 131a 1,4-
dioxane 
80 
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for 12 h (Table 1, entry 1). To our delight, this combination promoted 
the reaction with an excellent of yield of 80%. The use of 131b as diazo 
transfer agent resulted in a significant reduction in the yield of the title 
compound 132a to 25% (Table 1, entry 2). Subsequently, performing 
the reaction with other azido compounds that are known as diazo 
transfer reagents, such as 131c and 131d resulted in much lower 
efficiencies (Table 1, entries 3 & 4). One possible reason for this is the 
formation of corresponding sulfonamide as a side product which 
derived from the nucleophilic substitution reaction of 130a with 131c 
and 131d. Interestingly, among the different Bronsted acid catalysts 
tried, CH3COOH gave the best result (Table 1, entries 5-7). We then 
examined various stoichiometries of the building blocks and different 
loading of CH3COOH catalyst on the reaction performance (Table 1, 
entries 8-10). The best result was obtained while using 1.4 equivalents 
of 130a and 30 mol% of CH3COOH catalyst, and the desired three-
component-coupling product 132a was obtained in 93% yield (Table 1, 
entries 10).  
When performing the reactions with secondary amine catalysts such 
as L-proline and morpholine:p-toluenesulfonic acid salt, however, 
lower yields were obtained (Table 1, entry 12 and 13). Next, we 
performed the reaction with other azido compounds analogous to 
131a such as 4 azidobenzonitrile 131e (Table 1, entry 14) and ethyl 4-
azidobenzoate (Table 1, entry 15) 131f. These reactions of less 
electron poor aryl azides were less efficient than the ones performed 
with 131a and also required longer reaction times for the complete 
consumption of the starting materials. Remarkably, this reaction also 
worked fine under acid free conditions without significantly affecting 
the yield of 132a (85%) although the required reaction time was longer 
(24 h) (Table 1, entry 17). This observation can be viewed as an 
additional advantage as this transformation could also be extended to 
acid sensitive substrates. The yields of the reactions are also 
influenced by the solvent (Table 1, entries 18-24): MeCN (85%), THF 
(70%), ClCH2CH2Cl (56%), DMSO (78%), DMF (67%), EtOH (74%), 1,4-
dioxane (57%). Therefore, a three-component reaction of 129a, 130a 
and 131a in a respective molar ratio of 1:1.4:1.1 using 30 mol% of 
acetic acid (8 mg, 0.13 mmol) as catalyst over 4 Å molecular sieves in 
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1 molar solution of toluene at 100 °C in a sealed tube under argon 
atmosphere over a period of 12 h proved to be the conditions of choice  
After some optimization, we found that for the three-component 
reaction of 129a, 130a and 131a in a respective molar ratio of 1:1.4:1 
using 30 mol% of acetic acid as a catalyst over 4 Å molecular sieves in 
1 M solution of toluene at 100 C was the reaction condition of choice. 
The desired product 132a was obtained after 12 h with an isolated 
yield of 93%. As expected, quantitative conversion of 131a to 133a was 
also observed.  
We conducted several control experiments to understand the 
mechanism of the reaction. For instance, two separate experiments 
were conducted and monitored by 1H NMR spectroscopy, with the 
isolated adduct 134 and 131a in the presence and absence of the 
catalyst in CHCl3 at 65 °C in an NMR tube (Scheme 28). Interestingly, 
the reaction in the presence of acid was complete after 3 hours and 
exclusively yielded the expected products 132a and 133a in 1:1 ratio, 
presumably as a result of protonation of the N-3 of the aminotriazoline 
intermediate 134 followed by a ring opening/ring closure sequence 
(Scheme 28a). On the other hand, in the case of acid-free conditions, 
the reaction proceeded very slowly and complete conversion at 65°C 
was observed only after 40 hours. Furthermore, we monitored a one-
pot reaction starting from 129a, 130a and 131a under acidic conditions 
(30% AcOH) at 65°C and the reaction was finished only after 48 hours. 
This observation convincingly demonstrated that the Schiff base 
formation is slow at this temperature. Taken together, the results of 
these experiments are in agreement with the hypothesis that 
imine/enamine formation is the rate determining step. We presume 
that the imine/enamine species is in equilibrium with the starting 
material 129a and 130a, and the formation of the key intermediate 
134 from a 3+2 cycloaddition reaction between transiently generated 
enamine and 131a displaces this equilibrium (Scheme 29). 
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Scheme 28 Proposed mechanistic experiments and catalytic cycles 
[a] Scheme showing the synthesis of the triazoline intermediate 134 and its 
subsequent conversion to 132a and 133a. [b] The 1H NMR spectra showing 
the clean formation of the triazole 132a and 133a upon heating the triazoline 
intermediate 134 in presence of 8 mol% of CH3COOH in CDCl3 at 65 °C. 
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Scheme 29 Postulated mechanism. 
With this newly developed metal-free three-component protocol we 
first set out to survey the scope and limitations of this methodology 
with a variety of aromatic and aliphatic enolizable ketones. 
Acetophenones with both electron-donating and electronwithdrawing 
groups smoothly underwent these transformations (132a–132i) (Table 
2a). To our delight, various interesting heterocyclic moieties were 
amenable to the reaction providing access to triazole derivatives which 
are otherwise difficult to synthesize (132l–132n). The utility of this 
reaction was further demonstrated by the transformation of acetyl 
ferrocene and 6-acetyl uracil. It is worth mentioning that these 
reactions failed in an acidic environment but fortunately under acid-
free conditions the expected products 132o and 132p were obtained 
in good yields. Next, we investigated the scope of this reaction towards 
the synthesis of 1,4,5-trisubstituted 1,2,3-triazoles (Table 2b). For 
instance, aryl or alkyl ketone precursors such as aryl propanones or 5-
nonanone lead to the expected trisubstituted triazoles in excellent 
yield (132q–132t). However, the extension of this reaction to activated 
methylene ketones such as ethyl benzoylacetate leads to the well-
known Dimroth product formed by the 3+2 cycloaddition of 132a with 
either the enolate or enamine intermediate.10 An initial investigation 
with an unsymmetrical ketone, for example 2-butanone, gave mostly 
the expected product 132u together with a noticeable amount of 18% 
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of the other regioisomer 132v (Table 2c). In light of these results, we 
reasoned that during the course of the reaction an equilibrium mixture 
of the two enamines will form and the composition of this is in favor 
of the most substituted enamine. This eventually gives 132u as the 
major isomer. On the other hand, the ease of attack onto the less 
hindered enamine leads to a minor amount of the kinetic product 
132v. Interestingly, methyl isopropyl ketone led to 10% of the stable 
triazoline intermediate 134w derived from the more substituted 
enamine together with 56% of the kinetic product 132w. We then 
examined the scope of this reaction with respect to different cyclic 
ketones (Table 2d). The synthesis of N1-alkyl derivatives of carbo- as 
well as O- and N-heterocyclic fused triazole derivatives is scarcely 
reported (132x–132ab). Additionally, different aromatic bicyclic 
ketones were also compatible with the reaction (132ac–132ag). The 
high regioselectivity obtained with 2-tetralone shows that 
cycloaddition occurs with the most stable enamine, thus yielding 
132ag as the sole product.  
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Table 2 substrate scope with respect to ketones 
[a] Reaction conditions: 129 (1 equiv.), 130a (1.3 equiv.), 131a (1.0 equiv.), 
CH3COOH (30 mol%), toluene (0.4 mL), 100 oC, 12 h, Isolated yield. [b] 40 h.  
[c] 3 equivalent of 129g. [d] CH3COOH (0 mol%), 24 h. [e] CH3COOH (0 mol%), 
DMF (0.6mL), 12 h. [f] Reaction Conditions: 129p (1 equiv.), 130a (2.8 equiv.), 
131a (2.0 equiv.), toluene (1.5 mL), 100 oC, 72 h. [e] 24 h. 
In a next series of experiments the substitution pattern in the amine 
part was varied (132ah–132aq). More importantly, substrates bearing 
unprotected secondary amines such as 132ak and 132al could be 
effectively transformed using the current conditions. Remarkable 
functional group tolerance was observed in the case of allyl amine and 
2,2-dimethoxyethylamine where the alkene and acetal functionalities 
remained intact under acid-free conditions (132am & 132an). This 
elegant strategy was also applied to synthesize chiral-unit-containing 
triazoles by using different chiral amines (132ao & 132ap). As 
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expected, the extension of our protocol to aromatic amines gave a 
dissatisfactory yield of only 25% (132aq) caused by the lower reactivity 
of the intermediate enamines. However, the N-aryl triazoles are easily 
obtained by other methods (Table 3).5,7,8 
 
 
Table 3 Substrate scope with respect to amines  
[a] Reaction conditions: 129 (1 equiv.), 130a (1.3 equiv.), 131a (1.0 equiv.), 
CH3COOH (30 mol%), toluene (0.4 mL), 100 oC, 12 h, Isolated yield. [b] 
CH3COOH (0 mol%), 24 h. [c] 48 h, CH3COOH (30 mol%).  [d] 48 h. [e] 129 (1 
equiv.), 130 (2 equiv.), 131a (1.0 equiv.), CH3COOH (0 mol%), toluene (0.6 
mL), 100 oC, 48 h. 
To demonstrate the utility of this reaction in material science, novel 
oligotriazole derivatives 139 & 140 derived from bi/tri-acetyl 
compounds could be generated in good yields after multiple MCRs 
without being affected by any steric hindrance (Scheme 30). Polymeric 
or dendritic triazole materials are of current interest.1 The need for 
building blocks having multiple azide groups may be a limiting factor 
since they are potentially shock-sensitive compounds.11 We surmised 
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that the present approach is a safer alternative. Accordingly, readily 
available tris(2-aminoethyl)amine was subjected to reaction 
conditions to afford the C3-symmetric derivative 141 in good yield. To 
further demonstrate the utility of this approach to dendrimer 
chemistry, the modification of the 2nd generation dendron 142 with 
cyclohexanone was considered. Clean conversion to a monodisperse 
fused polytriazole amine 143 in reasonable yield was observed.  
 
 
Scheme 30 Substrate scope of the various multifunctional building blocks 
To fully exploit the versatility of this MCR, bioactive natural products 
containing functional groups such as primary amines and enolizable 
ketones were investigated to access novel and unique triazole-
containing natural products which are expected to enable SAR studies 
facilitating subsequent drug developments for human diseases (Table 
4). The application of the triazolation conditions to histamine 144a and 
tryptamine 144b led to the expected 1,5-disubstituted 1,2,3-triazoles 
in reasonable yields (145a and 145b). Leelamine 144c (an optically 
active diterpene amine which binds weakly to human cannabinoid 
receptors) was also structurally modified to new triazole entities 
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145c.12 Additionally sphingoid base, phytosphingosine 144d, was 
easily modified to non-hydrolysable ceramide analogue 145d (the 
amide bond of ceramide was replaced by bioisosteric 1,2,3-triazole 
functionality) in a single step without performing a laborious 
protection/ deprotection strategy.13 Several D-ring tethered 
heterocyclic compounds of estrone 144e were identified as useful 
templates for the design of inhibitors of steroidogenic enzymes such 
as 17β-hydroxysteroid dehydrogenases.14 This inspired us to 
synthesize estrone 16,17-fused 1,2,3-triazole derivatives 145e1 and 
145e2 via this strategy using slightly modified reaction circumstances 
to surpass the steric effects of the reactants. As expected, the less 
sterically hindered butylamine gave a better conversion as compared 
to 130a. The male hormone analogue, dihydrotestosterone 144f gave 
excellent regio-selective triazolization on the A-ring leading to 145f as 
a single product in 88% isolated yield. 
 
 
Table 4 Scope with respect to natural products 
[a] Reaction Conditions: 129 (1 equiv.), 130a (1.3 equiv.), 131a (1.0 equiv.), 
CH3COOH (30 mol%), toluene (0.4 mL), 100 oC, 12 h, Isolated yield. [b] 
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CH3COOH (0 mol%), 24 h. [c] 48 h. [d] CH3COOH (0 mol%), 48h. [e] 144e (1 
equiv.), 130 (2.8 equiv.), 131a (2.0 equiv.), CH3COOH (30 mol%), toluene (1 
mL), 100 oC, 72 h. [f] DMF (0.6mL), 24 h. 
2.3 Conclusion 
In conclusion, we have developed a universal approach to access 1,2,3-
triazole derivatives in a single step from simple and readily available 
enolizable carbonyl compounds and amines which could be 
considered not as the end point, but as the initial point for the rapid 
generation of complex triazole derivatives that are inaccessible by 
other means. In contrast to other well-established 1,5- or fused 
triazole syntheses where different organic azides that are non-
commercial and potentially dangerous are used to bring diversity, this 
strategy makes use of a readily available organic azide and readily 
available aliphatic amines as the sources of nitrogen of the triazole 
heterocycles. We successfully illustrated the utility of this reaction in 
natural products by systematically transforming them into diverse 
triazole derivatives. The fifty-five examples of this unprecedented 
triazole synthesis show the scope and limitations of this strategy. 
 
2.4 Experimental and Characterization data 
2.4.1 Experimental Procedures 
2.4.1.1 Preparation of 4-nitrophenyl azide (131a):  
4-Nitroaniline (28.0 g, 0.20 mol) was suspended in 2.4 N HCl solution 
(300 mL) and methanol (60 mL) was added to aid the solubility. After 
cooling the solution to 0 °C, NaNO2 (6 M, 40 mL) in water was added 
dropwise. The mixture was stirred at 0 °C for 30 minutes, after which 
a solution of NaN3 (4.1 M, 60 mL) in water was added dropwise over 
20 minutes and the whole reaction mixture was stirred for an hour at 
room temperature. The reaction mixture was extracted with diethyl 
ether and the organic fraction was washed with a saturated NaHCO3 
solution and brine, dried over MgSO4 and concentrated under reduced 
pressure affording the pure compound 131a as a yellow solid in 95% 
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yield (31.48 g). Spectroscopic data for 131a was consistent with 
previously reported data for this compound.  
 
2.4.1.2 General procedure for the preparation of substituted 1,2,3-
triazoles 
To an oven-dried screw-capped reaction tube equipped with a 
magnetic stirring bar was added the ketone, amine, 4-nitrophenyl 
azide (131a), acetic acid (0-30 mol%) and 4 Å molecular sieves (50 mg). 
The mixture was dissolved in the proper solvent and stirred at 100 °C 
for 12-72 hours. The crude reaction mixture was then directly purified 
by column chromatography (silica gel) at first with DCM as eluent to 
remove all 4-nitroaniline formed during the reaction followed by using 
a mixture of heptane and ethyl acetate as eluent to afford the 
corresponding 1,2,3-triazoles as off-white solids or semi-solids. 
 
2.4.2 Characterization data 
1-(4-Methoxybenzyl)-5-phenyl-1H-1,2,3-triazole (132a): 
Acetophenone (50 mg, 0.42 mmol), 4- methoxybenzylamine (80 mg, 
0.58 mmol), 4-nitrophenyl azide (68 mg, 0.42 mmol), acetic acid (8 mg, 
0.13 mmol), 4 Å molecular sieves (50 mg) and toluene (0.4 mL). 
Reaction time is 12 h. The product was purified by flash column 
chromatography (DCM followed by heptane/EtOAc = 6:4) affording 
132a (103 mg, 93% yield) as an off white semi-solid. 1H NMR (300 MHz, 
CDCl3) δ 7.72 (s, 1H), 7.45 - 7.42 (m, 3H), 7.28 - 7.25 (m, 2H), 7.01 (d, 
2H, J = 8.6 Hz), 6.79 (d, 2H, J = 8.7 Hz), 5.48 (s, 2H), 3.78 (s, 3H); 13C 
NMR (75 MHz, CDCl3) δ 159.5, 138.1, 133.4, 129.6, 129.1, 129.0, 128.8, 
127.6, 127.1, 114.3, 55.4, 51.5; MS (EI): m/z: 265 (M+ ); HRMS (ESI+ ): 
m/z calcd for C16H16N3O [M+H]+ : 266.1287, found 266.1284.  
 
1-(4-Methoxybenzyl)-5-(4-methoxyphenyl)-1H-1,2,3-triazole (132b): 
4-Methoxy acetophenone (63 mg, 0.42 mmol), 4-
methoxybenzylamine (80 mg, 0.58 mmol), 4-nitrophenyl azide (68 mg, 
0.42 mmol), acetic acid (8 mg, 0.13 mmol), 4 Å molecular sieves (50 
mg) and toluene (0.4 mL). Reaction time is 12 h. The product was 
purified by flash column chromatography (DCM followed by 
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heptane/EtOAc = 6:4) affording 132b (110 mg, 89% yield) as an off 
white semi-solid. 1H NMR (300 MHz, CDCl3) δ 7.66 (s, 1H), 7.18 (d, 2H, 
J = 8.5 Hz), 7.03 (d, 2H, J = 8.5 Hz), 6.94 (d, 2H, J = 8.6 Hz), 6.81 (d, 2H, 
J = 8.6 Hz), 5.45 (s, 2H), 3.85 (s, 3H), 3.78 (s, 3H); 13C NMR (75 MHz, 
CDCl3) δ 160.6, 159.5, 137.8, 133.1, 130.4, 128.7, 127.8, 119.2, 114.5, 
114.2, 55.5, 55.3, 51.3; MS (EI): m/z: 295 (M+); HRMS (ESI+ ): m/z calcd 
for C17H18N3O2 [M+H]+ : 296.1393, found 296.1399.  
 
4-(1- (4-Methoxybenzyl)-1H-1,2,3-triazol-5-yl)aniline (132c): 4-
Aminoacetophenone (56 mg, 0.42 mmol), 4-methoxybenzylamine (80 
mg, 0.58 mmol), 4-nitrophenyl azide (68 mg, 0.42 mmol), acetic acid (8 
mg, 0.13 mmol), 4 Å molecular sieves (50 mg) and toluene (0.4 mL). 
Reaction time is 40 h. The product was purified by flash column 
chromatography (DCM followed by heptane/EtOAc = 4:6) affording 
132c (79 mg, 68% yield) as an off white semi-solid. 1H NMR (300 MHz, 
CDCl3) δ 7.64 (s, 1H), 7.06 - 7.03 (m, 4H), 6.81 (d, 2H, J = 8.2 Hz), 6.69 
(d, 2H, J = 7.9 Hz), 5.44 (s, 2H), 3.89 (sbr, 1H), 3.78 (s, 3H); 13C NMR 
(125 MHz, CDCl3) δ 159.5, 147.7, 138.4, 132.9, 130.2, 128.8, 128.0, 
116.5, 115.1, 114.2, 55.4, 51.2; MS (EI): m/z: 280 (M+ ); HRMS (ESI+ ): 
m/z calcd for C16H17N4O [M+H]+ : 281.1397, found 281.1396. 
 
1-(4-Methoxybenzyl)-5-(o-tolyl)-1H-1,2,3-triazole (132d): 2-
Methylacetophenone (56 mg, 0.42 mmol), 4-methoxybenzylamine (80 
mg, 0.58 mmol), 4-nitrophenyl azide (68 mg, 0.42 mmol), acetic acid (8 
mg, 0.13 mmol), 4 Å molecular sieves (50 mg) and toluene (0.4 mL). 
Reaction time is 12 h. The product was purified by flash column 
chromatography (DCM followed by heptane/EtOAc = 6:4) affording 
132d (103 mg, 88% yield) as an off white semi-solid. 1H NMR (300 MHz, 
CDCl3) δ 7.62 (s, 1H), 7.40 - 7.35 (m, 1H), 7.23 (d, 2H, J = 7.0 Hz), 7.04 
(d, 1H, J = 7.5 Hz), 6.87 (d, 2H, J = 8.95 Hz), 6.71 (d, 2H, J = 8.74 Hz), 
5.27 (s, 2H), 3.75 (s, 3H), 1.86 (s, 3H); 13C NMR (75 MHz, CDCl3) δ 
159.60, 138.1, 136.5, 133.9, 130.5, 130.0, 129.5, 127.1, 126.7, 126.0, 
114.0, 55.4, 51.6, 19.7; MS (EI): m/z: 279 (M+); HRMS (ESI+): m/z calcd 
for C17H18N3O [M+H]+ : 280.1444, found 280.1445. 
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5-(4-Chlorophenyl)-1-(4-methoxybenzyl)-1H-1,2,3-triazole (132e): 4-
Chloroacetophenone (64 mg, 0.42 mmol), 4-methoxybenzylamine (80 
mg, 0.58 mmol), 4-nitrophenyl azide (68 mg, 0.42 mmol), acetic acid (8 
mg, 0.13 mmol), 4 Å molecular sieves (50 mg) and toluene (0.4 mL). 
Reaction time is 12 h. The product was purified by flash column 
chromatography (DCM followed by heptane/EtOAc = 6:4) affording 
132e (98 mg, 79% yield) as an off-white solid. m.p. 56 - 57 ˚C. 1H NMR 
(300 MHz, CDCl3) δ 7.71 (s, 1H), 7.40 (d, 2H, J = 8.1 Hz), 7.18 (d, 2H, J = 
8.5 Hz), 6.91 (d, 2H, J = 8.6 Hz), 6.80 (d, 2H, J = 8.7 Hz), 5.46 (s, 2H), 
3.78 (s, 3H); 13C NMR (100 MHz, CDCl3) δ 159.7, 136.9, 135.9, 133.6, 
130.4, 129.3, 128.7, 127.4, 125.6, 114.4, 55.4, 51.6; MS (EI): m/z: 299 
(M+); HRMS (ESI+): m/z calcd for C16H16ClN4O [M+H]+ : 300.0899, found 
300.0896. 
 
1-(4-Methoxybenzyl)-5-(4-nitrophenyl)-1H-1,2,3-triazole (132f): 4-
Nitroacetophenone (69 mg, 0.42 mmol), 4-methoxybenzylamine (80 
mg, 0.58 mmol), 4-nitrophenyl azide (68 mg, 0.42 mmol), acetic acid (8 
mg, 0.13 mmol), 4 Å molecular sieves (50 mg) and toluene (0.4 mL). 
Reaction time is 40 h. The product was purified by flash column 
chromatography (DCM followed by heptane/EtOAc = 6:4) affording 
132f (80 mg, 62% yield) as an off-white solid m.p. 86 - 87 ˚C. 1H NMR 
(300 MHz, CDCl3) δ 8.28 (d, 2H, J = 8.7 Hz), 7.82 (s, 1H), 7.46 (d, 2H, J = 
8.5 Hz), 7.00 (d, 2H, J = 8.5 Hz), 6.81 (d, 2H, J = 8.6 Hz), 5.54 (s, 2H), 
3.78 (s, 3H); 13C NMR (100 MHz, CDCl3) δ 159.8, 148.4, 135.9, 134.2, 
133.6, 129.9, 128.6, 126.9, 124.2, 114.5, 55.4, 52.1; MS (EI): m/z: 310 
(M+); HRMS (ESI+): m/z calcd for C16H15N4O3 [M+H]+ : 311.1138, found 
311.1130. 
 
1-(4-Methoxybenzyl)-5-methyl-1H-1,2,3-triazole (132g): Acetone (72 
mg, 1.26 mmol), 4- methoxybenzylamine (80 mg, 0.58 mmol), 4-
nitrophenyl azide (68 mg, 0.42 mmol), acetic acid (8 mg, 0.13 mmol), 
4 Å molecular sieves (50 mg) and toluene (0.4 mL). Reaction time is 12 
h. The product was purified by flash column chromatography (DCM 
followed by heptane/EtOAc = 6:4) affording 132g (52 mg, 62% yield) 
as an off-white solid. m.p. 69 - 70 ˚C. 1H NMR (300 MHz, CDCl3) δ 7.45 
(s, 1H), 7.12 (d, 2H, J = 8.5 Hz), 6.87 (d, 2H, J = 8.5 Hz), 5.43 (s, 2H), 3.79 
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(s, 3H), 2.18 (s, 3H); 13C NMR (75 MHz, CDCl3) δ 159.6, 133.6, 132.7, 
128.8, 126.9, 114.4, 55.4, 51.3, 8.6; MS (EI): m/z: 203 (M+); HRMS 
(ESI+): m/z calcd for C11H14N3O [M+H]+ : 204.1131, found 204.1131. 
 
5-tert-Butyl-1-(4-methoxybenzyl)-1H-1,2,3-triazole (132h): 
Pinacolone (41 mg, 0.42 mmol), 4- methoxybenzylamine (80 mg, 0.58 
mmol), 4-nitrophenyl azide (68 mg, 0.42 mmol), acetic acid (8 mg, 0.13 
mmol), 4 Å molecular sieves (50 mg) and toluene (0.4 mL). The product 
was purified by flash column chromatography (DCM followed by 
heptane/EtOAc = 6:4) affording 132h (85 mg, 83% yield) as an off white 
semi-solid. 1H NMR (300 MHz, CDCl3) δ 7.46 (s, 2H), 7.02 (d, 2H, J = 8.8 
Hz), 6.84 (d, 2H, J = 8.8Hz), 5.63 (s, 2H), 3.78 (s, 3H), 1.29 (s, 9H); 13C 
NMR (75 MHz, CDCl3) δ 159.4, 145.5, 131.7, 128.2, 128.0, 114.3, 55.4, 
52.6, 30.4, 30.0; MS (EI): m/z: 245 (M+); HRMS (ESI+): m/z calcd for 
C14H20N3O [M+H]+ : 246.1601, found 246.1601. 
 
5-(3,5-Bis(trifluoromethyl)phenyl)-1-(4-methoxybenzyl)-1H-1,2,3-
triazole (132i): 3´,5´-Bis (trifluoromethyl)acetophenone (107 mg, 0.42 
mmol), 4-methoxybenzylamine (80 mg, 0.58 mmol), 4- 12 nitrophenyl 
azide (68 mg, 0.42 mmol), (8 mg, 0.13 mmol), 4 Å molecular sieves (50 
mg) and toluene (0.4 mL). Reaction time is 12 h. The product was 
purified by flash column chromatography (DCM followed by 
heptane/EtOAc = 6:4) affording 132i (117 mg, 70% yield) as an off 
white solid. m.p. 70 - 71 ˚C. 1H NMR (300 MHz, CDCl3) δ 7.93 (s, 1H), 
7.82 (s, 1H), 7.63 (s, 2H), 7.02 (d, 2H, J = 8.5 Hz), 6.81 (d, 2H, J = 8.7 Hz), 
5.50 (s, 2H), 3.78 (s, 3H); 13C NMR (75 MHz, CDCl3) δ 160.0, 135.2, 
134.3, 132.8, 132.3, 129.5, 129.3, 128.8, 126.6, 124.7, 123.3, 121.0, 
114.6, 55.4, 52.4; MS (EI): m/z: 401 (M+); HRMS (ESI+): m/z calcd for 
C18H14F6N3O [M+H]+ : 402.1035, found 402.1039. 
 
1-(4-Methoxybenzyl)-5-(1-naphthyl)-1H-1,2,3-triazole (132j): 1-
Acetonaphthone (71 mg, 0.42 mmol), 4-methoxybenzylamine (80 mg, 
0.58 mmol), 4-nitrophenyl azide (68 mg, 0.42 mmol), acetic acid (8 mg, 
0.13 mmol), 4 Å molecular sieves (50 mg) and toluene (0.4 mL). 
Reaction time is 12 h. The product was purified by flash column 
chromatography (DCM followed by heptane/EtOAc = 6:4) affording 
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132j (105 mg, 80% yield) as an off white semi-solid. 1H NMR (300 MHz, 
CDCl3) δ 8.00 - 7.90 (m, 2H), 7.78 (s, 1H), 7.53 - 7.21 (m, 5H), 6.75 (d, 
2H, J = 8.6 Hz), 6.61 (d, 2H, J = 8.6 Hz), 5.26 (s, 2H), 3.70 (s, 3H); 13C 
NMR (75 MHz, CDCl3) δ 159.5, 135.8, 134.9, 133.6, 132.1, 130.4, 129.4, 
129.0, 128.6, 127.3, 127.1, 126.6, 125.1, 124.9, 124.6, 113.9, 55.3, 
51.9; MS (EI): m/z: 315 (M+); HRMS (ESI+): m/z calcd for C20H18N3O 
[M+H]+ : 316.1444, found 316.1444. 
 
1-(4-Methoxybenzyl)-5-(3-phenanthryl)-1H-1,2,3-triazole (132k): 3-
Acetyl phenanthrene (92 mg, 0.42 mmol), 4-methoxybenzylamine (80 
mg, 0.58 mmol), 4-nitrophenyl azide (68 mg, 0.42 mmol), acetic acid (8 
mg, 0.13 mmol), 4 Å molecular sieves (50 mg) and toluene (0.4 mL). 
Reaction time is 12 h. The product was purified by flash column 
chromatography (DCM followed by heptane/EtOAc = 6:4) affording 
132k (138 mg, 91% yield) as an off white solid. m.p. 164 - 165 ˚C. 1H 
NMR (300 MHz, CDCl3) δ 8.45 (s, 1H), 8.24 (d, 1H, J = 7.2 Hz), 7.94 (t, 
2H, J = 8.3 Hz), 7.88 (s, 1H), 7.84 - 7.75 (m, 2H), 7.66 - 7.58 (m, 2H), 
7.50 (d, 1H, J = 8.3 Hz), 7.11 (d, 2H, J = 8.7 Hz), 6.85 (d, 2H, J = 8.7 Hz), 
5.57 (s, 2H), 3.79 (s, 3H); 13C NMR (75 MHz, CDCl3) δ 159.7, 138.5, 
133.7, 132.4, 132.4, 130.3, 129.9, 129.4, 128.9, 128.8, 128.6, 128.1, 
127.4, 127.1, 126.9, 126.4, 124.9, 123.8, 122.8, 114.5, 55.5, 51.8; MS 
(EI): m/z: 365 (M+); HRMS (ESI+): m/z calcd for C24H20N3O [M+H]+ : 
366.1601, found 366.1606. 
 
2-(1-(4-Methoxybenzyl)-1H-1,2,3-triazol-5-yl)pyridine (132l): 2- 
Acetyl pyridine (51 mg, 0.42 mmol), 4- methoxybenzylamine (80 mg, 
0.58 mmol), 4-nitrophenyl azide (68 mg, 0.42 mmol), 4 Å molecular 
sieves (50 mg) and toluene (0.4 mL). Reaction time is 24 h. The product 
was purified by flash column chromatography (DCM followed by 
heptane/EtOAc = 3:7) affording 132l (91 mg, 82% yield) as an off white 
solid. m.p. 73 - 74 ˚C. 1H NMR (300 MHz, CDCl3) δ 8.72 (d, 1H, J = 4.7 
Hz), 7.98 (s, 1H), 7.77 - 7.71 (m, 1H), 7.55 - 7.52 (m, 1H), 7.31 - 7.27 (m, 
1H), 7.20 (d, 2H, J = 8.3), 6.77 - 6.74 (m, 2H), 6.09 (s, 2H), 3.73 (s, 3H); 
13C NMR (75 MHz, CDCl3) δ 159.3, 149.6, 147.2, 137.1, 135.5, 133.8, 
129.5, 128.3, 123.4, 122.9, 113.9, 55.3, 52.6; MS (EI): m/z: 266 (M+); 
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HRMS (ESI+): m/z calcd for C15H15N4O [M+H]+ : 267.1240, found 
267.1241. 
 
3-(1- (4-Methoxybenzyl)-1H-1,2,3-triazol-5-yl)-1H-indole (132m): 3-
Acetyl indole (67mg, 0.42 mmol), 4- methoxybenzylamine (80 mg, 0.58 
mmol), 4-nitrophenyl azide (68 mg, 0.42 mmol), acetic acid (8 mg, 0.13 
mmol), 4 Å molecular sieves (50 mg) and toluene (0.4 mL). Reaction 
time is 12 h. The product was purified by flash column chromatography 
(DCM followed by heptane/EtOAc = 5:5) affording 132m (106 mg, 83% 
yield) as an off white solid. m.p. 192 - 193 ˚C. 1H NMR (300 MHz, CDCl3) 
δ 8.57 (sbr, 1H), 7.89 (s, 1H), 7.54 (d, 1H, J = 7.9 Hz), 7.46 (d, 1H, J = 8.1 
Hz), 7.33 - 7.19 (m, 3H), 7.05 - 7.00 (m, 3H), 6.80 (d, 2H, J = 8.7 Hz), 
5.53 (s, 2H), 3.77 (s, 3H); 13C NMR (75 MHz, CDCl3) δ 159.4, 136.0, 
133.7, 132.6, 131.8, 128.5, 128.2, 126.3, 124.2, 123.4, 121.3, 119.3, 
114.3, 111.7, 55.4, 51.4; MS (EI): m/z: 304 (M+); HRMS (ESI+): m/z calcd 
for C18H17N4O [M+H]+ : 305.1397, found 305.1395. 
 
5-(Furan-2-yl)-1- (4-methoxybenzyl)-1H-1,2,3-triazole (132n): 2- 
Acetyl furan (46 mg, 0.42 mmol), 4- methoxybenzylamine (80 mg, 0.58 
mmol), 4-nitrophenyl azide (68 mg, 0.42 mmol), 4 Å molecular sieves 
(50 mg) and toluene (0.4 mL). Reaction time is 24 h. The product was 
purified by flash column chromatography (DCM followed by 
heptane/EtOAc = 6:4) affording 132n (96 mg, 68% yield) as an off white 
semi-solid. 1H NMR (300 MHz, CDCl3) δ 7.86 (s, 1H), 7.55 - 7.54 (m, 1H), 
7.13 (d, 2H, J = 88 Hz), 6.82 (d, 2H, J = 8.8 Hz), 6.53 - 6.48 (m, 2H), 5.71 
(s, 2H), 3.77 (s, 3H); 13C NMR (75 MHz, CDCl3) δ 159.6, 143.7, 141.5, 
132.5, 128.9, 128.8, 127.3, 114.3, 111.9, 110.5, 55.4, 52.5; MS (EI): 
m/z: 255 (M+); HRMS (ESI+): m/z calcd for C14H14N3O2 [M+H]+ : 
256.1080, found 256.1082. 
 
5-(1-(4-Methoxybenzyl)-1H-1,2,3-triazol-5-yl)pyrimidine-2,4 
(1H,3H)-dione (132o): 5-Acetyluracil (64 mg, 0.42 mmol), 4-
methoxybenzylamine (77 mg, 0.58 mmol), 4-nitrophenyl azide (68 mg, 
0.42 mmol), 4 Å molecular sieves (50 mg) and DMF (0.6 mL). Reaction 
time is 12 h. The product was purified by flash column chromatography 
(DCM followed by DCM/MeOH = 95:5) affording 132o (83 mg, 67% 
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yield) as an off-white solid. m.p. 253 - 254 ˚C. 1H NMR (300 MHz, d6-
DMSO) δ 8.28 (s, 1H), 7.67 (s, 1H), 7.56 (s, 1H), 7.05 (d, 2H, J = 8.6 Hz), 
6.85 (d, 2H, J = 8.6 Hz), 5.45 (s, 2H), 3.71 (s, 3H); 13C NMR (75 MHz d6-
DMSO) δ 162.3, 158.8, 151.7, 144.8, 137.5, 134.1, 129.7, 129.1, 127.8, 
113.9, 55.1, 51.3; MS (EI): m/z: 299 (M+); HRMS (ESI+): m/z calcd for 
C14H14N5O3 [M+H]+ : 300.1091, found 300.1096. 
 
1-(4-Methoxybenzyl)-5-ferrocenyl-1H-1,2,3-triazole (132p): 1-
Acetylferrocene (100 mg, 0.42 mmol), 4- methoxybenzylamine (168 
mg, 1.2 mmol), 4-nitrophenyl azide (143 mg, 0.88 mmol), 4 Å 
molecular sieves (50 mg) and toluene (1 mL). Reaction time is 72 h. The 
product was purified by flash column chromatography (DCM followed 
by heptane/EtOAc = 2:8) affording 132p (130 mg, 79% yield) as a red 
semisolid. 1H NMR (300 MHz, CDCl3) δ 7.74 (s, 1H), 7.03 (d, 2H, J = 8.5 
Hz), 6.86 (d, 2H, J = 8.5 Hz), 5.58 (s, 2H), 4.37 (s, 2H), 4.32 (s, 2H), 4.08 
(s, 4H), 3.79 (s, 3H); 13C NMR (75 MHz, CDCl3) δ 159.5, 136.3, 133.1, 
128.1, 127.9, 114.4, 70.9, 69.8, 69.6, 68.6, 55.4, 51.3; MS (EI): m/z: 373 
(M+); HRMS (ESI+): m/z calcd for C20H20FeN3O [M+H]+ : 374.0950, 
found 374.0958. 
 
1-(4-Methoxybenzyl)-5-methyl-1H-1,2,3-triazole-4-carbaldehyde 
(132q): Propiophenone (56 mg,0.42 mmol), 4-methoxybenzylamine 
(80 mg, 0.58 mmol), 4-nitrophenyl azide (68 mg, 0.42 mmol), acetic 
acid (8 mg, 0.13 mmol), 4 Å molecular sieves (50 mg) and toluene (0.4 
mL). Reaction time is 12 h. The product was purified by flash column 
chromatography (DCM followed by heptane/EtOAc = 6:4) affording 
132q (96 mg, 83% yield) as an off-white solid. m.p. 74 - 75 ˚C. 1H NMR 
(300 MHz, CDCl3) δ 7.43 -7.42 (m, 3H), 7.17 - 7.13 (m, 2H), 6.99 - 6.94 
(m, 2H), 6.79 - 6.74 (m, 2H), 5.35 (s, 2H), 3.76 (s, 3H), 2.28 (s, 3H); 13C 
NMR (75 MHz, CDCl3) δ 159.4, 141.7, 134.5, 129.7, 129.3, 129.0, 128.9, 
127.8, 127.7, 114.1, 55.4, 51.7, 10.7; MS (EI): m/z: 279 (M+); HRMS 
(ESI+): m/z calcd for C17H18N3O [M+H]+ : 280.1444, found 280.1443. 
 
5-Butyl-1-(4-methoxybenzyl)-4-propyl-1H-1,2,3-triazole (132r): 5-
nonanone (59 mg, 0.42 mmol), 4- methoxybenzylamine (80 mg, 0.58 
mmol), 4-nitrophenyl azide (68 mg, 0.42 mmol), acetic acid (8 mg, 0.13 
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mmol), 4 Å molecular sieves (50 mg) and toluene (0.4 mL). Reaction 
time is 12 h. The product was purified by flash column chromatography 
(DCM followed by heptane/EtOAc = 6:4) affording 132r (94 mg, 78% 
yield) as an off white semi-solid. 1H NMR (300 MHz, CDCl3) δ 7.10 (d, 
2H, J = 8.67 Hz), 6.85 (d, 2H, J = 8.67 Hz), 5.40 (s, 2H), 3.79 (s, 3H), 2.56 
(t, 2H, J = 7.53 Hz), 2.46 (t, 2H, J = 7.71 Hz), 1.74 - 1.64 (m, 4H), 1.28 - 
1.25 (m, 2H), 0.95 (t, 3H, J = 7.35 Hz), 0.87 - 0.82 (m, 3H); 13C NMR (75 
MHz, CDCl3) δ 159.6, 145.5, 133.2, 128.6, 127.7, 114.4, 55.4, 51.62, 
31.0, 27.3, 23.0, 22.6, 22.4, 14.1, 13.8; MS (EI): m/z: 287 (M+); HRMS 
(ESI+): m/z calcd for C17H26N3O [M+H]+ :288.2070, found 288.2072. 
 
1-(4-Methoxybenzyl)-4-methyl-5-(thiophen-2-yl)-1H-1,2,3-triazole 
(132s): 2- Propanoyl thiophene (59 mg, 0.42 mmol), 4-
methoxybenzylamine (80 mg, 0.58 mmol), 4-nitrophenyl azide (68 mg, 
0.42 mmol), acetic acid (8 mg, 0.13 mmol), 4 Å molecular sieves (50 
mg) and toluene (0.4 mL). Reaction time is 12 h. The product was 
purified by flash column chromatography (DCM followed by 
heptane/EtOAc =6:4) affording 132s (106 mg, 89% yield) as an off 
white semi-solid. 1H NMR (300 MHz, CDCl3) δ 7.49 - 7.47 (m, 1H), 7.13 
- 7.10 (m, 1H), 7.01 (d, 2H, J = 8.5 Hz), 6.95 - 6.94 (m, 1H), 6.80 (d, 2H, 
J = 8.7 Hz), 5.46 (s, 2H), 3.76 (s, 3H), 2.35 (s, 3H); 13C NMR (75 MHz, 
CDCl3) δ 159.5, 142.9, 129.3, 128.7, 128.3, 128.1, 127.7, 127.6, 127.0, 
114.1, 55.3, 51.8, 11.0; MS (EI): m/z: 285 (M+); HRMS (ESI+): m/z calcd 
for C15H16N3OS [M+H]+ : 286.1008, found 286.1009. 
 
2-(5- (9-Ethyl-9H-carbazol-3-yl)-1-(4-methoxybenzyl)-1H-1,2,3-
triazol-4-yl)acetic acid (132t): 4-(9-Ethyl-9H-carbazol-3-yl)-4-
oxobutanoic acid (50 mg, 0.17 mmol), 4-methoxybenzylamine (49 mg, 
0.35 mmol), 4-nitrophenyl azide (30 mg, 0.0.17 mmol), acetic acid (3 
mg, 0.05 mmol), 4 Å molecular sieves (10 mg) and toluene (0.4 mL). 
Reaction time is 40 h. The product was purified by flash column 
chromatography (DCM followed by heptane/EtOAc = 1:9) affording 
132t (53 mg, 74 %) as an off white solid. m.p. 90 - 91 ˚C. 1H NMR (300 
MHz, CDCl3) δ 7.95 (d, 1H, J = 7.9Hz), 7.80 (s, 1H), 7.52 - 7.44 (m, 3H), 
7.28 - 7.23 (m, 2H), 7.03 (d, 2H, J = 8.6 Hz), 6.79 (d, 2H, J = 8.5 Hz), 5.40 
(s, 2H), 4.41 (q, 2H, J = 7.2 Hz), 3.78 – 3.76 (m, 5H), 17 1.47 (t, 3H, J = 
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7.1Hz); 13C NMR (100 MHz, CDCl3) δ 173.1, 159.6, 140.5, 138.6, 137.2, 
129.3, 127.7, 127.1, 126.7, 123.3, 122.5, 122.3, 120.8, 119.7, 115.9, 
114.3, 109.1, 109.0, 55.4, 52.0, 37.2, 29.8, 14.0; MS (EI): m/z: 440 (M+); 
HRMS (ESI+): m/z calcd for C26H25N4O3 [M+H]+ : 441.1921, found 
441.1924. 
 
 
 
2-Butanone (30mg, 0.44 mmol), 4-methoxybenzylamine (80 mg, 0.58 
mmol), 4-nitrophenyl azide (68 mg, 0.42 mmol), acetic acid (8 mg, 0.13 
mmol), 4 Å molecular sieves (50 mg) and toluene (0.4 mL). Reaction 
time is 12 h. The products was purified by flash column 
chromatography (DCM followed by heptane/EtOAc =7:3) affording 
132u (53 mg, 59% yield) and 132v (16 mg, 18% yield) as colorless semi-
solids. 
 
1-(4-Methoxybenzyl)-4,5-dimethyl-1H-1,2,3-triazole (132u): 1H NMR 
(300 MHz, CDCl3) δ 7.11 (d, 2H, J = 8.5 Hz), 6.85 (d, 2H, J = 8.5 Hz), 5.38 
(s, 2H), 3.78 (s, 3H), 2.24 (s, 3H), 2.08 (s, 3H); 13C NMR (75 MHz, CDCl3) 
δ 159.5, 141.2, 129.1, 128.7, 127.1, 114.3, 55.4, 51.6, 10.3, 8.0; MS (EI): 
m/z: 217 (M+); HRMS (ESI+): m/z calcd for C12H16N3O [M+H]+: 218.1289, 
found 218.1284. 
 
5-Ethyl-1- (4-methoxybenzyl)-1H-1,2,3-triazole (132v): 1H NMR (300 
MHz, CDCl3) δ 7.47 (s, 1H), 7.11 (d, 2H, J = 8.6 Hz), 6.85 (d, 2H, J = 8.6 
Hz), 5.43 (s, 2H), 3.79 (s, 3H), 2.51 (q, 2H, J = 7.7 Hz), 1.19 (t, 3H, J = 7.5 
Hz); 13C NMR (75 MHz, CDCl3) δ 159.6, 138.7, 132.2, 128.7, 127.0, 
114.4, 55.4, 51.3, 16.9, 12.2; MS (EI): m/z: 217 (M+); HRMS (ESI+): m/z 
calcd for C12H16N3O [M+H]+: 218.1289, found 218.1282. 
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Methyl isopropyl ketone (36 mg, 0.42 mmol), 4-methoxybenzylamine 
(80 mg, 0.58 mmol), 4- nitrophenyl azide (68 mg, 0.42 mmol), acetic 
acid (8 mg, 0.13 mmol), 4 Å molecular sieves (50 mg) and toluene (0.4 
mL). Reaction time is 12 h. The products was purified by flash column 
chromatography (DCM followed by heptane/EtOAc = 5:5) affording 
132w (54 mg, 56% yield) and 141w (15 mg, 10% yield) as a colorless 
semi-solid.  
 
5-Isopropyl-1-(4-methoxybenzyl)-1H-1,2,3-triazole (132w): 1H NMR 
(300 MHz, CDCl3) δ 7.49 (s, 1H), 7.11 (d, 2H, J = 8.8 Hz), 6.85 (d, 2H, J = 
8.6Hz), 5.46 (s, 2H), 3.79 (s, 3H), 2.92 - 2.83 (m, 1H), 1.15 (d, 6H, J = 7.0 
Hz); 13C NMR (75 MHz, CDCl3) δ 159.6, 143.5, 130.9, 128.6, 127.3, 
114.4, 55.4, 51.3, 23.9, 22.5; MS (EI): m/z: 231 (M+); HRMS (ESI+): m/z 
calcd for C13H17N3O [M+H]+ : 232.1444, found 232.1449.  
 
N-(4-Methoxybenzyl)-4,4,5-trimethyl-1-(4-nitrophenyl)-4,5-dihydro-
1H-1,2,3-triazol-5-amine (134w): 1H NMR (300 MHz, CDCl3) δ 8.05 (d, 
2H, J = 8.8 Hz), 7.07 (d, 2H, J = 8.2 Hz), 6.84 (d, 2H, J = 8.5 Hz), 6.75 (d, 
2H, J = 8.7 Hz), 4.86 (s, 1H), 3.94 (s, 2H), 3.80 (s, 3H), 1.24 (s, 9H); 13C 
NMR (75 MHz, CDCl3) δ 160.8, 18 159.3, 141.0, 130.2, 129.0, 124.9, 
120.7, 114.3, 71.8, 70.5, 55.4, 48.0, 39.2, 29.7, 29.3; MS (EI): m/z: 369 
(M+); HRMS (ESI+): m/z calcd for C19H24N5O3 [M+H]+ : 370.1873, found 
370.1877. 
 
1-(4-Methoxybenzyl)-4,5,6,7-tetrahydro-1H-benzo[d][1,2,3]triazole 
(132x): Cyclohexanone (41 mg, 0.84 mmol), 4-methoxybenzylamine 
(80 mg, 0.58 mmol), 4-nitrophenyl azide (68 mg, 0.42 mmol), acetic 
acid (8 mg, 0.13 mmol), 4 Å molecular sieves (50 mg) and toluene (0.4 
mL). Reaction time is 12 h. The product was purified by flash column 
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chromatography (DCM followed by heptane/EtOAc = 6:4) affording 
132x (91 mg, 91% yield) as a solid. m.p. 91 - 92 ˚C. 1H NMR (300 MHz, 
CDCl3) δ 7.15 (d, 2H, J = 8.8 Hz), 6.85 (d, 2H, J = 8.8Hz), 5.36 (s, 2H), 
3.79 (s, 3H), 2.74 - 2.72 (m, 2H), 2.43 - 2.39 (m, 2H), 1.78 - 1.73 (m, 4H); 
13C NMR (75 MHz, CDCl3) δ 159.6, 144.0, 131.9, 129.1, 127.1, 114.3, 
55.4, 51.5, 22.6, 22.5, 22.0, 20.2; MS (EI): m/z: 243 (M+ ); HRMS (ESI+ 
): m/z calcd for C14H18N3O [M+H]+ : 244.1444, found 244.1440. 
 
1-(4-Methoxybenzyl)-4,5,6,7,8,9-hexahydro-1H-
cycloocta[d][1,2,3]triazole (132y): Cyclooctanone (52 mg, 0.42mmol), 
4-methoxybenzylamine (77 mg, 0.58 mmol), 4-nitrophenyl azide (68 
mg, 0.42 mmol), acetic acid (8 mg, 0.13 mmol), 4 Å molecular sieves 
(50 mg) and toluene (0.4 mL). Reaction time is 12 h. The product was 
purified by flash column chromatography (DCM followed by 
heptane/EtOAc = 6:4) affording 132y (101 mg, 89% yield) as a semi-
solid. 1H NMR (300 MHz, CDCl3) δ 7.10 (d, 2H, J = 8.8 Hz), 6.84 (d, 2H, J 
= 8.7 Hz), 5.39 (s, 2H), 3.78 (s, 3H), 2.89 (t, 2H, J = 6.4 Hz), 2.62 (t, 2H, J 
= 6.2 Hz), 1.74 - 1.72 (m, 2H), 1.54 - 1.50 (m, 2H), 1.39 - 1.37 (m, 4H); 
13C NMR (75 MHz, CDCl3) δ 159.5, 145.3, 133.2, 128.6, 127.6, 114.3, 
55.4, 51.4, 28.4, 26.0, 26.0, 24.9, 24.7, 21.9; MS (EI): m/z: 271 (M+); 
HRMS (ESI+): m/z calcd for C16H22N3O [M+H]+ : 272.1757, found 
272.1755. 
 
1-(4-Methoxybenzyl)-4,5,6,7,8,9, 10, 11, 12, 13-decahydro-1H-
cyclododeca[d][1,2,3]triazole (132z): Cyclododecanone (76 mg, 0.42 
mmol), 4-methoxybenzylamine (80 mg, 0.58 mmol), 4-nitrophenyl 19 
azide (68 mg, 0.42 mmol), acetic acid (8 mg, 0.13 mmol), 4 Å molecular 
sieves (50 mg) and toluene (0.4 mL). Reaction time is 12 h. The product 
was purified by flash column chromatography (DCM followed by 
heptane/EtOAc = 6:4) affording 132z (132 mg, 95% yield as a semisolid. 
1H NMR (300 MHz, CDCl3) δ 7.09 (d, 2H, J = 8.7 Hz), 6.84 (d, 2H, J = 8.7 
Hz), 5.42 (s, 2H), 3.78 (s, 3H), 2.59 (t, 2H, J = 7.0 Hz), 2.49 (t, 2H, J = 7.2 
Hz), 1.88 - 1.80 (m, 2H), 1.61 - 1.52 (m, 2H), 1.42 - 1.19 (m, 12H); 13C 
NMR (75 MHz, CDCl3) δ 159.5, 146.1, 133.3, 128.5, 127.5, 114.3, 55.4, 
51.7, 27.7, 26.2, 25.3, 24.8, 24.8, 24.5, 22.6, 22.6, 22.0, 19.6; MS (EI): 
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m/z: 327 (M+); HRMS (ESI+): m/z calcd for C20H30N3O [M+H]+ : 
328.2383, found 328.2382. 
 
1-(4-Methoxybenzyl)-1,4,6,7-tetrahydropyrano[3,4-d][1,2,3]triazole 
(132aa): Tetrahydro-4H-pyran-4- one (42 mg, 0.42 mmol), 4-
methoxybenzylamine (80 mg, 0.58 mmol), 4-nitrophenyl azide (68 mg, 
0.42 mmol), 4 Å molecular sieves (50 mg) and toluene (0.4 mL). 
Reaction time is 24 h. The product was purified by flash column 
chromatography (DCM followed by heptane/EtOAc = 6:4) affording 
132aa (78 mg, 76% yield) as an off white solid. m.p. 75 - 76 ˚C. 1H NMR 
(300 MHz, CDCl3) δ 7.16 (d, 2H, J = 8.8 Hz), 6.87 (d, 2H, J = 8.8 Hz), 5.42 
(s, 2H), 4.80 (s, 2H), 3.85 (t, 2H, J = 5.5), 3.80 (s, 3H), 2.55 (t, 2H, J = 
5.5); 13C NMR (75 MHz, CDCl3) δ 159.9, 142.3, 129.5, 129.3, 126.5, 
114.5, 64.2, 64.0, 55.4, 51.9, 22.0; MS (EI): m/z: 245 (M+); HRMS (ESI+): 
m/z calcd for C13H16N3O2 [M+H]+ : 246.1237, found 246.1239. 
 
5-Benzyl-1-(4-methoxybenzyl)-4,5,6,7-tetrahydro-1H-
[1,2,3]triazolo[4,5-c]pyridine (132ab): 1- Benzylpiperidin-4-one (79 
mg, 0.42 mmol), 4-methoxybenzylamine (80 mg, 0.58 mmol), 4-
nitrophenyl azide (68 mg, 0.42 mmol), 4 Å molecular sieves (50 mg) 
and toluene (0.4 mL). Reaction time is 24 h. The product was purified 
by flash column chromatography (DCM followed by heptane/EtOAc = 
5:2) affording 132ab (107 mg, 78% yield) as an off-white solid. m.p. 75 
-76 ˚C. 1H NMR (300 MHz, CDCl3) δ 7.32 - 7.26 (m, 5H), 7.16 (d, 2H, J = 
8.7 Hz), 6.85 (d, 2H, J = 8.6 Hz), 5.36 (s, 2H), 3.78 (s, 3H), 3.70 (s, 2H), 
3.67 (s, 2H), 2.71 (t, 2H, J = 5.8 Hz), 2.49 (t, 2H, J = 5.6 Hz); 13C NMR (75 
MHz, CDCl3) δ 159.7, 142.9, 138.0, 130.5, 129.3, 129.1, 128.5, 127.4, 
126.7, 114.4, 61.9, 55.4, 51.8, 49.9, 49.3, 21.0; MS (EI): m/z: 334 (M+); 
HRMS (ESI+ ): m/z calcd for C20H23N4O [M+H]+ : 335.1866, found 
335.1869. 
 
3-(4-Methoxybenzyl)-3,8-dihydroindeno[1,2-d][1,2,3]triazole 
(132ac): 1-indanone (55 mg, 0.42 mmol), 4-methoxybenzylamine (80 
mg, 0.58 mmol), 4-nitrophenyl azide (68 mg, 0.42 mmol), acetic acid (8 
mg, 0.13 mmol), 4 Å molecular sieves (50 mg) and toluene (0.4 mL). 
Reaction time is 12 h. The product was purified by flash column 
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chromatography (DCM followed by heptane/EtOAc = 6:4) affording 
132ac (99 mg, 95% yield) as an off white solid. m.p. 110 - 111 ˚C. 1H 
NMR (300 MHz, CDCl3) δ 7.52 - 7.49 (m, 1H), 7.29 - 7.25 (m, 4H), 7.13 
(t, 1H, J = 8.6 Hz), 6.88 (d, 2H, J = 8.6 Hz), 5.70 (s, 2H), 3.78 (s, 3H), 3.79 
(s, 2H); 13C NMR (75 MHz, CDCl3) δ 159.8, 155.9, 147.6, 141.3, 129.8, 
129.0, 127.3, 127.2, 127.0, 126.7, 120.1, 114.6, 55.4, 53.1, 29.1; MS 
(EI): m/z: 277 (M+ ); HRMS (ESI+ ): m/z calcd for C17H16N3O [M+H]+ : 
278.1288, found 278.1281. 
 
1-(4-Methoxybenzyl)-4,5-dihydro-1H-naphtho[1,2-d][1,2,3]triazole 
(132ad): 1-Tetralone (61 mg, 0.42mmol), 4-methoxybenzylamine (80 
mg, 0.58 mmol), 4-nitrophenyl azide (68 mg, 0.42 mmol), acetic acid (8 
mg, 0.13 mmol), 4 Å molecular sieves (50 mg) and toluene (0.4 mL). 
Reaction time is 12 h. The product was purified by flash column 
chromatography (DCM followed by heptane/EtOAc = 6:4) affording 
132ad (103 mg, 85% yield) as a solid. m.p. 84 ˚C. 1H NMR (300 MHz, 
CDCl3) δ 7.35 - 7.30 (m, 2H), 7.28 - 7.17 (m, 2H), 7.12 (d, 2H, J = 8.8 Hz), 
6.85 (d, 2H, J = 8.8Hz), 5.77 (s, 2H), 3.76 (s, 3H), 3.02 (s, 4H); 13C NMR 
(75 MHz, CDCl3) δ 159.5, 145.7, 137.3, 131.4, 129.2, 128.5, 127.9, 
127.3, 127.2, 125.0, 122.7, 114.5, 55.3, 52.7, 30.3, 20.8; MS (EI): m/z: 
291 (M+); HRMS (ESI+): m/z calcd for C18H18N3O [M+H]+ : 292.1444, 
found 292.1447. 
 
1-(4-Methoxybenzyl)-1,4,5,6-tetrahydrobenzo[3,4]cyclohepta[1,2-
d][1,2,3]triazole (132ae): 1- Benzosuberone (67 mg, 0.42 mmol), 4-
methoxybenzylamine (80 mg, 0.58 mmol), 4-nitrophenyl azide (68 mg, 
0.42 mmol), acetic acid (8 mg, 0.13 mmol), 4 Å molecular sieves (50 
mg) and toluene (0.4 mL). Reaction time is 12 h. The product was 
purified by flash column chromatography (DCM followed by 
heptane/EtOAc = 6:4) affording 132ae (119 mg, 94% yield) as an off 
white semi-solid. 1H NMR (300 MHz, CDCl3) δ 7.29 - 7.24 (m, 4H), 7.16 
(d, 2H, J = 8.7 Hz), 6.83 (d, 2H, J = 8.7 Hz), 5.59 (s, 2H), 3.77 (s, 3H), 2.93 
(t, 2H, J = 7.3 Hz), 2.57 (t, 2H, J = 6.0 Hz), 2.23 - 2.14 (m, 2H); 13C NMR 
(75 MHz, CDCl3) δ 159.4, 146.1, 142.4, 133.1, 130.1, 128.9, 128.3, 
127.5, 126.8, 126.6, 114.3, 55.3, 51.7, 32.8, 29.9, 23.3; MS (EI): m/z: 
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305 (M+); HRMS (ESI+): m/z calcd for C19H20N3O [M+H]+ : 306.1601, 
found 306.1605. 
 
1-(4-Methoxybenzyl)-1,8-dihydroindeno[1,2-d][1,2,3]triazole 
(132af): 2-Indanone (55 mg, 0.42mmol), 4-methoxybenzylamine (80 
mg, 0.58 mmol), 4-nitrophenyl azide (68 mg, 0.42 mmol), acetic acid (8 
mg, 0.13 mmol), 4 Å molecular sieves (50 mg) and toluene (0.4 mL). 
Reaction time is 12 h. The product was purified by flash column 
chromatography (DCM followed by heptane/EtOAc = 6:4) affording 
132af (86 mg, 75% yield) as an off white semi-solid. 1H NMR (300 MHz, 
CDCl3) δ 7.79 - 7.76 (m, 1H), 7.34 - 7.27 (m, 4H), 7.21 - 7.16 (m, 1H), 
6.91 (d, 2H, J = 8.7 Hz), 5.54 (s, 2H), 3.81 (s, 3H), 3.24 (s, 2H); 13C NMR 
(75 MHz, CDCl3) δ 160.1, 156.4, 144.8, 141.9, 133.7, 130.2, 127.6, 
126.1, 125.9, 125.8, 119.9, 114.6, 55.5, 53.3, 28.0; MS (EI): m/z: 277 
(M+); HRMS (ESI+): m/z calcd for C17H16N3O [M+H]+ : 278.1288, found 
278.1288. 
 
3-(4-Methoxybenzyl)-4,5-dihydro-3H-naphtho[1,2-d][1,2,3]triazole 
(132ag): 2-Tetralone (61 mg, 0.42 mmol), 4-methoxybenzylamine (80 
mg, 0.58 mmol), 4-nitrophenyl azide (68 mg, 0.42 mmol), acetic acid (8 
mg, 0.13 mmol), 4 Å molecular sieves (50 mg) and toluene (0.4 mL). 
Reaction time is 12 h. The product was purified by flash column 
chromatography (DCM followed by heptane/EtOAc = 6:4) affording 
132ag (100 mg, 82% yield) as a semi solid. 1H NMR (300 MHz, CDCl3) δ 
7.93 (d, 1H, J = 7.3 Hz), 7.30 - 7.26 (m, 1H), 7.18 - 7.15 (m, 4H), 6.85 (d, 
2H, J = 8.6 Hz), 5.47 (s, 2H), 3.78 (s, 3H), 3.0 (t, 2H, J = 7.7 Hz), 2.72 (t, 
2H, J = 7.8 Hz); 13C NMR (75 MHz, CDCl3) δ 159.7, 144.1, 133.4, 132.6, 
129.0, 128.7, 128.2, 127.5,127.4, 126.9, 122.1, 114.5, 55.4, 51.8, 28.5, 
19.1; MS (EI): m/z: 291 (M+); HRMS (ESI+): m/z calcd for C18H18N3O 
[M+H]+ : 292.1443, found 292.1445 
 
2-((5-Phenyl-1H-1,2,3-triazol-1-yl)methyl)pyridine (132ah): 
Acetophenone (52 mg, 0.42 mmol), pyridin- 2-ylmethanamine (64 mg, 
0.59 mmol), 4-nitrophenyl azide (68 mg, 0.42 mmol), 4 Å molecular 
sieves (50 mg) and toluene (0.4 mL). Reaction time is 24 h. The product 
was purified by flash column chromatography (DCM followed by 
66 
 
heptane/EtOAc =2:8) affording 132ah (70 mg, 67% yield) as an off 
white semi-solid. 1H NMR (300 MHz, CDCl3) δ 8.56 (d, 1H, J = 5), 7.80 
(s, 1H), 7.67 – 7.62 (m, 1H), 7.42 -7.40 (m, 5H), 7.27 -7.20 (m, 1H), 7.03 
(d, 1H, J = 8), 5.70 (s, 2H); 13C NMR (75 MHz, CDCl3) δ 155.5, 149.7, 
138.8, 137.2, 133.2, 129.6, 129.1, 128.9, 126.7, 123.1, 121.7, 53.4; MS 
(EI): m/z: 236 (M+); HRMS (ESI+): m/z calcd for C14H12N4 [M+H]+ : 
265.1448, found 265.1442. 
 
3-(1-(3,4,5-Trimethoxybenzyl)-1H-1,2,3-triazol-5-yl)-1H-indole 
(132ai): 3-Acetylindole (66 mg, 0.42 mmol), 3,4,5-
trimethoxybenzylamine (115 mg, 0.58 mmol), 4-nitrophenyl azide (68 
mg, 0.42 mmol), acetic acid (8 mg, 0.13 mmol), 4 Å molecular sieves 
(50 mg) and toluene (0.4 mL). Reaction time is 12 h. The product was 
purified by flash column chromatography (DCM followed by 
heptane/EtOAc = 6:4) affording 132ai (119 mg, 78% yield) as an off-
white solid. m.p. 180 - 181 ˚C. 1H NMR (300 MHz, CDCl3) δ 9.31 (s, 1H), 
7.89 (s, 1H), 7.50 - 7.46 (m, 2H), 7.31 - 7.26 (m, 1H), 7.22 - 7.16 (m, 1H), 
7.13 (d, 1H, J = 2.6 Hz), 6.23 (s, 2H), 5.52 (s, 2H),3.79 (s, 3H), 3.63 (s, 
6H); 13C NMR (75 MHz, CDCl3) δ 153.5, 137.6, 136.1, 133.7, 132.2, 
131.6, 126.3, 124.5, 123.3, 121.2, 119.2, 111.9, 104.3, 102.1, 60.9, 
56.0, 52.1; MS (EI): m/z: 364 (M+); HRMS (ESI+): m/z calcd for 
C20H21N4O3 [M+H]+ : 365.1608, found 365.1610. 
 
1-(4-Fluorobenzyl)-4,5-dihydro-1H-naphtho[1,2-d][1,2,3]triazole 
(132aj): 1-Tetralone (61 mg, 0.42 mmol), 4-flurobenzylamine (73 mg, 
0.58 mmol), 4-nitrophenyl azide (68 mg, 0.42 mmol), acetic acid (8 23 
mg, 0.13 mmol), 4 Å molecular sieves (50 mg) and toluene (0.4 mL). 
Reaction time is 12 h. The product was purified by flash column 
chromatography (DCM followed by heptane/EtOAc = 5:2) affording 
132aj (92 mg, 79% yield) as an off white semi-solid. 1H NMR (300 MHz, 
CDCl3) δ 7.32 - 7.14 (m, 6H), 7.06 - 7.0 (m, 2H), 5.81 (s, 2H), 3.04 (s, 4H); 
13C NMR (75 MHz, CDCl3) δ 164.2, 161.0, 145.9, 137.4, 131.5, 131.1, 
131.0, 129.4, 128.7, 128.5, 128.4, 127.2, 124.9, 122.5, 116.4, 116.1, 
52.5, 30.4, 20.8; MS (EI): m/z: 279 (M+); HRMS (ESI+): m/z calcd for 
C17H15FN3 [M+H]+ : 280.1244, found 280.1242. 
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N-(2-(5-Phenyl-1H-1,2,3-triazol-1-yl)ethyl)aniline (132ak): 
Acetophenone (52 mg, 0.42 mmol), phenylmethanediamine (71 mg, 
0.59 mmol), 4-nitrophenyl azide (68 mg, 0.42 mmol), 4 Å molecular 
sieves (50 mg) and toluene (0.4 mL). Reaction time is 24 h. The product 
was purified by flash column chromatography (DCM followed by 
DCM/MeOH = 95:5) affording 132ak (69 mg, 62% yield) as an off white 
semi solid. 1H NMR (300 MHz, CDCl3) δ 7.69 (s, 1H), 7.48 - 7.45 (m, 3H), 
7.41 - 7.35 (m, 2H), 7.30 - 7.21 (m, 5H), 4.45 (t, 2H, J = 6 Hz), 3.10 (t, 
2H, J = 6 Hz); 13C NMR (75 MHz, CDCl3) δ 139.7, 138.3, 133.1, 129.6, 
129.2, 129.0, 128.5, 128.1, 127.2, 127.1, 53.3, 48.2; MS (EI): m/z: 264 
(M+); HRMS (ESI+): m/z calcd for C16H17N4 [M+H]+ : 265.1448, found 
265.1442. 
 
4-(5-Phenyl-1H-1,2,3-triazol-1-yl)piperidine (132al): Acetophenone 
(50 mg, 0.42 mmol), 4- piperidineamine (58 mg, 0.58 mmol), 4-
nitrophenyl azide (68 mg, 0.42mmol), 4 Å molecular sieves (50 mg) and 
toluene (0.4 mL). Reaction time is 24 h. The product was purified by 
flash column chromatography (DCM followed by DCM/MeOH = 95:5) 
affording 132al (53 mg, 56% yield) as an off white semi-solid. 1H NMR 
(300 MHz, CDCl3) δ 7.68 (s, 1H), 7.53 - 7.50 (m, 3H), 7.36 - 7.33 (m, 2H), 
4.39 - 4.32 (m, 1H), 3.29 - 3.24 (m, 2H), 2.72 - 2.64 (m, 2H), 2.36 - 2.30 
(m, 2H), 2.28 - 1.98 (m, 2H); 13C NMR (100 MHz, CDCl3) δ 137.2, 133.0, 
129.6, 129.3, 129.1, 127.5, 56.5, 45.8, 34.1; MS (EI): m/z: 228 (M+); 
HRMS (ESI+): m/z calcd for C13H17N4 [M+H]+ : 229.1448, found 
229.1445. 
 
1-Allyl-5-phenyl-1H-1,2,3-triazole (132am): Acetophenone (52 mg, 
0.42 mmol), allylamine (34 mg, 0.59 mmol), 4-nitrophenyl azide (68 
mg, 0.42 mmol), 4 Å molecular sieves (50 mg) and toluene (0.4 mL). 
Reaction time is 24 h. The product was purified by flash column 
chromatography (DCM followed by heptane/EtOAc = 6:4) affording 
132am (49 mg, 61% yield) as an off white semi-solid. 1H NMR (300 
MHz, CDCl3) δ 7.74 (s, 1H), 7.50 - 7.40 (m, 5H), 6.09 - 5.96 (m, 1H), 5.27 
(d, 1H, J = 9.3 Hz), 5.07 - 4.97 (m, 3H); 13C NMR (75 MHz, CDCl3) δ 138.1, 
133.1, 132.2, 129.6, 129.1, 128.8, 127.0, 118.8, 50.6; MS (EI): m/z: 185 
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(M+); HRMS (ESI+): m/z calcd for C11H12N3 [M+H]+ : 186.1026, found 
186.1028. 
 
1-(2,2-Dimethoxyethyl)-5-phenyl-1H-1,2,3-triazole (132an): 
Acetophenone (50 mg, 0.42 mmol), 2,2- dimethoxyethanamine (61 
mg, 0.58 mmol), 4-nitrophenyl azide (68 mg, 0.42 mmol), 4 Å 
molecular sieves (50 mg) and toluene (0.4 mL). Reaction time is 24 h. 
The product was purified by flash column chromatography (DCM 
followed by heptane/EtOAc = 6:4) affording 132an (79 mg, 82% yield) 
as an offwhite solid. m.p. 120 - 121 ˚ C. 1H NMR (400 MHz, CDCl3) δ 7.70 
(s, 1H), 7.49 - 7.48 (m, 5H), 4.89 (t, 1H, J = 7.6 Hz), 4.41 (d, 2H, J = 7.5 
Hz), 3.33 (s, 6H); 13C NMR (100 MHz, CDCl3) δ 138.9, 132.8, 129.5, 
129.2, 129.0, 126.9, 103.4, 55.2, 49.6; MS (EI): m/z: 233 (M+); HRMS 
(ESI+): m/z calcd for C12H16N3O2 [M+H]+ : 234.1237, found 234.1238. 
 
(S)-5-Phenyl-1- (1-phenylethyl)-1H-1,2,3-triazole (132ao): 
Acetophenone (50 mg, 0.42 mmol), (S)-(−)-α- methylbenzylamine (71 
mg, 0.58 mmol), 4-nitrophenyl azide (68 mg, 0.42 mmol), acetic acid (8 
mg, 0.13 mmol), 4 Å molecular sieves (50 mg) and toluene (0.4 mL). 
Reaction time is 48 h. The product was purified by flash column 
chromatography (DCM followed by heptane/EtOAc = 5:2) affording 
132ao (91 mg, 87% yield) as an off-white solid. m.p. 53 - 54 ˚C. 1H NMR 
(300 MHz, CDCl3) δ 7.70 (s, 1H), 7.42 - 7.40 (m, 3H), 7.31 - 7.26 (m, 3H), 
7.20 - 7.17 (m, 4H), 5.57 (q, 1H, J = 7.1 Hz), 2.02 (d, 3H, J = 7.0 Hz); 13C 
NMR (100 MHz, CDCl3) δ 141.4, 138.0, 133.3, 129.5, 129.4, 129.0, 
128.9, 128.1, 127.3, 126.3, 58.5, 22.9; MS (EI): m/z: 249 (M+); HRMS 
(ESI+): m/z calcd for C16H16N3 [M+H]+ : 250.1339, found 250.1339. 
 
(S)-2-(5-Phenyl-1H-1,2,3-triazol-1-yl)butan-1-ol (132ap): 
Acetophenone (50 mg, 0.42 mmol), (S)-2- aminobutan-1-ol (51 mg, 
0.58 mmol), 4-nitrophenyl azide (68 mg, 0.42 mmol), 4 Å molecular 
sieves (50 mg) and toluene (0.4 mL). Reaction time is 48 h. The product 
was purified by flash column chromatography (DCM followed by 
heptane/EtOAc = 4:6) affording 132ap (75 mg, 83% yield) as an off 
white semi-solid. 1H NMR (300 MHz, CDCl3) δ 7.54 (s, 1H), 7.50 - 7.44 
(m, 5H), 4.46 - 4.31 (m, 2H), 4.0 - 3.97 (m, 1H), 3.73 (sbr, 1H), 2.06 - 
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1.79 (m, 2H), 0.69 (t, 3H, J = 7.3Hz); 13C NMR (75 MHz, CDCl3) δ 139.6, 
132.4, 129.6, 129.6, 129.1, 127.1, 65.0, 62.1, 25.1, 10.4; MS (EI): m/z: 
217 (M+ ); HRMS (ESI+ ): m/z calcd for C12H16N3O [M+H]+ : 218.1288, 
found 218.1287. 
 
1-(4-Methoxyphenyl)-5-phenyl-1H-1,2,3-triazole (132aq): 
Acetophenone (50 mg, 0.42 mmol), 4- methoxyaniline (72 mg, 0.58 
mmol), 4-nitrophenyl azide (68 mg, 0.42 mmol), acetic acid (8 mg, 0.13 
mmol), 4 Å molecular sieves (50 mg) and toluene (0.4 mL). Reaction 
time is 48 h. The product was purified by flash column chromatography 
(DCM followed by heptane/EtOAc = 6:4) affording 132aq (26 mg, 25% 
yield) as an off-white solid. m.p. 160 - 161 ˚C. 1H NMR (300 MHz, CDCl3) 
δ 7.85 (s, 1H), 7.36 - 7.24 (m, 7H), 6.93 (d, 2H, J = 8.8 Hz), 3.84 (s, 3H); 
13C NMR (75 MHz, CDCl3) δ 160.2, 137.4, 133.3, 129.7, 129.3, 129.0, 
128.7, 127.0, 126.7, 114.6, 55.7; MS (EI): m/z: 251 (M+); HRMS (ESI+): 
m/z calcd or C15H14N3O [M+H]+ : 252.1131, found 252.1132. 
 
1,1’-Bis(1-(4-methoxybenzyl)-1H-1,2,3-triazol-5-yl)ferrocene (139): 
1, 1′-Diacetylferrocene (100 mg, 0.37 mmol), 4-methoxybenzylamine 
(282 mg, 2.07 mmol), 4-nitrophenyl azide (121 mg, 0.74 mmol), 4 Å 
molecular sieves (50 mg) and toluene (1 mL). Reaction time is 72 h. The 
product was purified by flash column chromatography (DCM followed 
by heptane/EtOAc = 2:8) affording 139 (140 mg, 68% yield) as a red 
solid. m.p. 100 - 101 ˚C. 1H NMR (300 MHz, CDCl3) δ 7.65 (s, 2H), 6.96 
(d, 4H, J = 8.4 Hz), 6.84 (d, 4H, J = 8.5 Hz), 5.42 (s, 4H), 4.26 (s, 4H), 4.18 
(s, 4H), 3.79 (s, 6H); 13C NMR (75 MHz, CDCl3) δ 159.6, 135.1, 133.3, 
128.1, 127.5, 114.5, 72.2, 71.7, 70.0, 55.5, 51.5; MS (EI): m/z: 560 (M+ 
); HRMS (ESI+ ): m/z calcd for C30H29FeN6O2 [M+H]+ : 561.1695, found 
561.1691. 
 
1,3,5-Tris (1- (4-methoxybenzyl)-1H-1,2,3-triazol-5-yl)benzene (140): 
1,3,5-Triacetylbenzene (50 mg, 0.24 mmol), 4-methoxybenzylamine 
(140 mg, 1.03 mmol), 4-nitrophenyl azide (144 mg, 0.88 mmol), acetic 
acid (4 mg, 0.06 mmol), 4 Å molecular sieves (50 mg) and toluene (0.8 
mL). Reaction time is 48 h. The product was purified by flash column 
chromatography (DCM followed by heptane/EtOAc = 2:8) affording 
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140 (118 mg, 77% yield) an off-white solid. m.p. 167 - 168 ˚C. 1H NMR 
(300 MHz, CDCl3) δ 7.65 (s, 3H), 7.28 (s, 3H), 6.84 (d, 6H, J = 8.6 Hz), 
6.73 (d, 6H, J = 8.8Hz), 5.35 (s, 6H), 3.72 (s, 9H); 13C NMR (75 MHz, 
CDCl3) δ 159.8, 135.7, 133.9, 129.7, 128.8, 128.5, 126.9, 114.4, 55.4, 
52.0; MS (EI): m/z: 639 (M+); HRMS (ESI+): m/z calcd for C36H34N9O3 
[M+H]+ : 640.2779, found 640.2781. 
 
Tris (2-(5-phenyl-1H-1,2,3-triazol-1-yl)ethyl)amine (141): 
Acetophenone (295 mg, 2.4 mmol), tris(2- aminoethyl)amine (100 mg, 
0.68 mmol), 4-nitrophenyl azide (370 mg, 2.2 mmol), acetic acid (4 mg, 
0.06 mmol) 4 Å molecular sieves (30 mg) and toluene (0.6 
mL).Reaction time is 48 h. The product was purified by flash column 
chromatography (DCM followed by DCM/MeOH= 95:5) affording 141 
(230 mg, 65% yield) an off-white solid. m.p. 167 - 168 ˚C. 1H NMR (300 
MHz, CDCl3) δ 7.62 (s, 3H), 7.48 - 7.46 (m, 9H), 7.29 - 7.27 (m, 6H), 4.08 
- 4.03 (t, 6H, J = 6.6), 2.74 - 2.70 (t, 6H, J = 6.96); 13C NMR (75 MHz, 
CDCl3) δ 138.1, 133.2, 129.8, 129.4, 128.8, 127.0, 53.5, 46.2; MS (EI): 
m/z: 530 (M+); HRMS (ESI+): m/z calcd for C30H31N10 [M+H]+ : 531.2727, 
found 531.2728. 
 
1,N1'-(Butane-1,4-diyl)bis(N1-(3-(bis(3-(4,5,6,7-tetrahydro-1H-
benzo[d][1,2,3]triazol-1- yl)propyl)amino)propyl)-N3,N3-bis(3-
(4,5,6,7-tetrahydro-1H-benzo[d][1,2,3]triazol-1- yl)propyl)propane-
1,3-diamine) (143): Poly(propylene imine)-dendrimer of generation 2 
(70 mg, 0.09 mmol), cyclohexanone (106 mg, 1.08 mmol), 4-
nitrophenyl azide (178 mg, 1.08 mmol), 4 Å molecular sieves (30 mg) 
and dioxane (1.5 mL). Reaction time is 24 h. The product was 
precipitated out in diethyl ether and affording 143 (106 mg, 73% yield) 
as an off white solid. m.p. 101 ˚C. 1H NMR (300 MHz, CDCl3) δ 4.21 (sbr, 
16H), 3.35 (sbr, 4H), 2.71 (sbr, 16H), 2.60 (sbr, 16H), 2.45 (sbr, 32H), 
1.96 - 1.56 (m, 62H); 13C NMR (75 MHz, CDCl3) δ 143.4, 131.9, 52.2, 
50.9, 45.8, 29.8, 27.5, 25.8, 22.8, 22.6, 22.0, 20.2; MS (ESI)+: m/z: 1622 
(M+); HRMS (ESI+): m/z calcd for C88H145N30 [M+H]+ : 1622.2262, found 
1622.2211. 
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1-(2-(1H-imidazol-4-yl)ethyl)-5-phenyl-1H-1,2,3-triazole (145a): 
Acetophenone (52 mg, 0.42 mmol), histamine (65 mg, 0.59 mmol), 4-
nitrophenyl azide (68 mg, 0.42 mmol), 4 Å molecular sieves (50 mg) 
and toluene (0.4 mL). Reaction time is 12 h. The product was purified 
by flash column chromatography (DCM followed by DCM/MeOH = 
95:5) affording 145a (61 mg, 61% yield) as an off-white semi solid. 1H 
NMR (300 MHz, CDCl3) δ 7.65 (s, 1H), 7.52 (s, 1H), 7.45 - 7.43 (m, 3H), 
7.26 - 7.22 (m, 2H), 6.95 (sbr, 1H), 6.64 (s, 1H), 4.61 (t, 2H, J = 7.0 Hz), 
3.22 (t, 2H, J = 7.0 Hz); 13C NMR (75 MHz, CDCl3) δ 138.5, 135.1, 134.0, 
132.9, 129.2, 128.8, 126.8, 116.5, 48.2, 28.1; MS (EI): m/z: 239 (M+); 
HRMS (ESI+): m/z calcd for C13H14N5 [M+H]+ : 240.1243, found 
240.1248. 
 
3-(2-(5-Phenyl-1H-1,2,3-triazol-1-yl)ethyl)-1H-indole (145b): 
Acetophenone (50 mg, 0.42 mmol), tryptamine (94 mg, 0.59 mmol), 4-
nitrophenyl azide (68 mg, 0.42 mmol), acetic acid (8 mg, 0.13 mmol), 
4 Å molecular sieves (50 mg) and toluene (0.4 mL). Reaction time is 12 
h. The product was purified by flash column chromatography (DCM 
followed by heptane/EtOAc = 6:4) affording 145b (90 mg, 75% yield) 
as an off white solid. m.p. 123 - 124 ˚C. 1H NMR (300 MHz, CDCl3) δ 
8.09 (s, 1H), 7.63 (s, 1H), 7.41 - 7.14 (m, 6H), 7.06 - 7.00 (m, 3H), 6.83 
(s, 1H), 4.60 (t, 2H, J = 7.3 Hz), 3.33 (t, 2H, J = 7.3 Hz); 13C NMR (75 MHz, 
CDCl3) δ 138.4, 136.3, 133.0, 129.3, 128.9, 128.8, 127.1, 127.0, 122.6, 
122.2, 119.6, 118.2, 111.4, 111.2, 48.8, 26.6; MS (EI): m/z: 288 (M+); 
HRMS (ESI+ ): m/z calcd for C18H17N4 [M+H]+ : 289.1445, found 
289.1446. 
 
1-(((1S,4aS)-7-Isopropyl-1,4a-dimethyl-1,2,3,4,4a,9,10,10a-
octahydrophenanthren-1-yl)methyl)-5- phenyl-1H-1,2,3-triazole 
(145c): Acetophenone (50 mg, 0.42 mmol), dehydroabietylamine (166 
mg, 0.58 mmol), 4-nitrophenyl azide (68 mg, 0.42 mmol), acetic acid (8 
mg, 0.13 mmol), 4 Å molecular sieves (50 mg) and toluene (0.8 mL). 
Reaction time is 48 h. The product was purified by flash column 
chromatography (DCM followed by heptane/EtOAc = 5:5) affording 
145c (132 mg, 76% yield) as an offwhite solid. 1H NMR (300 MHz, 
CDCl3) δ 7.63 (s, 1H), 7.48 - 7.46 (m, 3H), 7.35 - 7.32 (m, 2H), 7.08 (d, 
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1H, J = 8.1 Hz), 6.94 (d, 1H, J = 8.1 Hz), 6.87 (s, 1H), 4.32 (s, 2H), 2.86 - 
2.76 (m, 3H), 2.19 - 2.15 (m, 1H), 1.80 - 1.31 (m, 6H), 1.22 (s, 3H), 1.20 
(s, 3H), 1.15 (s, 3H), 1.05 - 1.04 (m, 2H), 0.93 (s, 3H); 13C NMR (75 MHz, 
CDCl3) δ 147.0, 145.8, 139.1, 134.7, 133.1, 129.4, 129.3, 129.2, 128.3, 
127.0, 124.1, 123.9, 58.4, 45.9, 39.4, 38.1, 37.7, 36.6, 33.6, 29.9, 25.6, 
24.1, 24.0, 19.4, 18.7, 18.5; MS (EI): m/z: 413 (M+); HRMS (ESI+ ): m/z 
calcd for C28H36N3 [M+H]+ : 414.2903, found 414.2909. 
 
2-(5-Phenyl-1H-1,2,3-triazol-1-yl)octadecane-1,3,4-triol (145d): 
Acetophenone (50 mg, 0.42 mmol), phytosphingosine (185 mg, 0.58 
mmol), 4-nitrophenyl azide (68 mg, 0.42 mmol), 4 Å molecular sieves 
(50 mg) and toluene (1 mL). Reaction time is 48 h. The product was 
purified by flash column chromatography (DCM followed by 
DCM/MeOH = 95:5) affording 145d (150 mg, 81% yield) as an off white 
semi-solid. 1H NMR (300 MHz, CDCl3) δ 7.68 (s, 1H), 7.50 - 7.49 (m, 3H), 
7.45 - 7.43 (m, 2H), 4.81 - 4.78 (m, 1H), 4.37 - 4.33 (m, 1H), 4.11 - 4.07 
(m, 2H), 3.59 - 3.54 (m, 1H), 2.93 (sbr, 1H), 1.38 - 1.08 (m, 26H), 0.88 
(t, 3H, J = 7.0 Hz); 13C NMR (75 MHz, CDCl3) δ 139.0, 132.8, 130.0, 
129.4, 129.3, 126.5, 75.5, 72.3, 62.0, 60.3, 32.1, 29.8, 29.8, 29.8, 29.7, 
29.7, 29.5, 25.9, 22.8, 14.2; MS (EI): m/z: 445 (M+); HRMS (ESI+): m/z 
calcd for C26H44N3O3 [M+H]+ : 446.3376, found 446.3372. 
 
(6bS,8aS,12aS,12bR)-9-(4-Methoxybenzyl)-8a-methyl-
1,2,6b,7,8,8a,9,12,12a,12bdecahydronaphtho[2',1':4,5]indeno[1,2-
d][1,2,3]triazol-4-ol (145e1): Estrone (113 mg, 0.42 mmol), 4- 
methoxybenzylamine (160 mg, 1.18 mmol), 4-nitrophenyl azide (137 
mg, 0.84 mmol), acetic acid (8 mg, 0.13 mmol), 4 Å molecular sieves 
(50 mg) and toluene (1.5 mL). Reaction time is 72 h. The product was 
purified by flash column chromatography (DCM followed by 
heptane/EtOAc = 3:7) affording 145e1 (123 mg, 71% yield) as an off 
white solid. m.p. 210 – 211 ˚C. 1H NMR (300 MHz, CDCl3) δ 7.18 (d, 2H, 
J = 8.7 Hz), 7.09 (d, 1H, J = 8.7 Hz), 6.86 (d, 2H, J = 8.7 Hz), 6.65 - 6.58 
(m, 2H), 5.49 - 5.31 (m, 2H), 5.08 (sbr, 1H), 3.80 (s, 3H), 2.89 - 2.75 (m, 
3H), 2.48 - 2.23 (m, 4H), 2.07 - 2.03 (m, 2H), 1.95 - 1.42 (m, 4H), 0.73 
(s, 3H); 13C NMR (75 MHz, CDCl3) δ 159.8, 154.0, 149.3, 138.0, 131.7, 
129.2, 127.6, 126.2, 115.6, 114.3, 113.0, 61.7, 55.4, 52.7, 44.1, 41.5, 
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37.3, 34.0, 29.4, 30 27.4, 25.9, 24.6, 17.2; MS (EI): m/z: 415 (M+); HRMS 
(ESI+): m/z calcd for C26H30N3O2 [M+H]+ : 416.2332, found 416.2332. 
 
(6bS,8aS, 12aS, 12bR)-9-Butyl-8a-methyl-1,2,6b,7,8,8a,9, 12, 12a, 
12b-decahydronaphtho[2', 1':4,5]indeno[1,2-d][1,2,3]triazol-4-ol 
(145e2): Estrone (113 mg, 0.42 mmol), n-butyl amine (120 mg, 1.66 
mmol),4-nitrophenyl azide (137 mg, 0.84 mmol), acetic acid (8 mg, 
0.13 mmol), 4 Å molecular sieves (50 mg) and toluene (1.5 mL). 
Reaction time is 72 h. The product was purified by flash column 
chromatography (DCM followed by heptane/EtOAc = 3:7) affording 
145e2 (130 mg, 88% yield) as an off white solid. m.p. 264 - 265 ˚C. 1H 
NMR (300 MHz, CDCl3) δ 7.13 (d, 1H, J = 8.6 Hz), 6.70 - 6.66 (m, 1H), 
6.62 (s, 1H), 5.61 (sbr, 1H), 4.30 - 4.19 (m, 2H), 2.93 - 2.77 (m, 3H), 2.50 
- 2.25 (m, 5H), 1.98 - 1.92 (m, 4H), 1.89 - 1.35 (m, 5H), 1.05 (s, 3H), 0.97 
(t, 3H, J = 7.3 Hz); 13C NMR (75 MHz, CDCl3) δ 154.0, 154.3, 149.2, 
138.1, 131.8, 126.2, 115.6, 113.0, 61.7, 49.1, 44.2, 41.4, 37.3, 34.3, 
32.8, 29.5, 27.4, 26.0, 24.5, 20.0, 17.9, 13.7; MS (EI): m/z: 351 (M+); 
HRMS (ESI+): m/z calcd for C22H30N3O [M+H]+ : 352.2382, found 
352.2381. 
 
(1S,3aS,3bR,5aS,10aS,10bS,12aS)-7-(4-Methoxybenzyl)-10a,12a-
dimethyl- 1,2,3,3a,3b,4,5,5a,6,7,10,10a,10b,11,12,12a-
hexadecahydrocyclopenta[7,8]phenanthro[2,3- d][1,2,3]triazol-1-ol 
(145f): 5α-Dihydrotestosterone (120 mg, 0.42 mmol), 4-
methoxybenzylamine (80 mg, 0.58 mmol), 4-nitrophenyl azide (68 mg, 
0.42 mmol), acetic acid (8 mg, 0.13 mmol), 4 Å molecular sieves (50 
mg) and toluene (0.8 mL). Reaction time is 12 h. The product was 
purified by flash column chromatography (DCM followed by 
heptane/EtOAc = 4:6) affording 145f (160 mg, 88% yield) as an 
offwhite solid. m.p. 96 - 97 ˚C. 1H NMR (300 MHz, CDCl3) δ 7.13 (d, 2H, 
J = 8.5 Hz), 6.86 (d, 2H, J = 8.7 Hz), 5.35 (s, 2H), 3.79 (s, 3H), 3.65 (t, 1H, 
J = 8.5 Hz), 2.85 (d, 1H, J = 15.6 Hz), 2.40 - 2.24 (m, 2H), 2.09 - 1.83 (m, 
3H), 1.72 - 1.22 (m, 11H), 1.15 - 0.85 (m, 4H), 0.75 (s, 3H), 0.66 (s, 3H); 
13C NMR (75 MHz, CDCl3) δ 159.6, 143.8, 130.6, 128.9, 127.1, 114.3, 
81.8, 55.4, 53.8, 51.5, 50.9, 42.9, 42.2, 36.8, 36.7, 36.2, 35.6, 31.2, 30.5, 
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28.9, 24.6, 31 23.5, 20.8, 11.7, 11.2; MS (EI): m/z: 435 (M+); HRMS 
(ESI+): m/z calcd for C27H38N3O2 [M+H]+ : 436.2958, found 436.2956. 
 
4.3 Preparation of N- (4-Methoxybenzyl)-1- (4-nitrophenyl)-5-
phenyl-4,5-dihydro-1H-1,2,3-triazol-5- amine (134): To an oven-dried 
screw-capped reaction tube equipped with a magnetic stir bar was 
added acetophenone (500 mg, 4.2mmol), 4-methoxybenzylamine (800 
mg, 5.8 mmol) and 4 Å molecular sieves (500 mg). The mixture was 
dissolved in anhydrous toluene (4 mL) and stirred at 100 °C for 2 h. 
After cooling it down to room temperature, an equivalent of 4-
nitrophenyl azide (680 mg, 4.2 mmol) was added and the reaction 
mixture was stirred for another 6 h at 50°C. The resulting reaction 
mixture was precipitated in diethyl ether, filtered and dried to afford 
1.2 g of the triazoline intermediate 134 in 75% yield. m.p. 153 – 154 
˚C. 1H NMR (300 MHz, CDCl3) δ 8.09 (d, 2H, J = 8.7 Hz), 7.54 – 7.26 (m, 
7H), 7.01 (d, 2H, J = 8.2 Hz), 6.79 (d, 2H, J = 8.5 Hz), 4.82 (d, 1H, J = 18 
Hz), 4.35 (d, 1H, J = 18.7 Hz), 3.77 (s, 3H), 3.37 (t, 1H, J = 10.9 Hz), 2.96 
(d, 1H, J = 12.0 Hz), 2.60 (d, 1H, J = 10.1 Hz); 13C NMR (75 MHz, CDCl3) 
δ 159.2, 144.7, 142.6, 141.5, 130.1, 129.7, 129.6, 129.0, 125.7, 125.6, 
114.7, 114.1, 81.6, 80.2, 55.4, 45.9; MS (EI): m/z: 403 (M+); HRMS 
(ESI+): m/z calcd for C22H22N5O3 [M+H]+ : 404.1717; found 404.1717. 
 
2.4.3 Bulk synthesis of 1,2,3-triazole (132a) and the regeneration of the 
4-nitrophenyl azide (131a) 
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To a 250 mL round-bottom flask equipped with a magnetic stir bar was 
added an equivalent of acetophenone (5 g, 42mmol), 1.4 equivalents 
of 4-methoxybenzylamine (8 g, 58mmol), one equivalent of 4-
nitrophenyl azide (6.8 g, 42mmol), 30 mol% of acetic acid (8 mg, 0.13 
mmol) (0.8 mL, 12.6mmol) and 4 Å molecular sieves (5 g). The mixture 
was dissolved in anhydrous toluene (30 mL) and stirred at 100 °C for 
12 hr. The solvent was evaporated off and the resulting reaction 
mixture was suspended in hydrochloric acid (3N, 100mL) and 
methanol (30 mL) was added to aid the solubility. After cooling the 
solution to 0 °C, NaNO2 (6g) in water (20 mL) was added dropwise. The 
resulting solution was stirred at 0 °C for 30 minutes, after which 
reaction mixture was extracted with ethyl acetate at 0-5 °C. The 
aqueous layer was collected separately and the organic fraction was 
washed with a saturated NaHCO3 32 solution and brine, dried over 
MgSO4 and concentrated in vacuo to afford 1,5-disubstituted 1,2,3- 
triazole 132a (9.7 g) in sufficent purity with an overall yield of 88%. To 
the aqueous layer, a solution of NaN3 (4 g) in 20 mL of water was added 
dropwise at 0 °C and the whole was stirred for at least an hour at room 
temperature. The reaction mixture was extracted with diethyl ether 
and the organic fraction was washed with a saturated NaHCO3 
solution and brine, dried over MgSO4 and concentrated in vacuo to get 
the desired azide compound 131a (5.6 g) in sufficient purity (82% 
yield). 
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Chapter 3 
A Single-Step Acid Catalyzed reaction for Rapid Assembly of NH-
1,2,3-Triazoles 
 
Reproduced in part with permission from [“A single-step acid catalyzed 
reaction for rapid 
assembly of NH-1,2,3-triazoles” Joice Thomas, Sampad Jana, Sandra Liekens 
and Wim Dehaen Chem. Commun., 2016,52, 9236-9239] Copyright © [2016] 
Royal Society of chemistry 
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3.1 Introduction 
NH-1,2,3-Triazoles are an important class of heterocyclic compounds 
which are widely used in cutting edge research for various applications 
that range from drug discovery to advanced materials. The close 
resemblance of these moieties to amide bonds has been successfully 
exploited in the discovery of a considerable number of privileged 
medicinal scaffolds (Fig. 5a–d).1 In material chemistry, various 5-
pyridyl-substituted 1H-triazolyl moieties have been employed as 
versatile ligands to synthesize co-ordination complexes for 
optoelectronic applications.2 Interestingly, they also serve as key 
synthetic intermediates for a series of important transformations in 
organic synthesis. For example, N-2 functionalization of NH-triazoles 
via alkylation3a and arylation3b,c was achieved with high regioselectivity 
and very recently, asymmetric transannulation of N-unsubstituted 
1,2,3-triazoles with olefins to 2,3-dihydropyrroles was reported by 
using a chiral dirhodium catalyzed reaction.3d,e Moreover, post-
functionalization of these building blocks led to the synthesis of 
various potential antibacterial and anticancer agents (Figure 5e–g).1e  
 
 
Figure 5 Illustration of pharmaceutically active NH-1,2,3-triazoles and 
N-substituted derivatives. 
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Figure 6 Summary of pre vious[1 & 7] and present work. 
Many selective protocols for synthesizing 1,2,3-triazoles have been 
developed in the past years, inspired by the Cu- or Ru-catalyzed azide–
alkyne cycloaddition (CuAAC or RuAAC) reactions4 or organocatalytic 
cycloaddition reactions of azides with enolizable groups.5 
Nevertheless, most of these strategies result in 1,4/1,5- disubstituted-
1,2,3-triazoles, and only few yield NH-triazoles.5a Most of the 
publicized routes cover the CuAAC reaction of trimethylsilyl azide 
(TMSN3) and an alkyne followed by the deprotection of the 
trimethylsilyl group,1a,e,6c Pd-catalyzed synthesis of NH-triazoles from 
sodium azide and alkenyl bromides6f and 1,3-dipolar cycloaddition of 
nitroolefins and sodium azide6d,h (Figure 6).6  
 
3.2 Results and discussions 
Despite the progress of metal catalyzed reactions, organocatalytic 
reactions towards NH-1,2,3-triazoles remain underexplored. 
Moreover, carbocyclic fused NH-triazoles are obtained in a multistep 
manner where hazardous hydrazine is used as one of the reagents 
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(Figure 6a).6a This could explain why fused NH-triazoles are not readily 
available and cannot be obtained from sensitive cyclic ketones. Thus, 
the development of a novel complementary protocol devoid of these 
drawbacks, currently represents an important goal in the field of 
triazole chemistry. Recently, we have developed a general metal-free 
triazolization route that enables the direct preparation of various 
1,2,3-triazoles from readily available building blocks such as primary 
amines, enolizable ketones and 4-nitrophenyl azide as a renewable 
source of dinitrogen. Mechanistic studies indicated that the triazoline, 
which was formed via a [3+2] cycloaddition reaction between 131a 
and a transiently generated enamine, is the key synthetic intermediate 
in this transformation.7 The triazoline intermediate subsequently 
undergoes aromatization with the loss of a molecule of 4-nitroaniline 
133 via an acid catalyzed pathway leading to the respective triazole in 
a regiospecific manner. We presume that our new approach towards 
the synthesis of NH-triazoles also follows a similar mechanistic 
pathway Herein, we disclose the successful implementation of our 
protocol by the replacement of the primary amine by an ammonium 
salt resulting in the synthesis of N-unsubstituted 1,2,3-triazoles (Figure 
6b). Despite the elegance of the other well established methods,7 the 
significance of the present chemistry is twofold: (1) the rapid and easy 
access to NH-triazoles in a single step from commercially available 
ketones. (2) This strategy enables great scaffold diversity in NH-
triazole skeletons such as 4-substituted, 4,5-disubstituted and very 
importantly, previously inaccessible or scarcely reported fused NH-
triazoles in a single step. 
We started our study by investigating the triazolization of 1-tetralone 
146a. Among the various ammonium salts (NH4OH, (NH4)2CO3, 
NH4OAc and NH4Cl) and solvents (toluene, ethanol, DMF and DMSO) 
screened, NH4OAc and DMF gave the best result. Thus, through the 
optimization of the appropriate reaction parameters, we were able to 
develop a method which involves a one-pot reaction of 146a, 131 and 
NH4OAc in a respective molar ratio of 1:1.3:5 in a solution of DMF at 
80 °C over a period of 12 h affording NH-1,2,3-triazole 148a with an 
isolated yield of 87%.  
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entry Ammonium salts solvent Temp (°C) Time 
(h) 
Yield 
(%)a 
1 NH4OH(1 equiv.) toluene 80 12 13 
2 NH4CO3(1 equiv.) toluene 80 12 18 
3 NH4OAc(1 equiv.) toluene 80 12 46 
4 NH4Cl(1 equiv.) toluene 80 12 18 
5 NH4OAc(1 equiv.) DMF 80 12 62 
6 NH4OAc(1 equiv.) DMSO 80 12 51 
7 NH4OAc(1 equiv.) EtOH 80 12 43 
8 NH4OAc(3 equiv.) DMF 80 12 77 
9 NH4OAc(5 equiv.) DMF 80 12 86 
10 NH4OAc(6 equiv.) DMF 80 12 84 
11 NH4OAc(5 equiv.) DMF 60 24 77 
12 NH4OAc(5 equiv.) DMF 100 12 81 
Table 4 optimization study 
[a]Isolated yield  
 
Subsequently, the optimized conditions for the triazolization reaction 
were applied to a variety of cyclic ketones to synthesize 4,5-fused NH-
triazoles. Aromatic bicyclic ketone 146b was compatible with the 
presented reaction; benzannulated triazole derivative 148b was 
obtained as the exclusive product in excellent yield. Interestingly, an 
array of cyclic ketones containing five to eight carbon atoms gave high 
yields under the standard conditions (148c–f). In order to further 
highlight the potential applicability of this methodology, azaspinacine 
derivative 148g was also synthesized in a single step. This piperidine 
annulated triazole derivative 148g could be considered as a ticlopidine 
analogue (an adenosine diphosphate receptor inhibitor) containing a 
triazole moiety instead of the thiophene nucleus.8a Thus, this single 
step protocol addresses the previous limitations in triazole chemistry, 
such as the synthesis of 4,5-fused NH-triazoles.  
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Table 5 Generality of triazole synthesis[a]  
[a]Reaction conditions: 146a (1.0 equiv.), NH4OAc (5 equiv.), 131a (1.3 
equiv.), DMF (1 mL), 80o C, 12 h, Isolated yield. [b]24 h. 
Next, we examined the scope of this protocol towards the synthesis of 
N-unsubstituted 4-aryl-1,2,3-triazoles starting from various 
substituted acetophenones. In general, all of the examined 
acetophenones were well tolerated and the desired products were 
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isolated in excellent yield, regardless of the presence of electron-
withdrawing and electron-donating groups on the aromatic rings 
(148h–k). It is noteworthy that heterocyclic moieties such as 
thiophene, indole and carbazole were amenable to the reaction and 
afforded the corresponding products in good yields (148l–n). Our 
interest in skeletal diversity also led us to investigate the synthesis of 
4,5-disubstituted 1,2,3-triazoles. Different aryl or alkyl ketones such as 
aryl propanones or 5-pentanone gave the corresponding disubstituted 
triazoles (148o–q) in good to excellent yield (Table 5a-b). 
We then tackled the triazolization of unsymmetrical ketones, with two 
possible places for enamine formation, in a regiospecific manner. In 
our previous studies, we observed that the reaction with 
unsymmetrical 2-ketone and a primary amine gave a mixture of two 
products with higher preference for the trisubstituted 1,2,3-triazole.7 
Contrary to this observation, the reaction with 2-heptanone 146r only 
gave the product derived from the highly substituted enamine 148r. 
The relatively acidic conditions and lower steric hindrance of the 
triazoline adduct of the NH-triazole 148r, as compared to the reaction 
circumstances with primary amines, explains why only one of two 
potential enamines and triazoline intermediates forms, which solves 
the regiochemistry problem. Similarly, the reaction with 3-heptanone 
146s also led to a single product 148s derived from the 
thermodynamically more stable enamine (Table 5c).  
 
 
Figure 7 Substrate scope of the multifunctional building blocks. 
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Table 6 Triazolization of natural products[a]  
[a]Reaction conditions: 152 (1.0 equiv.), NH4OAc (5 equiv.), 131a (1.4 
equiv.), DMF (1 mL), 80o C, 12 h, Isolated yield. [b]24 h.  
During the last years, many groups have been investigating bis-triazole 
compounds as potential ligands for various supramolecular 
applications.2,8b To validate the utility of this reaction in designing 
various receptors in a supramolecular perspective, different bis-NH-
1,2,3-triazoles 5–7 were synthesized in a single step starting from the 
corresponding bis-acetyl derivatives (Figure 7). Functionalization of 
natural products with a triazole nucleus has emerged as an attractive 
strategy in designing new classes of nature-inspired structural entities 
with medicinal benefits. These transformations usually require 
multistep strategies which involve the post-functionalization of the 
respective natural products with ‘‘clickable’’ alkyne or azido 
functionalities followed by a metal-catalyzed cycloaddition reaction.8c 
The presented protocol provides a streamlined strategy for the 
triazolization of dozens of readily available natural products in the 
search for new drug candidates. Triazolization of acetovanillone 152a 
occurred smoothly using our optimized conditions which led to the 
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expected NH-triazole 153a in good yield. Next, we successfully applied 
this reaction to the flavonoid-related compound 152b giving rise to the 
benzopyran fused triazole 153b as the sole product. Several 
terpenoids with fused or tethered triazole heterocycles were proven 
to have enhanced biological or pharmacological activities as compared 
to the parent compounds.1c,f For example, betulinic acid is a naturally 
occurring pentacyclic triterpenoid and conjugation with triazoles has 
been reported to be effective against a variety of cancer cell lines.8d In 
addition, the presence of various fused heterocyclic rings at the C-2 
and the C-3 positions of betulinic acid is known to result in diverse 
potent biological activities.8e However, fused 1,2,3-triazole derivatives 
of these triterpenoids have not been investigated to date. Application 
of the present methodology to betulonic acid 152c, the 3-oxo 
derivative of betulinic acid, which has a 3-OH, led to rapid access to 
triazole ring-fused derivative 153c. To show the versatility of this novel 
approach of triazolization, a number of other terpenes were also 
converted into the desired NH-triazoles with good yields. Notably, the 
analogous allobetulone 152d underwent a similar transformation on 
the A-ring giving rise to the expected product 153d in excellent yield.8f 
Similarly, the anti-HIV agent platanic acid 152e also provided the 
expected product 153e, in 61% yield.8g Next, we addressed the 
functionalization of the male sex hormone analogue, 
dihydrotestosterone 152f, which gave the expected product 153f in 
high yield with excellent regioselectivity on the less hindered position. 
In a similar manner, cholesterol-derived oxysterols, cholestan-3-one 
152g underwent highly selective ring fusion at C2 and C3 carbon, 
providing 153g as the only regioisomer.  
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Table 7 Applications towards the synthesis of active pharmaceutical 
agents and supramolecular receptors 
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This novel triazolization strategy provides a convenient gateway to 
synthesize high value NH-1,2,3-triazole derivatives which are known to 
be active pharmaceutical agents, or potential supramolecular 
receptors in a single step from simple and readily available building 
blocks. The examples below highlight the synthetic advantages of our 
new method with respect to selected compounds of interest 156a–g, 
the synthesis of which often takes quite a bit of effort. Various 
commercially available acetophenone derivatives and indanone can 
be readily converted to the biologically relevant molecules 156a–c in a 
single step.1a,f Recently, a D-ring-fused NH-1,2,3-triazole derivative of 
estrogen 156d was reported to have potent antiproliferative activity 
without affecting healthy cells.1d Nevertheless, the downside of this 
work is the seven-step synthesis to yield the final compound 156d 
starting from the parent compound estrone 154d. Our approach is a 
truly elegant solution to this issue since we synthesized 156d in a single 
step from the same precursor 154d. Using the new triazolization 
methodology, we could synthesize an NH-triazole derivative of 
pregnenolone 156e which was recently identified as a contraceptive 
agent.1f A thirteen-step synthesis using the same starting material 
154e was previously followed for the synthesis of this compound. In a 
final venture to illustrate the potential efficiency of this strategy, we 
were able to apply the triazolization process to the synthesis of the 
well-known bi- and tridentate ligands 156f and 156g in a single step 
from commercially available acetyl pyridines 155f and 155g.2a,c  
3.3 Conclusion 
Given the importance of these ligands in supramolecular chemistry for 
various optoelectronic applications, we trust that this operationally 
simple strategy will make these materials readily available to the 
scientific community. In summary, the combination of enolizable 
ketones, nitrophenyl azide and NH4OAc is shown to be a powerful 
method to achieve various mono-, di- or fused NH-triazole derivatives, 
and we expect many future developments using this strategy. Novel 
and notable features of this tandem reaction include metal-free 
conditions, regiospecificity, and high functional group tolerance. 
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Extension of the protocol to the direct conversion of compounds 
containing multiple keto groups to the corresponding triazole 
heterocycles in a safe manner is especially notable. Importantly, this 
new reaction provides an operationally simple pathway for the 
triazolization of natural products containing enolizable ketone 
functionalities.  
 
3.4 Experimental Procedures 
3.4.1 General procedure for the preparation of substituted 
NH-1,2,3-triazoles 
To an oven-dried screw-capped reaction tube equipped with a 
magnetic stir bar were added the ketone, ammonium acetate, and 4-
nitrophenyl azide. The mixture was dissolved in DMF and stirred at 80 
°C for 12 - 24 h. Upon completion, the DMF was removed in vacuo and 
purified by column chromatography (silica gel), at first with CH2Cl2 as 
eluent to remove all 4-nitroaniline 4 formed during the reaction 
followed by using a mixture of heptane and ethyl acetate as eluent to 
afford the corresponding NH-1,2,3-triazole as off-white solids or semi-
solids. 
 
3.4.2 Experimental data 
4,5-Dihydro-1H-naphtho[1,2-d][1,2,3]triazole (148a): Tetralone (69 
mg, 0.47 mmol), ammonium acetate (180 mg, 2.35 mmol), 4-
nitrophenyl azide (100 mg, 0.61 mmol), and DMF (1 mL). Reaction time 
was 12 h. The product was purified by flash column chromatography 
(CH2Cl2 followed by heptane/EtOAc = 5:2) afforded 148a (69 mg, 86% 
yield) as an off-white solid. m.p. 113 - 114 ˚ C. 1H NMR (300 MHz, CDCl3) 
δ 7.90 - 7.88 (m, 1H), 7.34 - 7.27 (m, 3H), 3.12 - 3.05 (m, 4H). 13C NMR 
(75 MHz, CDCl3) δ 144.0, 143.2, 136.2, 128.7, 128.5, 127.5, 127.4, 
123.2, 29.2, 20.2. HRMS (ESI+): m/z calcd for C10H10N3 [M+H]+: 
172.0869, found 172.0865. Spectroscopic data for 3a are consistent 
with previously reported data for the compound.1 
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1,4,5,6-Tetrahydrobenzo[3,4]cyclohepta[1,2-d][1,2,3]triazole 
(148b): 6,7,8,9-Tetrahydro-5H-benzo[7]annulen-5-one (75 mg, 0.47 
mmol), ammonium acetate (180 mg, 2.35 mmol), 4-nitrophenyl azide 
(100 mg, 0.61 mmol), and DMF (1 mL). Reaction time is 12 h. The 
product was purified by flash column chromatography (CH2Cl2 
followed by heptane/EtOAc = 5:2) afforded 148b (70 mg, 81% yield) as 
an off-white solid. m.p. 173 - 174 ˚C. 1H NMR (400 MHz, MeOD) δ 7.91 
(d, J = 7.6 Hz, 1H), 7.19 – 7.07 (m, 3H), 2.96 (t, J = 6.7 Hz, 2H), 2.80 (t, J 
= 5.3 Hz, 2H), 1.97 – 1.91 (m, 2H). 13C NMR (100 MHz, MeOD) δ 141.9, 
130.9, 130.0, 129.0, 127.6, 36.2, 26.6, 25.2. HRMS (ESI+): m/z calcd for 
C11H11N3 [M+H]+: 186.1025, found 186.1033. 
1,4,5,6-Tetrahydrocyclopenta[d][1,2,3]triazole (148c): 
Cyclopentanone (40 mg, 0.47 mmol), ammonium acetate (180 mg, 
2.35 mmol), 4-nitrophenyl azide (100 mg, 0.61 mmol), and DMF (1 mL). 
Reaction time was 12 h. The product was purified by flash column 
chromatography (CH2Cl2 followed by heptane/EtOAc = 4:6) afforded 
148c (34 mg, 65% yield) as a colorless solid. m.p. 141 - 142 ˚C. 1H NMR 
(400 MHz, CDCl3) δ 2.81 (t, J = 7.4 Hz, 4H), 2.62 - 2.52 (m, 2H). 13C NMR 
(100 MHz, MeOD) δ 156.1, 29.4, 22.1. HRMS (ESI+): m/z calcd for 
C5H7N3 [M+H]+: 110.0712, found 110.0725. 
 
4,5,6,7-Tetrahydro-1H-benzo[d][1,2,3]triazole (148d): 
Cyclohexanone (46 mg, 0.47 mmol), ammonium acetate (180 mg, 2.35 
mmol), 4-nitrophenyl azide (100 mg, 0.61 mmol), DMF (1 mL). 
Reaction time is 12 h. The product was purified by flash column 
chromatography (DCM followed by hexane/EtOAc = 5:2) afforded 
148d (48 mg, 84% yield) as a colorless solid. m.p. 77 - 78 ˚C. 1H NMR 
(300 MHz, CDCl3) δ 2.76 (s, 4H), 1.86 (s, 4H). 13C NMR (75 MHz, CDCl3) 
δ 142.5, 142.4, 23.2, 21.6. HRMS (ESI+): m/z calcd for C6H10N3 [M+H]+: 
124.0869, found 124.0867. 
1,4,5,6,7,8-Hexahydrocyclohepta[d][1,2,3]triazole (148e): 
Cycloheptanone (53 mg, 0.47 mmol), ammonium acetate (180 mg, 
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2.35 mmol), 4-nitrophenyl azide (100 mg, 0.61 mmol), and DMF (1 mL). 
Reaction time is 12 h. The product was purified by flash column 
chromatography (CH2Cl2 followed by heptane/EtOAc = 4:6) afforded 
148e (47 mg, 72% yield) as a colorless solid. m.p. 83 - 84 ˚C. 1H NMR 
(600 MHz, CDCl3) δ 2.85 (t, J = 5.4 Hz, 4H), 1.89 – 1.85 (m, 2H), 1.73 – 
1.69 (m, 4H). 13C NMR (150 MHz, CDCl3) δ 146.6, 31.5, 27.5, 26.6. 
HRMS (ESI+): m/z calcd for C7H11N3 [M+H]+: 138.1025, found 138.1018. 
 
4,5,6,7,8,9-Hexahydro-1H-cycloocta[d][1,2,3]triazole (148f): 
Cyclooctanone (60 mg, 0.47 mmol), ammonium acetate (180 mg, 2.35 
mmol), 4-nitrophenyl azide (100 mg, 0.61 mmol), and DMF (1 mL). 
Reaction time is 12 h. The product was purified by flash column 
chromatography (CH2Cl2 followed by heptane/EtOAc = 4:6) afforded 
148f (65 mg, 91% yield) as a colorless semi-solid. 1H NMR (400 MHz, 
CDCl3) δ 2.89 (t, J = 6.4 Hz, 4H), 1.76 (sbr, 4H), 1.48 (sbr, 4H). 13C NMR 
(100 MHz, CDCl3) δ 143.8, 28.3, 25.5, 23.4. HRMS (ESI+): m/z calcd for 
C8H13N3 [M+H]+: 152.1182, found 152.1187.  
 
5-Benzyl-4,5,6,7-tetrahydro-1H-[1,2,3]triazolo[4,5-c]pyridine (148g): 
1-benzylpiperidin-4-one (88 mg, 0.47 mmol), ammonium acetate (180 
mg, 2.35 mmol), 4-nitrophenyl azide (100 mg, 0.61 mmol), and DMF (1 
mL). Reaction time is 12 h. The product was purified by flash column 
chromatography (CH2Cl2 followed by heptane/EtOAc = 1:1) afforded 
148g (78 mg, 78% yield) as an off white solid. m.p. 245 - 246 ˚C. 1H 
NMR (300 MHz, MeOD) δ 7.40 – 7.26 (m, 5H), 3.78 (s, 2H), 3.63 (s, 2H), 
2.89 - 2.81(m, 4H). 13C NMR (75 MHz, MeOD) δ 141.2, 139.8, 138.7, 
130.5, 129.5, 128.6, 62.7, 51.2, 49.9, 22.5. HRMS (ESI+): m/z calcd for 
C12 H14N4 [M+H]+: 215.1291, found 215.1290. 
 
5-Phenyl-1H-1,2,3-triazole (148h): Acetophenone (56 mg, 0.47 mmol), 
ammonium acetate (180 mg, 2.35 mmol), 4-nitrophenyl azide (100 mg, 
0.61 mmol), and DMF (1 mL). Reaction time is 12 h. The product was 
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purified by flash column chromatography (DCM followed by 
heptane/EtOAc = 5:2) afforded 148h (62 mg, 93% yield) as an off-white 
solid. m.p. 148 - 149 ˚C. 1H NMR (300 MHz, CDCl3) δ 7.8 (s, 1H), 7.85 - 
7.82 (m, 2H), 7.49 - 7.36 (m, 3H). 13C NMR (75 MHz, DMSO-d6) δ 147.5, 
129.9, 129.1, 128.9, 126.3. HRMS (ESI+): m/z calcd for C8H8N3 [M+H]+: 
146.0713, found 146.0716. Spectroscopic data for 3h are consistent 
with previously reported data for the compound.2 
 
5-(4-Methoxyphenyl)-1H-1,2,3-triazole (148i): 1-(4-
methoxyphenyl)ethan-1-one (71 mg, 0.47 mmol), ammonium acetate 
(180 mg, 2.35 mmol), 4-nitrophenyl azide (100 mg, 0.61 mmol), and 
DMF (1 mL). Reaction time is 24 h. The product was purified by flash 
column chromatography (CH2Cl2 followed by heptane/EtOAc = 4:6) 
afforded 148i (73 mg, 89% yield) as an off white semi-solid. m.p. 162 - 
163 ˚C. 1H NMR (300 MHz, MeOD) δ 8.03 (s, 1H), 7.74 (d, J = 8.8 Hz, 
2H), 6.99 (d, J = 8.8 Hz, 2H), 3.38 (s, 3H). 13C NMR (75 MHz, MeOD) δ 
161.4, 128.3, 123.5, 115.4, 55.7. HRMS (ESI+): m/z calcd for C9H9N3O 
[M+H]+: 176.0818, found: 176.0827.  
 
Methyl 4-(1H-1,2,3-triazol-5-yl)benzoate (148j): Methyl 4-
acetylbenzoate (83mg, 0.47 mmol), ammonium acetate (180 mg, 2.35 
mmol), 4-nitrophenyl azide (100 mg, 0.61 mmol), and DMF (1 mL). 
Reaction time is 12 h. The product was purified by flash column 
chromatography (CH2Cl2 followed by heptane/EtOAc = 4:6) afforded 
148j (75 mg, 80% yield) as an off white solid. m.p. 197.5 – 198.5 ˚C. 1H 
NMR (300 MHz, MeOD) δ 8.27 (s, 1H), 8.09 (d, J = 8.4 Hz, 2H), 7.97 (d, 
J = 8.4 Hz, 2H), 3.92 (s, 3H). 13C NMR (100 MHz, MeOD) δ 168.1, 136.2, 
131.2, 131.0, 126.7, 52.7; HRMS (ESI+): m/z calcd for C10H9N3O2 
[M+H]+: 204.0767, found: 204.0770.  
 
1-(4-(1H-1,2,3-Triazol-5-yl)phenyl)piperidine (148k): 1-(4-(piperidin-
1-yl)phenyl)ethan-1-one (95 mg, 0.47 mmol), Ammonium acetate (180 
mg, 2.35 mmol), 4-nitrophenyl azide (100 mg, 0.61 mmol), and DMF (1 
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mL). Reaction time is 24 h. The product was purified by flash column 
chromatography (CH2Cl2 followed by heptane/EtOAc = 1:1) afforded 
148k (68 mg, 64% yield) as an off white solid. m.p. 222 - 223 ˚C. 1H 
NMR (400 MHz, DMSO-d6) δ 8.09 (s, 1H), 7.67 (d, J = 8.4 Hz, 2H), 6.97 
(d, J = 8.6 Hz, 2H), 3.18 (Sbr, 4H), 1.61 – 1.58 (m, 6H). 13C NMR (75 MHz, 
DMSO-d6) δ 151.3, 146.6, 129.9, 126.5, 126.1, 115.6, 49.1, 25.1, 23.9. 
HRMS (ESI+): m/z calcd for C13H16N4 [M+H]+: 229.1447, found 
229.1435. 
 
5-(Thiophen-2-yl)-1H-1,2,3-triazole (148l): 1-(thiophen-2-yl)ethan-1-
one (60 mg, 0.47 mmol), ammonium acetate (180 mg, 2.35 mmol), 4-
nitrophenyl azide (100 mg, 0.61 mmol), and DMF (1 mL). Reaction time 
is 12 h. The product was purified by flash column chromatography 
(CH2Cl2 followed by heptane/EtOAc = 4:6) afforded 148l (51 mg, 71% 
yield) as an off white semi-solid. m.p. 67 - 68 ˚C. 1H NMR (300 MHz, 
CDCl3) δ 7.92 (s, 1H), 7.44 – 7.43 (m, 1H), 7.36 – 7.34 (m, 1H), 7.12 – 
7.09 (m, 1H). 13C NMR (75 MHz, CDCl3) δ 142.5, 132.1, 129.0, 127.9, 
126.0, 125.3. HRMS (ESI+): m/z calcd for C6H5N3S [M+H]+: 152.02769, 
found: 152.0276. 
 
3-(1H-1,2,3-Triazol-5-yl)-1H-indole (148m): 1-(1H-indol-3-yl)ethan-1-
one (74 mg, 0.47 mmol), ammonium acetate (180 mg, 2.35 mmol), 4-
nitrophenyl azide (100 mg, 0.61 mmol), and DMF (1 mL). Reaction time 
is 24 h. The product was purified by flash column chromatography 
(CH2Cl2 followed by heptane/EtOAc = 4:6) afforded 148m (80 mg, 92% 
yield) as an off white solid. m.p. 197.5 – 198.5 ˚C. 1H NMR (300 MHz, 
MeOD) δ 8.06 (s, 1H), 7.95 (d, J = 7.5 Hz, 1H), 7.70 (s, 1H), 7.43 (d, J = 
7.9 Hz, 1H), 7.22 – 7.12 (m, 2H). 13C NMR (75 MHz, MeOD) δ 138.2, 
126.3, 126.2, 124.4, 123.2, 121.1, 120.52, 112.6. HRMS (ESI+): m/z 
calcd for C10H8N4 [M+H]+: 185.08216, found:185.0828.  
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9-(4-(1H-1,2,3-Triazol-5-yl)phenyl)-3,6-di-tert-butyl-9H-carbazole 
(148n): 1-(4-(3, 6-di-tert-butyl-9H-carbazol-9-yl) phenyl) ethan-1-one 
(186 mg, 0.47 mmol), ammonium acetate (180 mg, 2.35 mmol), 4-
nitrophenyl azide (100 mg, 0.61 mmol), and DMF (1 mL). Reaction time 
is 24 h. The product was purified by flash column chromatography 
(CH2Cl2 followed by heptane/EtOAc = 6:4) afforded 148n (150 mg, 76% 
yield) as an off white solid. m.p. 130 - 131 ˚ C. 1H NMR (300 MHz, CDCl3) 
δ 8.15 (s, 2H), 8.06 (t, J = 8.4 Hz, 3H), 7.66 (d, J = 8.5 Hz, 2H), 7.48 – 
7.38 (m, 4H), 1.46 (s, 18 h). 13C NMR (75 MHz, CDCl3) δ 146.8, 143.2, 
139.1, 138.7, 129.6, 128.4, 127.6, 127.2, 123.8, 123.6, 116.4, 109.3, 
34.9, 32.1. HRMS (ESI+): m/z calcd for C28H30N4 [M+H]+: 423.2543, 
found 423.2527. 
 
4-Methyl-5-phenyl-1H-1,2,3-triazole (148o): propiophenone (62 mg, 
0.47 mmol), ammonium acetate (180 mg, 2.35 mmol), 4-nitrophenyl 
azide (100 mg, 0.61 mmol), and DMF (1 mL). Reaction time is 12 h. The 
product was purified by flash column chromatography (CH2Cl2 
followed by heptane/EtOAc = 6:4) afforded 148o (65 mg, 89% yield) as 
an off white solid. m.p. 142.5 – 143.5 ˚C. 1H NMR (400 MHz, CDCl3) δ 
7.72 (d, J = 7.3 Hz, 2H) 7.47 (t, J = 7.8 Hz, 2H), 7.39 (t, J = 7.4 Hz, 1H), 
2.55 (s, 3H). 13C NMR (75 MHz, CDCl3) δ 130.8, 128.9, 128.3, 127.4, 
11.7. HRMS (ESI+): m/z calcd for C9H9N3 [M+H]+: 160.0869, found 
160.0873.  
 
4-Methyl-5-(thiophen-2-yl)-1H-1,2,3-triazole (148p): 1-(thiophen-2-
yl)propan-1-one (66 mg, 0.47 mmol), ammonium acetate (180 mg, 
2.35 mmol), 4-nitrophenyl azide (100 mg, 0.61 mmol), and DMF (1 mL). 
Reaction time is 12 h. The product was purified by flash column 
chromatography (CH2Cl2 followed by heptane/EtOAc = 4:6) afforded 
148p (55 mg, 71% yield) as an off white semi-solid. m.p. 155 - 156 ˚C. 
1H NMR (300 MHz, CDCl3) δ 7.38 – 7.36 (m, 2H), 7.15 – 7.12 (m, 1H), 
2.56 (s, 3H). 13C NMR (75 MHz, CDCl3) δ 132.9, 127.8, 125.8, 125.3, 
96 
 
11.3. HRMS (ESI+): m/z calcd for C7H7N3S [M+H]+: 166.04334, found: 
166.0435. 
 
4-Ethyl-5-methyl-1H-1,2,3-triazole (148q) pentan-3-one (40 mg, 0.47 
mmol), ammonium acetate (180 mg, 2.35 mmol), 4-nitrophenyl azide 
(100 mg, 0.61 mmol), and DMF (1 mL). Reaction time is 12 h. The 
product was purified by flash column chromatography (CH2Cl2 
followed by heptane/EtOAc = 6:4) afforded 148q (38 mg, 72% yield) as 
a colorless semi-solid. 1H NMR (300 MHz, CDCl3) δ 2.73 – 2.66 (m, 2H), 
2.31(s, 3H), 1.30 – 1.25(t, J = 7.6 Hz, 3H). 13C NMR (75 MHz, CDCl3) δ 
145.4, 139.4, 17.8, 13.4, 9.6. HRMS (ESI+): m/z calcd for C5H9N3 
[M+H]+: 112.0869, found 112.0860.  
 
4-Butyl-5-methyl-1H-1,2,3-triazole (148r): heptan-2-one (53 mg, 0.47 
mmol ), ammonium acetate (180 mg, 2.35 mmol), 4-nitrophenyl azide 
(100 mg, 0.61 mmol), and DMF (1 mL). Reaction time is 12 h. The 
product was purified by flash column chromatography (CH2Cl2 
followed by heptane/EtOAc = 4:6) afforded 148r (57 mg, 88% yield) as 
an off white semi-solid. 1H NMR (300 MHz, CDCl3) δ 2.67 (t, J = 7.8 Hz, 
2H), 2.30 (s, 3H), 1.67 – 1.61 (m, 2H), 1.37 – 1.32 (m, 2H), 0.94 - 0.89 
(m, 3H). 13C NMR (75 MHz, CDCl3) δ 143.9, 139.4, 31.2, 24.0, 22.4, 13.9, 
9.6. HRMS (ESI+): m/z calcd for C7H13N3 [M+H]+: 140.11821, found: 
140.1190. 
 
5-Ethyl-4-propyl-1H-1,2,3-triazole (148s): heptan-3-one (53 mg, 0.47 
mmol), ammonium acetate (180 mg, 2.35 mmol), 4-nitrophenyl azide 
(100 mg, 0.61 mmol), and DMF (1 mL). Reaction time is 12 h. The 
product was purified by flash column chromatography (CH2Cl2 
followed by heptane/EtOAc = 6:4) afforded 148s (62 mg, 95% yield) as 
a colorless semi-solid. 1H NMR (600 MHz, CDCl3) δ 2.73 – 2.62 (m, 4H), 
1.76 – 1.64 (m, 2H), 1.29 (t, J = 7.6 Hz, 3H), 0.96 (t, J = 7.4 Hz, 3H). 13C 
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NMR (150 MHz, CDCl3) δ 145.3, 143.6, 26.4, 22.6, 17.9, 13.9, 13.7. 
HRMS (ESI+): m/z calcd for C7H13N3 [M+H]+: 140.1182, found 140.1196. 
 
1,3-Di(1H-1,2,3-triazol-5-yl)benzene (149): 1,3-diacetylbenzene ( 76 
mg, 0.46 mmol), ammonium acetate (360 mg, 4.70 mmol), 4-
nitrophenyl azide (200 mg, 1.2 mmol), and DMF (1 mL). Reaction time 
is 48 h. The product was purified by flash column chromatography 
(CH2Cl2 followed by heptane/EtOAc = 6:4) afforded 149 ( mg, 83% 
yield) as an off white solid. m.p. 238 - 239 ˚C. 1H NMR (400 MHz, 
DMSO - d6) δ 8.45 (s, 2H), 8.40 (s, 2H), 7.88 – 7.86 (m, 2H), 7.57 (t, J = 
7.7 Hz, 1H). 13C NMR (100 MHz, DMSO - d6) δ 162.3, 145.2, 131.1, 
129.6, 125.2, 122.6. HRMS (ESI+): m/z calcd for C10H8N6 [M+H]+: 
213.08831, found: 213.0887. 
 
1,2-Bis(2-(2-(1H-1,2,3-triazol-5-yl)phenoxy)ethoxy)ethane (150): 
1,1'-((((ethane-1,2-diylbis(oxy))bis(ethane-2,1-diyl))bis(oxy))bis(2,1-
phenylene))bis(ethan-1-one) (80 mg, 0.20 mmol), ammonium acetate 
(158 mg, 2 mmol), 4-nitrophenyl azide (90 mg, 0.56 mmol), and DMF 
(1 mL). Reaction Temperature 60˚C, and Reaction time is 4 d. The 
product was purified by flash column chromatography (CH2Cl2 
followed by heptane/EtOAc = 1:4) afforded 150 (36 mg, 41% yield) as 
an off white oily liquid. 1H NMR (400 MHz, CDCl3) δ 7:85 (s, 2H), 7.45 
(d, J = 7.6 Hz, 2H), 7.26 – 7.21 (m, 2H), 7.00 – 6.95 (m, 2H), 6.85 (d, J = 
8.2 Hz, 2H), 4.17 – 4.13 (m, 4H), 4.06 (s, 4H), 4.00 – 3.97 (m, 4H). 13C 
NMR (100 MHz, CDCl3) δ 162.7, 154.7, 133.8, 130.0, 127.8, 121.9, 
113.7, 70.3, 69.2, 67.4. HRMS (ESI+): m/z calcd for C22H24N6O4 [M+H]+: 
437.19316, found: 437.1922. 
 
9-(2-Ethylhexyl)-3,6-di(1H-1,2,3-triazol-5-yl)-9H-carbazole (151): 
1,1'-(9-(2-ethylhexyl)-9H-carbazole-3,6-diyl)bis(ethan-1-one) (121 mg, 
0.335 mmol), ammonium acetate (257 mg, 3.35 mmol), 4-nitrophenyl 
azide (139 mg, 0.84 mmol), and DMF (1 mL). Reaction time is 48 h. The 
product was purified by flash column chromatography (CH2Cl2 
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followed by heptane/EtOAc = 4:6) afforded 151 (99 mg, 72% yield) as 
an off white solid. m.p. 94 - 95 ˚C. 1H NMR (300 MHz, DMSO-d6) δ 8.74 
(s, 2H), 8.37 (s, 2H), 8.01 – 7.98 (m, 2H), 7.67 (d, J = 8.6 Hz, 2H), 4.31 
(d, J = 7.4 Hz, 2H), 1.37 – 1.14 (m, 9H), 0.87 (t, J = 7.3 Hz, 3H) – 0.78 (t, 
J = 7.3 Hz, 3H). 13C NMR (100 MHz, DMSO-d6) δ 162.3, 146.1, 140.7, 
124.0, 122.4, 121.5, 117.7, 110.1, 46.7, 38.7, 30.2, 28.0, 23.7, 22.5, 
13.8, 10.7. HRMS (ESI+): m/z calcd for C24 h27N7 [M+H]+: 414.24005, 
found 414.2405. 
 
2-Methoxy-5-(1H-1,2,3-triazol-5-yl)phenol (153a): 1-(3-hydroxy-4-
methoxyphenyl)ethan-1-one (78 mg, 0.47 mmol), ammonium acetate 
(180 mg, 2.35 mmol), 4-nitrophenyl azide (100 mg, 0.61 mmol), and 
DMF (1 mL). Reaction time is 24 h. The product was purified by flash 
column chromatography (CH2Cl2 followed by heptane/EtOAc = 4:6) 
afforded 153a (74 mg, 82% yield) as an off white solid. m.p. 156 – 157 
˚C. 1H NMR (300 MHz, DMSO - d6) δ 8.18 (s, 1H), 7.39 (s, 1H), 7.26 (d, J 
= 8.1 Hz, 1H), 6.83 (d, J = 8.1 Hz, 1H), 3.83 (s, 3H). 13C NMR (75 MHz, 
DMSO - d6) δ 148.0, 146.8, 118.5, 115.8, 109.7, 55.7. HRMS (ESI+): m/z 
calcd for C9H9N3O2 [M+H]+: 192.07674, found 192.0761. 
 
8-Methoxy-4-phenyl-1,4-dihydrochromeno[3,4-d][1,2,3]triazole 
(153b): 6-methoxy-2-phenylchroman-4-one (119 mg, 0.47 mmol), 
ammonium acetate (180 mg, 2.35 mmol), 4-nitrophenyl azide (100 mg, 
0.61 mmol), and DMF (1 mL). Reaction time is 12 h. The product was 
purified by flash column chromatography (CH2Cl2 followed by 
heptane/EtOAc = 6:4) afforded 153b (112 mg, 85% yield) as an off 
white solid. m.p. 175 - 176 ˚C. 1H NMR (300 MHz, CDCl3) δ 7.47 – 
7.31(m, 6H), 7.00 (d, J = 8.9 Hz, 1H), 6.87 – 6.83 (m, 1H), 6.52 (s, 1H), 
3.82 (s, 3H). 13C NMR (75 MHz, CDCl3) δ 155.0, 147.6, 142.8, 139.5, 
138.6, 129.0, 128.8, 127.2, 118.9, 117.2, 116.3, 107.2, 75.9, 57.0. 
HRMS (ESI+): m/z calcd for C16H13N3O2 [M+H]+: 280.1080, found 
280.1075. 
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(1R,3aS,5aR,5bR,7aR,12aR,12bR,14aR,14bR)-5a,5b,8,8,12a-
Pentamethyl-1-(prop-1-en-2-yl)-
2,3,4,5,5a,5b,6,7,7a,8,9,12,12a,12b,13,14,14a,14b-
octadecahydrocyclopenta[7,8]chryseno[2,3-d][1,2,3]triazole-3a(1H)-
carboxylic acid (153c): Betulonic acid (213 mg, 0.47 mmol), 
ammonium acetate (180 mg, 2.35 mmol), 4-nitrophenyl azide (100 mg, 
0.61 mmol), and DMF (1 mL). Reaction time is 24 h. The product was 
purified by flash column chromatography (CH2Cl2 followed by 
heptane/EtOAc = 2:8) affording 153c (195 mg, 87% yield) as an off-
white solid. m.p. 146 - 147 ˚C. 1H NMR (300 MHz, CDCl3) δ 4.76 (s, 1H), 
4.63 (s, 1H), 3.06 - 2.87 (m, 2H), 2.33 - 1.98 (m, 6H), 1.79 (s, 3H), 1.71 - 
1.43 (m, 14H), 1.31 - 1.29 (m, 4H), 1.20 – 1,22 (m, 4H), 1,01 (s, 3H), 
0.99 (s, 3H), 0.78 (s, 3H). 13C NMR (75 MHz, CDCl3) δ 181.0, 150.6, 
149.3, 139.9, 109.8, 56.5, 53.6, 49.3, 49.2, 47.0, 42.6, 40.9, 39.2, 38.5, 
37.4, 37.2, 33.4, 32.3, 31.0, 30.7, 29.9, 25.6, 23.8, 21.5, 19.5, 19.3, 16.4, 
15.8, 14.8. HRMS (ESI+): m/z calcd for C30H46N3O2 [M+H]+: 480.3584; 
found 480.3580. 
 
(1R,4aR,6aR,6bR,8aR,13aR,13bR,15aR,15bR)-2,2,6a,6b,9,9,13a-
heptamethyl-
1,2,3,4,5,6,6a,6b,7,8,8a,9,10,13,13a,13b,14,15,15a,15b-icosahydro-
1,4a-(epoxymethano)piceno[2,3-d][1,2,3]triazole (153d): 
Allobetulone (206 mg, 0.47 mmol), ammonium acetate (180 mg, 2.35 
mmol), 4-nitrophenyl azide (100 mg, 0.61 mmol), and DMF (1 mL). 
Reaction time is 24 h. The product was purified by flash column 
chromatography (CH2Cl2 followed by heptane/EtOAc = 4:6) afforded 
153d (204 mg, 94% yield) as an off white solid. m.p. above 300 ˚C. 1H 
NMR (400 MHz, CDCl3) δ 3.81 (d, J = 7.2 Hz, 1H), 3.58 (s, 1H), 3.47 (d, J 
= 7.8 Hz, 1H), 2.94 (d, J = 15.5 Hz, 1H), 2.16 (d, J = 15.5 Hz, 1H), 1.61 – 
1.56 (m, 6H), 1.53 – 1.50 (m, 4H), 1.49 – 1.42 (m, 3H), 1.39 – 1.32 (m, 
7H), 1.29 – 1.23 (m, 5H), 1.19 – 1.55(m, 1H), 1.04 (s, 3H), 0.95 (d, J = 
2.4 Hz, 6H), 0.82 (s, 6H). 13C NMR (100 MHz, CDCl3) δ 149.8, 140.3, 
88.1, 71.4, 53.7, 49.8, 46.9, 41.6, 40.9, 40.8, 39.2, 37.7, 36.8, 36.4, 34.4, 
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33.5, 33.0, 32.8, 31.2, 29.0, 26.6, 26.5, 26.3, 24.7, 23.9, 21.6, 19.2, 16.7, 
15.5, 13.6. HRMS (ESI+): m/z calcd for C30H47N3O [M+H]+: 466.3791 , 
found 466.3799. 
 
(1R,3aS,5aR,5bR,9S,11aR)-9-hydroxy-5a,5b,8,8,11a-pentamethyl-1-
(1H-1,2,3-triazol-5-yl)icosahydro-3aH-cyclopenta[a]chrysene-3a-
carboxylic acid (153e): Platanic acid (215 mg, 0.47 mmol), ammonium 
acetate (180 mg, 2.35 mmol), 4-nitrophenyl azide (100 mg, 0.61 
mmol), and DMF (1 mL). Reaction time is 24 h. The product was 
purified by flash column chromatography (CH2Cl2 followed by 
heptane/EtOAc = 4:6) afforded 153e (139 mg, 61% yield) as an off 
white solid. m.p. above 300 ˚ C. 1H NMR (400 MHz, DMSO – d6) δ 7.57(s, 
1H), 4.23 (d, J = 4.9 Hz, 1H), 3.62 – 3.57 (m, 1H), 2.96 – 2.89 (m, 1H), 
2.24 – 2.03 (m, 3H), 1.90 – 1.82 (m, 2H), 1.76 – 1.67 (m, 1H), 1.50 – 
1.41 (m, 7H), 1.33 – 1.31 (m, 2H), 1.18 – 1.05 (m, 5H), 0.89 (s, 3H), 0.86 
(s, 6H), 0.81 – 0.76 (m, 1H), 0.73 (s, 3H), 0.64 (s, 3H), 0.61 – 0.59 (m, 
1H), 0.46 – 0.43 (m, 1H). 13C NMR (100 MHz, DMSO-d6 + TFA, 1drop) δ 
177.7, 150.5, 127.4, 77.4, 55.9, 55.3, 53.7, 50.1, 42.3, 40.6, 38.7, 37.9, 
37.1, 35.1, 34.3, 33.0, 29.6, 28.4, 27.4, 26.6, 20.8, 18.3, 16.2, 16.1, 16.1, 
14.6. HRMS (ESI+): m/z calcd for C29H45N3O3 [M+H]+: 484.35334 , found 
484.3522. 
 
(1S,3aS,3bR,5aS,10aS,10bS,12aS)-10a,12a-dimethyl-
1,2,3,3a,3b,4,5,5a,6,7,10,10a,10b,11,12,12a-
hexadecahydrocyclopenta[7,8]phenanthro[2,3-d][1,2,3]triazol-1-ol 
(153f): Dihydrotestosterone (136 mg, 0.47 mmol), ammonium acetate 
(180 mg, 2.35 mmol), 4-nitrophenyl azide (100 mg, 0.61 mmol), and 
DMF (1 mL). Reaction time is 12 h. The product was purified by flash 
column chromatography (CH2Cl2 followed by heptane/EtOAc = 4:6) 
afforded 153f (142 mg, 96% yield) as an off white semi-solid. m.p. 174 
- 175 ˚C. 1H NMR (400 MHz, DMSO-d6) δ 4.83(sbr, 1H), 3.44 (t, J = 8.6Hz, 
1H), 2.70 – 2.57 (m, 2H), 2.22 – 2.16(m, 2H), 1.88 – 1.76 (m, 2H), 1.67 
101 
 
– 1.47 (m, 5H), 1.39 – 1.30 (m, 4H), 1.23 – 1.13 (m, 2H), 1.04 – 0.97 (m, 
1H), 0.93 – 0.85 (m, 3H), 0.67 (s, 3H), 0.65 (s, 3H). 13C NMR (100 MHz, 
MeOD) δ 139.8, 138.7, 82.5, 52.1, 49.8, 44.0, 43.2, 38.1, 38.0, 37.9, 
37.0, 35.0, 32.2, 30.6, 29.8, 25.2, 24.3, 22.0, 11.9, 11.6. HRMS (ESI+): 
m/z calcd for C19H29N3O [M+H]+: 316.23832, found 316.2390. 
 
(1R,3aS,3bR,5aS,10aS,10bS,12aR)-10a,12a-dimethyl-1-((R)-6-
methylheptan-2-yl)-1,2,3,3a,3b,4,5,5a,6,7,10,10a,10b,11,12,12a-
hexadecahydrocyclopenta[7,8]phenanthro[2,3-d][1,2,3]triazole 
(153g) : Cholestan-3-one (181 mg, 0.47 mmol), ammonium acetate 
(180 mg, 2.35 mmol), 4-nitrophenyl azide (100 mg, 0.61 mmol), and 
DMF (1 mL). Reaction time is 12 h. The product was purified by flash 
column chromatography (CH2Cl2 followed by heptane/EtOAc = 4:6) 
afforded 153g (169 mg, 88% yield) as an off white solid. m.p. 170 – 171 
˚C. 1H NMR (400 MHz, CDCl3) δ 2.84 (d, J = 15.9 Hz, 1H), 2.74 – 2.69 (m, 
1H), 2.37 – 2.29 (m, 2H), 2.07 – 2.02 (m, 1H), 1.86 – 1.80 (m, 1H), 1.75 
– 1.71 (m, 1H), 1.63 – 1.57 (m, 3H), 1.54 – 1.47 (m, 2H), 1.39 – 1.32 (m, 
4H), 1.27 – 1.22 (m, 4H), 1.16 – 1.09 (m, 5H), 1.06 – 0.98 (m, 3H), 0.95 
– 0.91 (m, 4H), 0.87 (d, J = 1.7 Hz, 3H), 0.86 (d, J = 1.7 Hz, 3H), 0.75 (s, 
3H), 0.69 (s, 3H). 13C NMR (100 MHz, CDCl3) δ 142.7, 141.7, 56.5, 56.4, 
53.9, 42.6, 42.6, 40.1, 39.7, 37.0, 36.3, 35.9, 35.7, 35.6, 31.8, 29.3, 28.4, 
28.1, 25.9, 24.4, 24.0, 23.0, 22.7, 21.4, 18.8, 12.1, 11.8. HRMS (ESI+): 
m/z calcd for C27H45N3 [M+H]+: 412.36860, found 412.3675. 
 
5-chloro-2-(1H-1,2,3-triazol-5-yl)phenol (156a): 1-(4-chloro-2-
hydroxyphenyl) ethan-1-one (80 mg, 0.47 mmol), ammonium acetate 
(180 mg, 2.35 mmol), 4-nitrophenyl azide (100 mg, 0.61 mmol), and 
DMF (1 mL). Reaction time is 24 h. The product was purified by flash 
column chromatography (CH2Cl2 followed by heptane/EtOAc = 6:4) 
afforded 156a (71 mg, 77% yield) as an off white solid. m.p. 76 - 77 ˚C. 
1H NMR (300 MHz, DMSO-d6) δ 8.31 (s, 1H), 7.91 (s, 1H), 7.24 – 7.20 
(m, 1H), 6.99 (d, J = 8.7 Hz, 1H). 13C NMR (75 MHz, DMSO-d6) δ 153.1, 
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128.4, 126.2, 122.9, 117.8. HRMS (ESI+): m/z calcd for C8H6ClN3O 
[M+H]+: 196.0272, found 196.0268. 
 
5-(3,4-dibromophenyl)-1H-1,2,3-triazole (156b): 1-(3,4-
dibromophenyl)ethan-1-one (129 mg, 0.47 mmol), ammonium acetate 
(180 mg, 2.35 mmol), 4-nitrophenyl azide (100 mg, 0.61 mmol), and 
DMF (1 mL). Reaction time is 24 h. The product was purified by flash 
column chromatography (CH2Cl2 followed by heptane/EtOAc = 6:4) 
afforded 156b (112 mg, 80% yield) as an off white solid. m.p. 163 - 164 
˚C. 1H NMR (300 MHz, DMSO-d6) δ 8.52 (s, 1H), 8.25 (s, 1H), 7.87 - 7.80 
(m, 2H). 13C NMR (75 MHz, DMSO-d6) δ 134.3, 131.8, 130.2, 126.1, 
124.5, 123.0. HRMS (ESI+): m/z calcd for C8H5Br2N3 [M+H]+: 301.8924, 
found 301.8926.  
 
3,8-dihydroindeno[1,2-d][1,2,3]triazole (156c): 1-Indanone (61 mg, 
0.47 mmol), ammonium acetate (180 mg, 2.35 mmol), 4-nitrophenyl 
azide (100 mg, 0.61 mmol), and DMF (1 mL). Reaction time is 12 h. The 
product was purified by flash column chromatography (CH2Cl2 
followed by heptane/EtOAc = 4:6) afforded 156c (55 mg, 75% yield) as 
an off white semi-solid. m.p. 121 – 122 ˚C. 1H NMR (400 MHz, DMSO-
d6) δ 7.72 (d, J = 7.4 Hz, 1H), 7.60 (d, J = 7.4 Hz, 1H), 7.42 – 7.32 (m, 
2H), 3.81(s, 2H). 13C NMR (75 MHz, DMSO-d6) δ 154.0, 148.2, 133.0, 
128.4, 127.3, 121.5, 28.6. HRMS (ESI+): m/z calcd for C9H7N3 [M+H]+: 
158.07127, found 158.0697.  
 
(6bS,8aS,12aS,12bR)-8a-methyl-1,2,6b,7,8,8a,9,12,12a,12b-
decahydronaphtho[2',1':4,5]indeno[1,2-d][1,2,3]triazol-4-ol (156d): 
Estrone (127 mg, 0.47 mmol), ammonium acetate (180 mg, 2.35 
mmol), 4-nitrophenyl azide (100 mg, 0.61 mmol), and DMF (1 mL). 
Reaction time is 48 h. The product was purified by flash column 
chromatography (CH2Cl2 followed by heptane/EtOAc = 4:6) afforded 
156c (112 mg, 81% yield) as an off white semi-solid. m.p. 264 – 265 ˚C. 
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1H NMR (400 MHz, DMSO-d6) δ 7.06 (d, J = 8.5 Hz, 1H), 6.54 – 6.52 (m, 
1H), 6.47 (1H, J = 2.4 Hz, 1H), 2.86 – 2.67 (m, 3H), 2.45 – 2.26 (m, 3H), 
2.19 – 2.09 (m, 2H), 1.92 – 1.88 (m, 1H), 1.81 – 1.71 (m, 1H), 1.69 – 
1.63 (m, 1H), 1.59 – 1.49 (m, 1H), 1.47 – 1.35 (m, 1H), 1.26 – 1.16 (m, 
1H), 0.94 (s, 3H). 13C NMR (100 MHz, MeOD) δ 161.3, 156.0, 151.2, 
137.0, 130.1, 125.8, 115.0, 112.8, 60.7, 43.8, 39.2, 37.1, 33.8, 29.0, 
27.0, 25.7, 23.1, 18.3. HRMS (ESI+): m/z calcd for C18 h21N3O [M+H]+: 
296.17572, found 296.1757.  
 
(3S,8S,9S,10R,13S,14S,17S)-17-((S)-4,5-dihydro-1H-1,2,3-triazol-5-
yl)-10,13-dimethyl-2,3,4,7,8,9,10,11,12,13,14,15,16,17-
tetradecahydro-1H-cyclopenta[a]phenanthren-3-ol (156e): 
Pregnenolone (148 mg, 0.47 mmol), ammonium acetate (180 mg, 2.35 
mmol), 4-nitrophenyl azide (100 mg, 0.61 mmol), and DMF (1 mL). 
Reaction time is 24 h. The product was purified by flash column 
chromatography (CH2Cl2 followed by heptane/EtOAc = 4:6) afforded 
156e (110 mg, 69% yield) as an off white semi-solid. m.p. 237-238 ˚C. 
1H NMR (300 MHz, DMSO – d6 + TFA, 1 drop) δ 7.85 (s, 1H), 5.31 (s, 
1H), 3.32 – 3.23 (m, 1H), 2.82 – 2.75 (m, 1H), 2.20 – 1.92 (m, 4H), 1.77 
– 1.55 (m, 5H), 1.45 – 1.18 (m, 7H), 1.03 – 0.86 (m, 6H), 0.49 – 0.43 (m, 
3H). 13C NMR (100 MHz, MeOD) δ 142.3, 142.2, 122.3, 72.4, 57.3, 51.8, 
51.4, 44.9, 43.0, 38.6, 37.8, 33.7, 33.3, 33.0, 32.3, 27.7, 25.5, 22.0, 19.9, 
13.5. HRMS (ESI+): m/z calcd for C21H31N3O [M+H]+: 342.25397, found 
342.2545. 
 
2-(1H-1,2,3-triazol-5-yl)pyridine (156f): 2-Acetopyridine (57 mg, 0.47 
mmol), ammonium acetate (180 mg, 2.35 mmol), 4-nitrophenyl azide 
(100 mg, 0.61 mmol), and DMF (1 mL). Reaction time is 12 h. The 
product was purified by flash column chromatography (CH2Cl2 
followed by heptane/EtOAc = 4:6) afforded 156f (61 mg, 89% yield) as 
an off white solid. m.p. 142 - 143 ˚C. 1H NMR (300 MHz, MeOD) δ 8.58 
(d, J = 8 Hz, 1H), 8.30 (s, 1H), 8.03 (d, J = 8 Hz, 1H), 7.93 – 7.87 (m, 1H), 
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7.93 – 7.34 (m, 1H). 13C NMR (75 MHz, CDCl3) δ 149.7, 137.4, 126.1, 
124.7, 123.5, 121.1. HRMS (ESI+): m/z calcd for C7H6N4 [M+H]+: 
147.06651, found 147.0663.  
 
2,6-di(1H-1,2,3-triazol-5-yl)pyridine (156g): 2,6-Diacetylpyridine (77 
mg, 0.47 mmol), ammonium acetate (360 mg, 4.70 mmol), 4-
nitrophenyl azide (200 mg, 1.22 mmol), and DMF (1 mL). Reaction time 
is 48 h. The product was purified by flash column chromatography 
(CH2Cl2 followed by heptane/EtOAc = 4:6) afforded 12g (70 mg, 70% 
yield) as an off white semi-solid. m.p. 158 - 159 ˚C. 1H NMR (400 MHz, 
DMSO-d6) δ 8.53 (s, 2H), 8.03 - 7.94 (m, 3H). 13C NMR (75 MHz, DMSO-
d6) δ 149.6, 145.7, 138.9, 128.6, 119.6. HRMS (ESI+): m/z calcd for 
C9H7N7 [M+H]+: 214.0835, found 214.0838. Spectroscopic data for 
156g are consistent with previously reported data for the compound.9 
3.4.3 Bulk synthesis of NH-1,2,3-triazole 148a 
 
 
To a 100 mL round-bottom flask equipped with a magnetic stir bar was 
added an equivalent of 146a (2 g, 13.7 mmol), ammonium acetate (5.2 
g, 68.5 mmol), 131a (2.9 g, 17.7 mmol). The mixture was dissolved in 
anhydrous DMF (20 mL) and stirred at 80 °C for 12 hr. Upon 
completion, the solvent was evaporated off and the resulting reaction 
mixture was diluted with ethyl acetate (3x 200 mL), washed with 
water, dried over MgSO4 and evaporated under reduced pressure. The 
residue was further purified by column chromatography (silica gel), at 
first with CH2Cl2 as eluent to remove of all 4-nitroaniline formed during 
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the reaction followed by using a mixture of heptane/EtOAc = 5:2 as 
eluent to afford 148a (1.92 g, 82%) as an off-white solid. 
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Chapter 4 
A one-pot procedure for the synthesis of “click-ready” 
triazoles from ketones   
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4.1 Introduction 
The propargyl group is a key functional group which is widely used in 
forefront research for various applications in organic, medicinal, and 
material chemistry.1a-f For instance, propargyl derivatives have been 
used as essential starting materials to synthesize various heterocyclic 
moieties such as triazole, indole, imidazole, and pyrazoline via C-C, or 
C-X (X= O and N) bond formation reactions.1a-f Propargyl moieties are 
also used as starting points in various metathesis and oligomerization 
reactions.2b In medicinal chemistry, this group has been found to be a 
key functionality in various biologically active molecules. Of the 
compounds shown in figure 8, Rasagiline a and slegiline b are 
monoamine oxidase inhibitors and also they are known as commercial 
drugs for Parkinson disease,2c the showdomycin probe c is attached to 
a fluorophore to identify diverse enzymes,2d the duocarmycin  
derivative d exhibits antitumor activity,2e and arylsulfonyl-NH-1,2,3-
triazole e  is a VIM-2 β-lactamase inhibitor (Figure 8).2g Moreover, 
propargyl group functionalized drug molecules are widely used as 
bioorthogonal tags for detecting drug like activities in cells by 
spontaneous Raman spectroscopic techniques.2h 
 
 
Figure 8 Illustration of pharmaceutically active propargyl moieties. 
 
1,2,3-Triazoles are of great importance in organic synthesis due to 
their higher stability towards biodegradationin comparison to their 
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isosteres such as amide bonds.2a Cu(I)- and Ru(II)-catalyzed 
regioselective azide alkyne cycloaddition reactions are widely used to 
synthesize 1,4- and 1,5-disubstituted 1,2,3-triazoles, respectively.4  
Considering the importance of the triazole moieties several analogous 
methodologies have been discovered.4,5 Interestingly, the N-
substituted propargyl triazoles are scarcely reported. This could be due 
to the instability of propargyl azide even at room temperature.6 
However, in 2010 Shi and co-workers have reported an iron(III)-
catalyzed procedure for the preparation of propargyl substituted 
triazoles starting from NH-triazoles and propargyl alcohols (scheme 
31, equation 2).7 Unfortunately, the scope of this reaction is limited 
due to the lack of regioselectivity. Consequently, a cost effective and a 
general methodology from readily available building blocks is desired 
to functionalize triazole heterocycles with propargyl functionalities. 
Such compounds would be very useful to click a second moiety to the 
triazole. 
 
Scheme 31. Three distinct approaches to N-substituted propargyl 1,2,3-
triazole 
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Very recently, we have developed a potent triazolization strategy 
towards the synthesis of 1,5–disubstituted or fused 1,2,3-triazole form 
commercially available ketones and amines.3 Our initial attempts to 
synthesize the propargyl substituted triazole by this method resulted 
in a complicated reaction mixture which could be due to elevated 
temperature (100 °C) used in this reaction. A careful analysis and 
separation of this crude reaction mixture resulted in the isolation of 
15% of the bis-triazole derivative 159, which was derived from the 
thermal cycloaddition reaction of 4-nitrophenyl azide 131a with the 
propargyl group before or after the triazolization reaction (Scheme 
32). However, from the mechanistic study of our previous 
triazolization reaction, it was evident that enamine formation was the 
rate determining step which usually requires 100 °C to proceed at a 
workable speed. Thus, we assumed that the presence of Lewis acid 
catalyst could increase the reaction rate by activating the keto group 
at comparatively lower temperature and the subsequent triazolization 
reaction could also proceed under these relative mild conditions.  
 
Scheme 32 Formation of undesired bis-triazole. 
4.2 Results and discussions 
In order to prove this hypothesis, we initiated our studies with 
cyclohexanone (1 equiv.), propargyl amine (2 equiv.), and 4-
nitrophenyl azide (1.4 equiv.) as standard substrates. Interestingly, 
initial screening of 10 mol% Sc(OTf)3 in CH2Cl2 at 40 °C afforded the 
triazolization product up to 39% yield after 24 h (entry 1, Table 1). 
Inspired by this result, several Lewis acid catalysts such as Fe(OTf)3, 
Zn(OTf)2, BF3.OEt2, and Zn(OAc)2 were screened in our model reactions 
(entry 2-5, Table 8). Among these. Zn(OAc)2 showed the best catalytic 
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activity which gave the expected product in 54% of isolated yield (entry 
5, Table 8). A gradual increase in the yield was observed when the 
amount of Zn(OAc)2 was increased from 10 to 100 mol% (entry 5-7, 
Table 8). 
 
 Entry catalyst 
(mol%) 
temp 
(°C) 
solvent Time 
(h) 
Yieldb 
(%) 
1 Sc(OTf)3 (10 mol% ) 40 DCM 24 39 
2 Fe(OTf)3 (10 mol% ) 40 DCM 24 43 
3 Zn(OTf)2 (10 mol% ) 40 DCM 24 52 
4 BF3.OEt2 (10 mol%) 40 DCM 24 32 
5 Zn(OAc)2 (10 mol% ) 40 DCM 24 54 
6 Zn(OAc)2 (50 mol% ) 40 DCM 24 62 
7 Zn(OAc)2 (100 mol%) 40 DCM 24 67 
8 Zn(OAc)2 (100 mol%) 40 DMF 24 66 
9 Zn(OAc)2 (100 mol%) 60 DMF 10 75 
10 Zn(OAc)2 (100 mol%) 70 DMF 6 61 
11 Zn(OAc)2 (100 mol%) 60 Ethanol 10 28 
12 Zn(OAc)2 (100 mol%) 60 THF 10 62 
13 Zn(OAc)2 (100 mol%) 60 DMSO 10 51 
14 Zn(OAc)2( 100 mol%) 60 EtOH 10 13 
15 no 60 DMF 10 23 
 
Table 8 Optimization of reactions conditionsa 
[a]Standard reaction condition: 1 equiv. of cyclohexanone 129, 2 equiv. of 
propargyl amine 157, 1.4 equivalent of 4- nitrophenyl azide 131a, 40 mg of 
4Å MS and 1 equiv. Zn(OAc)2 were mixed in 0.2 mL solution of DMF at 60 °C. 
[b]Isolated yield. 
Interestingly, a slight improvement in the yield was observed when we 
replaced CH2Cl2 with DMF (entry 8, Table 8). Further investigation 
showed that this reaction is highly temperature dependent, increasing 
temperature from 40 to 60 ˚C in DMF resulted in 75% yield after 10 h 
(entry 9, Table 8) whereas an increase in temperature from 60 to 70 ˚C 
resulted in diminished yield (61%, entry 10, Table 8). Among the tested 
solvents, DMF and CH2Cl2 gave best result whereas DMSO, THF and 
ACN gave moderate yield and protic solvent such as EtOH afforded 
114 
 
lower yield. As expected, a small amount of desired product was 
obtained while performing the reaction without any Lewis acid 
catalyst (entry 15, Table 8). We found that cyclohexanone, propargyl 
amine, and 4-nitrophenyl azide 3 in a respective molar ratio of 1:2:1.4 
using 1 equiv. of Zn(OAc)2 in a 2.5 molar solution of DMF over a period 
of 10 h at 60 °C afforded 5 in 75% yield. 
 
 
Table 9 Substrate scope with respect to a variety of ketonesa 
[a]reaction conditions: 135 (1 equiv.), 164 (2 equiv.), 137a (1.4 equiv.), Zn(OAc)2 (1 
equiv.), DMF (0.4 mL), 60 °C, 10 h, Isolated yields. [b]8 h, [c]24 h. [d]40 °C, 24 h. 
[e]36 h. 
With these optimized conditions in hand, the scope of this 
triazolization reactions was investigated. An array of cyclic ketones 
were employed in the optimized reaction condition which afforded the 
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propargyl functionalized triazole derivatives 158a – 158f in good yields 
regardless of the size of cyclic ketones (Table 9). Similarly, screening of 
different aromatic bicyclic ketones also leads to the corresponding 
products 158g – 158j in excellent yield (Table 9). It is worth mentioning 
that high regioselectivity was observed for the product 158g derived 
from 2-tetralone (Table 9).   Evidently, the product formation occurs 
through the cycloaddition of azide with the more stable enamine 
conjugated to the aromatic ring.  
Next, we investigated the scope of the reaction with respect to acetyl 
substituted aromatic hydrocarbons such as acetophenone and 3-acetyl 
phenanthrene which delivered moderate yields of the expected 
products under the optimized reaction circumstances (158k & 158l) 
(Table 9). The extension of this protocol to symmetrical acyclic ketones 
resulted in the formation of 1,4,5-trisubstituted 1,2,3-triazoles in good 
yield (158m & 158n) (Table 9). The utility of this reaction is further 
proved in heterocycles of interest in material research such as 
dibenzofuran and carbazole. Thus, this triazolization strategy 
decorated these useful heterocycles with propargyl groups (158o & 
158p) (Table 9) in good yield even though these reactions required 
longer reaction time than the previously optimized conditions. 
Modification of natural products such as alkaloids, nucleosides, and 
steroids with propargyl groups for various applications such as Cu(I) 
triggered immobilization are of common interest in the area of 
medicinal chemistry.2a By taking into account the fact that enolizable 
ketones are abundantly available in various natural products, this 
protocol provides an easy pathway for the functionalization of natural 
products with a ‘clickable’ propargyl group. The application of this 
methodology to dihydrotestosterone 129q, an androgen hormone, led 
to highly regioselective 2,3-A ring fused triazole 158q in good yield. In 
a similar manner, cholesterol-derived cholestan-3-one 129r under this 
reaction circumstances afforded the A-ring fused triazole 158r in good 
yield (Scheme 33).  
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Scheme 33 Substrate scope with respect to the natural products 
Thus, in order to prove the usefulness of these propargyl substituted 
triazoles, a series of bis-triazole derivatives 160a – 160g (Table 10) 
have been prepared via CuAAc click reaction. Although there are 
several reports on C-C and N-N linked bis-triazoles formation, a 
suitable methodology for formation of N-C linked unsymmetrical bis-
triazoles was still lacking.8 Here we report for the first time a N-C linked 
bis-triazole hybrid of porphyrin and carbazole 160a (entry 1). 
Barthélémy et al. reported that the uptake of oligonucleotide 
increased manyfold across the cell membrane when it is attached with 
lipophilic cholesterol with triazole linkage.9 As a possible alternative to 
this previously reported synthetic strategy, we also developed a bis-
triazole linked compound 160b derived from azidothymidine (AZT) 
159b and propargyl derived cholestan-3-one 158r in a straightforward 
manner (entry 2).  The amphiphilic cholesterol derivative 160c has 
been prepared in good yield from cholesterol 158r and tri-ethylene 
glycol azide 159c (entry 3).10  The propargyl substituted steroid 158q 
was further functionalized with azido sugar 159d, leading to a new 
type of bis-triazole hybrid system 160d in excellent yield (entry 4). The 
sugar azide 159e also coupled with propargyl triazole 158k to give 
160e in excellent yield (entry 5). 
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Table 10 Synthesis of N-C linked unsymmetrical bis-triazole derivatives:a 
[a]158 (1 equiv.), 159 (1.2 equiv.), CuSO4 (0.05 equiv.), Na-Ascorbate (0.11 
equiv.), rt, 12 h, isolated yield. [b]t-BuOH/H2O/DCM (1:1:1), 6 h. [c]t-
BuOH/H2O/THF (1:1:1), 36 h 
On the basis of previously reported work, here we have proposed a 
plausible mechanism for this reaction (Scheme 34). Initially, enamine 
is formed from propargyl amine and enolizable ketone in a Lewis acid 
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mediated reaction. Then the enamine undergoes cycloaddition with 
azide to form a triazoline intermediate. Subsequently, the triazoline 
intermediate leads to the desired product via ring opening and ring 
closing intermediates with the elimination of a molecule of 4–
nitrophenyl aniline. 
 
 
Scheme 34 Proposed mechanism for the formation of propargyl triazole 
4.3 Conclusion 
In conclusion, we have developed a highly efficient and regiospecific 
Zn(OAc)2 mediated synthesis of propargyl functionalized triazole 
derivatives in a single step from ketones and propargyl amine. 
Subsequently, Cu(I) reactions of these propargyl triazoles with various 
organic azides having supramolecular and medicinal interest lead to 
novel N-C linked bis-triazole moieties in a regioselective manner with 
excellent yield. This newly developed method has the following 
advantages: (1) it gives access in a single step to propargyl triazoles, 
which is not possible by any other reported methods (2) it uses cheap 
and readily available building blocks, (3) it can be extended to natural 
products containing enolizable ketone groups. Considering the 
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importance of these products we believe that this methodology could 
draw attention for various applications in the field of medicinal and 
material chemistry. Further studies of these propargyl triazole 
analogues for medicinal chemistry applications as well as for metal 
ligand binding studies are under investigation and will be reported in 
due course. 
4.4 Experimental Section 
4.4.1 Experimental procedure 
4.4.1.1  General procedure for the preparation of propargyl 
substituted 1,2,3-triazoles  
To an oven-dried screw-capped reaction tube equipped with a 
magnetic stirring bar was added the ketone, propargyl amine, 4-
nitrophenyl azide, Zn(OAc)2 and 4 Å molecular sieves. The mixture was 
dissolved in DMF (0.4 mL) and stirred at 60 °C for 10-36 hour. Upon 
completion, the solvent was removed in vacuo. The crude reaction 
mixture was then directly purified by column chromatography (silica 
gel) at first with CH2Cl2 as eluent to remove all 4-nitroaniline formed 
during the reaction followed by using a mixture of heptane and ethyl 
acetate as eluent to afford the corresponding propargyl substituted 
1,2,3-triazoles as off-white solids or semi-solids. 
 
4.4.2 Charactarization data 
1-(Prop-2-yn-1-yl)-4,5,6,7-tetrahydro-1H-
benzo[d][1,2,3]triazole(158a): cyclohexanone (100 mg, 1.01 mmol), 
propargyl amine (112 mg, 2.03 mmol), 4-nitrophenyl azide (234 mg, 
1.42 mmol), zinc acetate (187 mg, 1.01 mmol), 4 Å molecular sieves 
(40 mg) and DMF (0.4 mL). Reaction time was 10 h. The product was 
purified by flash column chromatography (CH2Cl2 followed by 
heptane/EtOAc = 3:2) affording 158a (123 mg, 75% yield) as an off 
white semi-solid. 1H NMR (300 MHz, CDCl3) δ 5.05 (t, J = 2.1 Hz, 2H), 
2.73 (dd, J = 13.3, 6.8 Hz, 4H), 2.45 (t, J = 2.6 Hz, 1H), 1.90 – 1.77 (m, 
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4H). 13C NMR (75 MHz, CDCl3) δ 144.1, 132.23, 75.6, 74.6, 37.6, 22.6, 
22.4, 21.9, 20.1. HRMS (ESI+): m/z calcd for C9H11N3 [M+H]+: 162.1025, 
found 162.1034. 
 
1-(Prop-2-yn-1-yl)-1,4,5,6,7,8-
hexahydrocyclohepta[d][1,2,3]triazole(158b): cycloheptanone (100 
mg, 0.89 mmol), propargyl amine (98 mg, 1.78 mmol), 4-nitrophenyl 
azide (204 mg, 1.24 mmol), zinc acetate (164 mg, 0.89 mmol), 4 Å 
molecular sieves (40 mg) and DMF (0.4 mL). Reaction time is 8 h. The 
product was purified by flash column chromatography (CH2Cl2 
followed by heptane/EtOAc = 3:2) affording 158b (125 mg, 77% yield) 
as an off white semi-solid. 1H NMR (300 MHz, CDCl3) δ 5.06 (d, J = 2.6 
Hz, 2H), 2.92 – 2.78 (m, 4H), 2.43 (t, J = 2.6 Hz, 1H), 1.91 – 1.81 (m, 
2H), 1.80 – 1.68 (m, 4H). 13C NMR (75 MHz, CDCl3) δ 147.8, 135.1, 
76.01, 74.4, 37.9, 30.8, 27.3, 27.2, 26.8, 24.2. HRMS (ESI+): m/z calcd 
for C10H13N3 [M+H]+: 176.1182, found 176.1193. 
 
1-(Prop-2-yn-1-yl)-4,5,6,7,8,9-hexahydro-1H-
cycloocta[d][1,2,3]triazole(158c): cyclooctanone (100 mg, 0.78 
mmol), propargyl amine (87 mg, 1.58 mmol), 4-nitrophenyl azide (179 
mg, 1.09 mmol), zinc acetate (145 mg, 0.79 mmol), 4 Å molecular 
sieves (40 mg) and DMF (0.4 mL). Reaction time is 8 h. The product was 
purified by flash column chromatography (CH2Cl2 followed by 
heptane/EtOAc = 3:2) affording 158c (105 mg, 70% yield) as an off 
white semi-solid. 1H NMR (300 MHz, CDCl3) δ 5.06 (d, J = 2.6 Hz, 2H), 
2.95 – 2.83 (m, 4H), 2.45 (t, J = 2.6 Hz, 1H), 1.92 – 1.84 (m, 2H), 1.80 – 
1.71 (m, 2H), 1.59 – 1.41 (m, 4H). 13C NMR (75 MHz, CDCl3) δ 145.2, 
133.4, 76.1, 74.5, 37.7, 28.1, 26.0, 25.9, 24.7, 24.5, 21.7. HRMS (ESI+): 
m/z calcd for C11H15N3 [M+H]+: 190.1338 , found 190.1336. 
 
5-Benzyl-1-(prop-2-yn-1-yl)-4,5,6,7-tetrahydro-1H-
[1,2,3]triazolo[4,5-c]pyridine(158d): 1-benzylpiperidin-4-one (100 
mg, 0.52 mmol), propargyl amine (58.2 mg, 1.05 mmol), 4-nitrophenyl 
azide (121 mg, 0.73 mmol), zinc acetate (97 mg, 0.52 mmol), 4 Å 
molecular sieves (40 mg) and DMF (0.4 mL). Reaction time is 10 h. The 
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product was purified by flash column chromatography (CH2Cl2 
followed by heptane/EtOAc = 3:2) affording 158d (85 mg, 64% yield) 
as an off white semi-solid. 1H NMR (300 MHz, CDCl3) δ 7.35 – 7.26 (m, 
5H), 5.07 (d, J = 2.6 Hz, 2H), 3.76 (s, 2H), 3.69 (s, 2H), 2.83 (s, 4H), 2.46 
(t, J = 2.6 Hz, 1H). 13C NMR (75 MHz, CDCl3) δ 143.1, 138.0, 131.0, 
129.1, 128.5, 127.5, 75.3, 75.0, 61.8, 49.8, 49.2, 37.9, 21.0. HRMS 
(ESI+): m/z calcd for C15H16N4 [M+H]+: 253.1447 , found 253.1451. 
 
5-Phenyl-1-(prop-2-yn-1-yl)-4,5,6,7-tetrahydro-1H-
benzo[d][1,2,3]triazole (158e): 4-phenylcyclohexan-1-one (100 mg, 
0.57 mmol), propargyl amine (63.2 mg, 1.14 mmol), 4-nitrophenyl 
azide (132 mg, 0.80 mmol), zinc acetate (105 mg, 0.57 mmol), 4 Å 
molecular sieves (40 mg) and DMF (0.4 mL). Reaction time is 10 h. The 
product was purified by flash column chromatography (CH2Cl2 
followed by heptane/EtOAc = 3:2) affording 158e (118 mg, 87% yield) 
as an off white semi-solid. 1H NMR (400 MHz, CDCl3) δ 7.40 – 7.32 (m, 
2H), 7.27 – 7.23 (m, 3H), 5.1 – 5.0 (m, 2H), 3.13 (dd, J = 15.4, 4.9 Hz, 
1H), 3.06 – 2.96 (m, 1H), 2.93 – 2.76 (m, 3H), 2.47 (t, J = 2.6 Hz, 1H), 
2.26 – 2.17 (m, 1H), 2.09 – 1.96 (m, 1H). 13C NMR (101 MHz, CDCl3) δ 
144.93, 144.35, 132.04, 128.76, 126.98, 126.75, 75.50, 74.84, 40.61, 
37.86, 30.03, 29.73, 20.12. HRMS (ESI+): m/z calcd for C15H15N3 
[M+H]+: 238.1338, found 238.1338. 
 
4-(1-(Prop-2-yn-1-yl)-4,5,6,7-tetrahydro-1H-benzo[d][1,2,3]triazol-5-
yl)phenol (158f): 4-(4-hydroxyphenyl)cyclohexan-1-one (100 mg, 0.52 
mmol), propargyl amine (87.9 mg, 1.05 mmol), 4-nitrophenyl azide 
(121 mg, 0.73 mmol), zinc acetate (96 mg, 0.52 mmol), 4 Å molecular 
sieves (40 mg) and DMF (0.4 mL). Reaction time is 10 h. The product 
was purified by flash column chromatography (CH2Cl2 followed by 
heptane/EtOAc = 3:2) affording 158f (110 mg, 83% yield) as an off 
white solid. m.p. 186 – 187 ˚C. 1H NMR (300 MHz, DMSO-d6) δ 9.21 (s, 
1H), 7.11 (d, J = 8.5 Hz, 2H), 6.71 (d, J = 8.5 Hz, 2H), 5.24 (d, J = 2.5 Hz, 
2H), 3.55 (t, J = 2.6 Hz, 1H), 2.90 – 2.80 (m, 3H), 2.78 – 2.60 (m, 2H), 
2.08 – 1.79 (m, 2H). 13C NMR (75 MHz, DMSO-d6) δ 155.75, 143.17, 
135.49, 132.04, 127.75, 115.13, 77.05, 76.69, 36.99, 29.76, 29.41, 
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19.29. HRMS (ESI+): m/z calcd for C15H15N3O1 [M+H]+: 254.1287, found 
254.1291. 
 
3-(Prop-2-yn-1-yl)-4,5-dihydro-3H-naphtho[1,2-d][1,2,3]triazole 
(158g): 3,4-dihydronaphthalen-2(1H)-one (100 mg, 0.68 mmol), 
propargyl amine (75 mg, 1.36 mmol), 4-nitrophenyl azide (157 mg, 
0.95 mmol), zinc acetate (126 mg, 0.68 mmol), 4 Å molecular sieves 
(40 mg) and DMF (0.4 mL). Reaction time is 10 h. The product was 
purified by flash column chromatography (CH2Cl2 followed by 
heptane/EtOAc = 3:2) affording 158g (103 mg, 72% yield) as an off 
white solid. m.p. 86.5 – 87.5 ˚C. 1H NMR (300 MHz, CDCl3) δ 7.93 (d, J 
= 7.4 Hz, 1H), 7.34 – 7.27 (m, 1H), 7.25 – 7.18 (m, 2H), 5.15 (d, J = 2.6 
Hz, 2H), 3.21 – 2.94 (m, 4H), 2.48 (t, J = 2.6 Hz, 1H). 13C NMR (101 MHz, 
CDCl3) δ 144.2, 133.5, 132.9, 128.5, 128.3, 127.7, 127.4, 122.1, 75.3, 
75.1, 38.0, 28.5, 19.1. HRMS (ESI+): m/z calcd for C13H11N3 [M+H]+: 
210.1025, found 210.1026. 
 
1-(Prop-2-yn-1-yl)-4,5-dihydro-1H-naphtho[1,2-d][1,2,3]triazole 
(158h): 3,4-dihydronaphthalen-1(2H)-one (100 mg, 0.68 mmol), 
propargyl amine (75 mg, 1.36 mmol), 4-nitrophenyl azide (157 mg, 
0.95 mmol), zinc acetate (126 mg, 0.68 mmol), 4 Å molecular sieves 
(40 mg) and DMF (0.4 mL). Reaction time is 10 h. The product was 
purified by flash column chromatography (CH2Cl2 followed by 
heptane/EtOAc = 3:2) affording 158h (82 mg, 57% yield) as an off white 
semi-solid. 1H NMR (400 MHz, CDCl3) δ 7.74 (d, J = 7.4 Hz, 1H), 7.38 - 
7.28 (m, 3H), 5.38 (d, J = 2.2 Hz, 2H), 3.12 – 2.89 (m, 4H), 2.51 (s, 1H). 
13C NMR (101 MHz, CDCl3) δ 145.7, 137.3, 131.5, 129.3, 128.9, 127.4, 
124.8, 123.1, 76.1, 75.6, 39.7, 30.3, 20.8. HRMS (ESI+): m/z calcd for 
C13H11N3 [M+H]+: 210.1025, found 210.1029. 
 
3-(Prop-2-yn-1-yl)-3,8-dihydroindeno[1,2-d][1,2,3]triazole (158i): 
2,3-dihydro-1H-inden-1-one (100 mg, 0.75 mmol), propargyl amine 
(83 mg, 1.51 mmol), 4-nitrophenyl azide (173 mg, 1.05 mmol), zinc 
acetate (139 mg, 0.75 mmol), 4 Å molecular sieves (40 mg) and DMF 
(0.4 mL). Reaction time is 10 h. The product was purified by flash 
column chromatography (CH2Cl2 followed by heptane/EtOAc = 3:2) 
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affording 158i (72 mg, 49% yield) as an off white semi-solid. 1H NMR 
(300 MHz, CDCl3) δ 7.79 – 7.75 (m, 1H), 7.56 (dd, J = 6.6, 0.8 Hz, 1H), 
7.41 (td, J = 7.3, 3.9 Hz, 1H), 7.35 (td, J = 7.5, 1.4 Hz, 1H), 5.37 (d, J = 
2.6 Hz, 2H), 3.77 (s, 2H), 2.56 (t, J = 2.6 Hz, 1H). 13C NMR (75 MHz, 
CDCl3) δ 156.0, 147.7, 141.5, 129.5, 127. 6, 127.4, 126.7, 121.0, 75.6, 
75.5, 39.2, 29.2. HRMS (ESI+): m/z calcd for C12H9N3 [M+H]+: 196.0869, 
found 196.0874. 
 
7,8-Dimethoxy-3-(prop-2-yn-1-yl)-4,5-dihydro-3H-naphtho[1,2-
d][1,2,3]triazole (158j): 6,7-dimethoxy-3,4-dihydronaphthalen-1(2H)-
one (100 mg, 0.48 mmol), propargyl amine (53.4 mg, 0.97 mmol), 4-
nitrophenyl azide (111 mg, 0.67 mmol), zinc acetate (89 mg, 0.48 
mmol), 4 Å molecular sieves (40 mg) and DMF (0.4 mL). Reaction time 
is 10 h. The product was purified by flash column chromatography 
(CH2Cl2 followed by heptane/EtOAc = 3:2) affording 158j (92 mg, 71% 
yield) as an off white solid. m.p. 147 – 148 ˚ C. 1H NMR (300 MHz, CDCl3) 
δ 7.48 (s, 1H), 6.77 (s, 1H), 5.15 (d, J = 2.6 Hz, 2H), 3.95 (s, 3H), 3.89 (s, 
3H), 3.04 (s, 4H), 2.49 (t, J = 2.6 Hz, 1H). 13C NMR (101 MHz, CDCl3) δ 
148.4, 148.4, 144.3, 131.9, 125.8, 121.2, 111.8, 105.6, 75.3, 75.1, 56.2, 
56.1, 38.01, 28.1, 19.3. HRMS (ESI+): m/z calcd for C15H15N3O2 [M+H]+: 
270.1236, found 270.1242. 
 
5-Phenyl-1-(prop-2-yn-1-yl)-1H-1,2,3-triazole (158k): acetophenone 
(100 mg, 0.83 mmol), propargyl amine (92 mg, 1.66 mmol), 4-
nitrophenyl azide (191 mg, 1.16 mmol), Zinc acetate (153 mg, 0.83 
mmol), 4 Å molecular sieves (40 mg) and DMF (0.4 mL). Reaction time 
is 24 h. The product was purified by flash column chromatography 
(CH2Cl2 followed by heptane/EtOAc = 3:2) affording 158k (91 mg, 60% 
yield) as an off white semi-solid. 1H NMR (300 MHz, CDCl3) δ 7.75 (s, 
1H), 7.63 – 7.47 (m, 5H), 5.13 (d, J = 2.6 Hz, 2H), 2.48 (t, J = 2.6 Hz, 1H). 
13C NMR (75 MHz, CDCl3) δ 138.1, 133.1, 129.9, 129.3, 129.0, 128.8, 
126.5, 76.6, 74.9, 38.3. HRMS (ESI+): m/z calcd for C11H9N3 [M+H]+: 
184.0869, found 184.0869. 
 
5-(Phenanthren-3-yl)-1-(prop-2-yn-1-yl)-1H-1,2,3-triazole(158l): 1-
(phenanthren-3-yl)ethan-1-one (100 mg, 0.45 mmol), propargyl amine 
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(50 mg, 0.90 mmol), 4-nitrophenyl azide (104 mg, 0.63 mmol), zinc 
acetate (83 mg, 0.45 mmol), 4 Å molecular sieves (40 mg) and DMF 
(0.4 mL). Reaction time is 24 h. The product was purified by flash 
column chromatography (CH2Cl2 followed by heptane/EtOAc = 3:2) 
affording 158l (70 mg, 54% yield) as an off white solid. m.p. 126 – 127 
˚C. 1H NMR (300 MHz, CDCl3) δ 8.81 (d, J = 8.7 Hz, 1H), 8.72 (d, J = 8.0 
Hz, 1H), 8.08 (d, J = 1.8 Hz, 1H), 7.94 (dd, J = 7.7, 1.4 Hz, 1H), 7.89 (s, 
1H), 7.85 (d, J = 8.9 Hz, 1H), 7.81 – 7.76 (m, 2H), 7.75 – 7.64 (m, 2H), 
5.22 (d, J = 2.6 Hz, 2H), 2.51 (t, J = 2.5 Hz, 1H). 13C NMR (75 MHz, CDCl3) 
δ 138.0, 133.4, 132.6, 132.2, 131.0, 129.8, 128.9, 128.9, 128.5, 127.6, 
127.3, 126.6, 126.4, 124.4, 123.8, 123.0, 75.1, 38.5. HRMS (ESI+): m/z 
calcd for C19H13N3 [M+H]+: 284.1182, found 284.1187. 
 
5-Ethyl-4-methyl-1-(prop-2-yn-1-yl)-1H-1,2,3-triazole (158m): 
pentan-3-one (100 mg, 1.16 mmol), propargyl amine (128 mg, 2.32 
mmol), 4-nitrophenyl azide (267 mg, 1.62 mmol), zinc acetate (213 mg, 
1.16 mmol), 4 Å molecular sieves (40 mg) and DMF (0.4 mL). Reaction 
time is 24 h. The product was purified by flash column chromatography 
(CH2Cl2 followed by heptane/EtOAc = 4:1) affording 158m (137 mg, 
79% yield) as an off white semi-solid. 1H NMR (300 MHz, CDCl3) δ 5.06 
(d, J = 2.6 Hz, 2H), 2.76 (q, J = 7.6 Hz, 2H), 2.44 (t, J = 2.6 Hz, 1H), 2.29 
(s, 3H), 1.24 (t, J = 7.6 Hz, 3H). 13C NMR (75 MHz, CDCl3) δ 141.0, 134.6, 
76.2, 74.5, 37.9, 16.1, 13.0, 10.5. HRMS (ESI+): m/z calcd for C8H11N3 
[M+H]+: 150.1025, found 150.1022. 
 
5-Methyl-1-(prop-2-yn-1-yl)-1H-1,2,3-triazole (158n): Acetone (71 
mg, 1.21 mmol), propargyl amine (47.9 mg, 0.87 mmol), 4-nitrophenyl 
azide (100 mg, 0.60 mmol), zinc acetate (79 mg, 0.43 mmol), 4 Å 
molecular sieves (40 mg) and DMF (0.4 mL). Reaction time is 24 h. The 
product was purified by flash column chromatography (CH2Cl2 
followed by heptane/EtOAc = 4:1) affording 158n (56 mg, 76 % yield) 
as an off white semi-solid. 1H NMR (300 MHz, CDCl3) δ 7.47 (s, 1H), 
5.11 (d, J = 2.6 Hz, 2H), 2.47 (t, J = 2.6 Hz, 1H), 2.42 (d, J = 0.7 Hz, 3H). 
13C NMR (75 MHz, CDCl3) δ 133.5, 133.0, 75.4, 74.8, 37.7, 8.5. HRMS 
(ESI+): m/z calcd for C6H7N3 [M+H]+: 122.0712, found 122.0705. 
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5-(Dibenzo[b,d]furan-2-yl)-1-(prop-2-yn-1-yl)-1H-1,2,3-triazole 
(158o): 1-(dibenzo[b,d]furan-2-yl)ethan-1-one (100 mg, 0.47 mmol), 
propargyl amine (52.4 mg, 0.95 mmol), 4-nitrophenyl azide (109 mg, 
0.66 mmol), zinc acetate (87 mg, 0.47 mmol), 4 Å molecular sieves (40 
mg) and DMF (0.4 mL). Reaction time is 36 h. The product was purified 
by flash column chromatography (CH2Cl2 followed by heptane/EtOAc 
= 6:4) affording 158o (60 mg, 46 % yield) as an off white solid. m.p. 93 
– 94 ˚C . 1H NMR (300 MHz, CDCl3) δ 8.13 (d, J = 1.4 Hz, 1H), 7.99 (dd, J 
= 7.7, 0.6 Hz, 1H), 7.82 (s, 1H), 7.73 – 7.69 (m, 1H), 7.66 – 7.58 (m, 2H), 
7.57 – 7.51 (m, 1H), 7.41 (td, J = 7.6, 1.0 Hz, 1H), 5.17 (d, J = 2.6 Hz, 2H), 
2.51 (t, J = 2.6 Hz, 1H). 13C NMR (75 MHz, CDCl3) δ 156.9, 156.8, 138.2, 
133.3, 128.3, 127.8, 125.3, 123.5, 123.4, 121.4, 121.5, 121.0, 112.6, 
112.1, 77.2, 75.0, 38.3. HRMS (ESI+): no mass detected. 
 
3,6-Di-tert-butyl-9-(4-(1-(prop-2-yn-1-yl)-1H-1,2,3-triazol-5-
yl)phenyl)-9H-carbazole (158p): 1-(4-(3,6-di-tert-butyl-9H-carbazol-9-
yl)phenyl)ethan-1-one (100 mg, 0.25 mmol), propargyl amine (41.6 
mg, 0.75 mmol), 4-nitrophenyl azide (61.9 mg, 0.37 mmol), zinc 
acetate (46.1 mg, 0.25 mmol), 4 Å molecular sieves (40 mg) and DMF 
(0.4 mL). Reaction time is 24 h. The product was purified by flash 
column chromatography (CH2Cl2 followed by heptane/EtOAc = 3:2) 
affording 158p (61 mg, 53 % yield) as an off white solid. m.p. 220 – 221 
˚C. 1H NMR (300 MHz, CDCl3) δ 8.16 (d, J = 1.3 Hz, 2H), 7.86 (s, 1H), 7.76 
(d, J = 2.0 Hz, 4H), 7.51 - 7.41 (m, 4H), 5.25 (d, J = 2.5 Hz, 2H), 2.53 (t, J 
= 2.5 Hz, 1H), 1.48 (s, 18H). 13C NMR (101 MHz, CDCl3) δ 143.7, 139.9, 
138.9, 137.5, 133.4, 130.3, 127.2, 124.7, 124.0, 123.9, 116.6, 109.2, 
76.6, 75.2, 38.5, 34.9, 32.1. HRMS (ESI+): m/z calcd for C31H32N4 
[M+H]+: 461.2699, found 461.2692. 
 
(1S,3aS,3bR,5aS,10aS,10bS,12aS)-10a,12a-Dimethyl-7-(prop-2-yn-1-
yl)-1,2,3,3a,3b,4,5,5a,6,7,10,10a,10b,11,12,12a-
hexadecahydrocyclopenta[7,8]phenanthro[2,3-d][1,2,3]triazol-1-ol 
(158q): 5α-Dihydrotestosterone (90 mg, 0.31 mmol), propargyl amine 
(34.1 mg, 0.62 mmol), 4-nitrophenyl azide (71.2 mg, 0.43 mmol), zinc 
acetate (56.9 mg, 0.31 mmol), 4 Å molecular sieves (40 mg) and DMF 
(0.4 mL). Reaction time is 24 h. The product was purified by flash 
126 
 
column chromatography (CH2Cl2 followed by heptane/EtOAc = 3:2) 
affording 158q (63 mg, 57.5 % yield) as an off white solid. m.p. 198 – 
199 ˚C. 1H NMR (400 MHz, CDCl3) δ 5.05 (t, J = 2.5 Hz, 2H), 3.66 (t, J = 
8.5 Hz, 1H), 2.86 (d, J = 15.5 Hz, 1H), 2.68 (dd, J = 15.9, 5.0 Hz, 1H), 2.45 
(t, J = 2.6 Hz, 1H), 2.33 – 2.25 (m, 2H), 2.14 – 2.02 (m, 1H), 1.87 (dt, J = 
12.4, 3.3 Hz, 1H), 1.79 – 1.72 (m, 1H), 1.72 – 1.57 (m, 5H), 1.53 – 1.36 
(m, 4H), 1.34 – 1.22 (m, 1H), 1.12 (td, J = 12.8, 4.1 Hz, 1H), 1.04 – 0.85 
(m, 3H), 0.77 (s, 3H), 0.74 (s, 3H).  13C NMR (101 MHz, CDCl3) δ 144.0, 
131.0, 82.0, 75.6, 74.7, 53.9, 50.9, 43.0, 42.3, 37.8, 36.9, 36.7, 36.2, 
35.7, 31.3, 30.6, 29.0, 24.6, 23.6, 20.9, 11.8, 11.2. HRMS (ESI+): m/z 
calcd for C22H31N3O1 [M+H]+: 354.2539, found 354.2532. 
 
(1R,3aS,3bR,5aS,10aS,10bS,12aR)-10a,12a-Dimethyl-1-((R)-6-
methylheptan-2-yl)-7-(prop-2-yn-1-yl)-
1,2,3,3a,3b,4,5,5a,6,7,10,10a,10b,11,12,12a-
hexadecahydrocyclopenta[7,8]phenanthro[2,3-d][1,2,3]triazole 
(158r): (5S,8R,9S,10S,13R,14S,17R)-10,13-dimethyl-17-((R)-6-
methylheptan-2-yl)hexadecahydro-3H-cyclopenta[a]phenanthren-3-
one (100 mg, 0.25 mmol), propargyl amine (28.5 mg, 0.51 mmol), 4-
nitrophenyl azide (59.4 mg, 0.36 mmol), zinc acetate (47.4 mg, 0.25 
mmol), 4 Å molecular sieves (40 mg) and DMF (0.4 mL). Reaction time 
is 24 h. The product was purified by flash column chromatography 
(CH2Cl2 followed by heptane/EtOAc = 3:2) affording 158r (72 mg, 62% 
yield) as an off white solid. m.p. 132 – 133 ˚ C. 1H NMR (600 MHz, CDCl3) 
δ 5.11 – 5.01 (m, 2H), 2.85 (d, J = 15.2 Hz, 1H), 2.66 (dd, J = 15.6, 5.2 
Hz, 1H), 2.44 (t, J = 2.6 Hz, 1H), 2.32 – 2.25 (m, 2H), 2.06 - 2.03 (m, 1H), 
1.87 - 1.80 (m, 1H), 1.76 - 1.72 (m, 1H), 1.68 – 1.57 (m, 4H), 1.54 - 1.46 
(m, 2H), 1.42 – 1.31 (m, 6H), 1.28 – 1.23 (m, 2H), 1.18 – 1.06 (m, 6H), 
1.04 - 0.99 (m, 2H), 0.92 (d, J = 6.5 Hz, 3H), 0.87 (d, J = 2.6 Hz, 3H), 0.86 
(d, J = 2.6 Hz, 3H), 0.73 (s, 3H), 0.68 (s, 3H). 13C NMR (75 MHz, CDCl3) δ 
144.2, 131.1, 77.4, 75.6, 74.7, 56.4, 53.8, 42.6, 42.3, 40.0, 39.6, 37.8, 
36.8, 36.3, 36.2, 35.9, 35.7, 31.7, 29.1, 28.4, 28.2, 24.6, 24.4, 24.0, 23.0, 
22.7 21.3, 18.8, 12.1, 11.8. HRMS (ESI+): m/z calcd for C30H47N3 [M+H]+: 
450.3842, found 450.3844. 
Carbazole porphyrin conjugate (160a): 3,6-di-tert-butyl-9-(4-(1-(prop-
2-yn-1-yl)-1H-1,2,3-triazol-5-yl)phenyl)-9H-carbazole (69 mg, 0.15 
127 
 
mmol), Zn-TPP (192 mg, 0.18 mmol), CuSO4 (1.195 mg, 0.00749 mmol), 
sodium (R)-2-((S)-1,2-dihydroxyethyl)-4-hydroxy-5-oxo-2,5-
dihydrofuran-3-olate (3.26 mg, 0.02 mmol), t-BuOH:DCM:H2O (1:1:1). 
Reaction time is 6 h. After the reaction was completed, the reaction 
mixture was extracted with DCM 3 times (3 X 100 mL). Dried over 
MgSO4 and concentrated under reduced pressure to afford the desired 
product 160a in 78 % yield (178 mg) as an off white solid. m.p. 253 – 
254 ˚C. 1H NMR (400 MHz, CDCl3) δ 9.10 (d, J = 4.6 Hz, 2H), 9.00 (s, 4H), 
8.94 (d, J = 4.6 Hz, 2H), 8.30 (d, J = 7.9 Hz, 2H), 8.15 (d, J = 1.6 Hz, 4H), 
8.11 (d, J = 1.6 Hz, 2H), 8.07 (d, J = 1.6 Hz, 2H), 7.83 (s, 2H), 7.78 (s, 1H), 
7.46 (d, J = 8.4 Hz, 2H), 7.40 – 7.34 (m, 4H), 7.23 (d, J = 8.7 Hz, 3H), 7.03 
(d, J = 7.8 Hz, 2H), 6.77 (s, 1H), 5.59 (s, 2H), 4.82 (s, 2H), 1.54 (s, 36H), 
1.52 (s, 18H), 1.40 (s, 18H). 13C NMR (101 MHz, CDCl3) δ 150.7, 150.5, 
150.2, 149.9, 148.8, 148.5, 144.6, 143.6, 142.7, 142.6, 142.1, 139.8, 
138.7, 136.0, 135.2, 133.8, 132.2, 131.4, 130.4, 129.9, 126.8, 125.3, 
123.9, 123.8, 123.6, 122.8, 122.4, 122.2, 120.9, 120.8, 119.5, 116.5, 
109.2, 35.3, 35.2, 34.9, 32.1, 32.0, 31.9. HRMS (ESI+): m/z calcd for 
C100H109N11Zn [M+H]+: 1528.8231, found 1528.8428. 
 
1-(4-(4-(((1R,3aS,3bR,5aS,10aS,10bS,12aR)-10a,12a-Dimethyl-1-
((R)-6-methylheptan-2-yl)-
2,3,3a,3b,4,5,5a,6,10,10a,10b,11,12,12a-
tetradecahydrocyclopenta[7,8]phenanthro[2,3-d][1,2,3]triazol-
7(1H)-yl)methyl)-1H-1,2,3-triazol-1-yl)-5-
(hydroxymethyl)tetrahydrofuran-2-yl)-5-methylpyrimidine-
2,4(1H,3H)-dione (160b): 158r (150 mg, 0.33 mmol), AZT (107 mg, 
0.40 mmol), CuSO4 (2.66 mg, 0.02 mmol), sodium (R)-2-((S)-1,2-
dihydroxyethyl)-4-hydroxy-5-oxo-2,5-dihydrofuran-3-olate (7.27 
mg, 0.04 mmol), t-BuOH:H2O (1:1). Reaction time is 12 h. After the 
reaction was completed, the reaction mixture was extracted with 
DCM 3 times (3 X 100 mL), dried over MgSO4 and concentrated 
under reduced pressure to afford the desired product 160b in 84 % 
yield (201 mg) as an off white solid. m.p. 188 – 189 ˚C. 1H NMR (400 
MHz, DMSO) δ 11.34 (s, 1H), 8.32 (s, 1H), 7.80 (s, 1H), 6.41 (t, J = 6.5 
Hz, 1H), 5.55 (s, 2H), 5.36 (dt, J = 10.4, 5.3 Hz, 1H), 5.27 (t, J = 5.0 Hz, 
1H), 4.18 (d, J = 4.7 Hz, 1H), 3.73 – 3.57 (m, 2H), 2.62 – 2.50 (m, 4H), 
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2.20 (t, J = 14.7 Hz, 2H), 1.98 (d, J = 12.1 Hz, 1H), 1.80 (s, 4H), 1.65 
(d, J = 10.8 Hz, 1H), 1.62 – 1.45 (m, 5H), 1.32 (s, 6H), 1.22 – 1.03 (m, 
7H), 1.00 (d, J = 6.7 Hz, 2H), 0.90 (d, J = 6.2 Hz, 3H), 0.87 – 0.81 (m, 
6H), 0.65 (s, 3H), 0.63 (s, 3H). 13C NMR (101 MHz, DMSO) δ 163.7, 
150.4, 142.1, 136.2, 130.9, 123.5, 109.6, 84.4, 83.9, 60.7, 59.4, 55.8, 
54.9, 52.8, 42.4, 42.0, 41.5, 39.5, 37.1, 36.2, 35.6, 35.6, 35.2, 35.0, 
31.2, 28.4, 27.8, 27.4, 23.86, 23.7, 23.2, 22.6, 22.4, 20.7, 18.5, 12.2, 
11.8, 11.4. HRMS (ESI+): m/z calcd for C40H60N8O4 [M+H]+: 717.4809, 
found 717.4813. 
 
2-(2-(2-(4-(((1R,3aS,3bR,5aS,10aS,10bS,12aR)-10a,12a-Dimethyl-1-
((R)-6-methylheptan-2-yl)-2,3,3a,3b,4,5,5a,6,10,10a,10b,11,12,12a-
tetradecahydrocyclopenta[7,8]phenanthro[2,3-d][1,2,3]triazol-
7(1H)-yl)methyl)-1H-1,2,3-triazol-1-yl)ethoxy)ethoxy)ethan-1-ol 
(160c): 158r (150 mg, 0.33 mmol), 2-(2-(2-azidoethoxy)ethoxy)ethan-
1-ol (70.1 mg, 0.40 mmol), CuSO4 (2.66 mg, 0.02 mmol), sodium (R)-2-
((S)-1,2-dihydroxyethyl)-4-hydroxy-5-oxo-2,5-dihydrofuran-3-olate 
(7.27 mg, 0.04 mmol), t-BuOH:H2O:THF (1:1:1). Reaction time is 12 h. 
After the reaction was completed, the reaction mixture was extracted 
with DCM 3 times (3 X 100 mL), dried over MgSO4 and concentrated 
under reduced pressure to afford the desired product 160c in 67 % 
yield (143 mg). as an off white solid. m.p. 101 – 102 ˚C 1H NMR (600 
MHz, MeOD) δ 8.04 (s, 1H), 5.47 (s, 2H), 4.47 (s, 2H), 3.77 (d, J = 4.2 Hz, 
2H), 3.56 – 3.52 (m, 2H), 3.48 (ddd, J = 8.2, 6.0, 2.9 Hz, 4H), 3.41 – 3.39 
(m, 2H), 2.63 (s, 1H), 2.13 (s, 2H), 1.98 (d, J = 12.0 Hz, 1H), 1.82 – 1.73 
(m, 1H), 1.67 – 1.64 (m, 1H), 1.58 – 1.48 (m, 3H), 1.46 - 1.40 (m, 3H), 
1.34 – 1.24 (m, 6H), 1.22 – 1.12 (m, 2H), 1.12 – 0.98 (m, 6H), 0.98 – 
0.89 (m, 2H), 0.86 (d, J = 6.4 Hz, 4H), 0.79 (d, J = 2.3 Hz, 3H), 0.78 (d, J 
= 2.3 Hz, 3H), 0.63 (s, 3H), 0.59 (s, 3H). 13C NMR (101 MHz, MeOD) δ 
126.1, 73.7, 71.4, 70.2, 62.2, 57.7, 55.0, 54.8, 51.5, 44.1, 43.6, 43.4, 
41.3, 40.7, 37.7, 37.4, 37.2, 37.0, 36.9, 32.8, 29.9, 29.3, 29.2, 25.3, 25.0, 
23.2, 23.0, 22.3, 19.3, 12.4, 12.0. HRMS (ESI+): m/z calcd for 
C36H60N6O3 [M+H]+: 625.4799, found 625.4813. 
 
(2R,3S,4R,5R)-2-((benzoyloxy)methyl)-5-(4-
(((1S,3aS,3bR,5aS,10aS,10bS,12aS)-1-hydroxy-10a,12a-dimethyl-
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2,3,3a,3b,4,5,5a,6,10,10a,10b,11,12,12a-
tetradecahydrocyclopenta[7,8]phenanthro[2,3-d][1,2,3]triazol-
7(1H)-yl)methyl)-1H-1,2,3-triazol-1-yl)tetrahydrofuran-3,4-diyl 
dibenzoate (160d): 158q (100 mg, 0.28 mmol), (2R,3R,4S,5R)-2-azido-
5-((benzoyloxy)methyl)tetrahydrofuran-3,4-diyl dibenzoate (165 mg, 
0.34 mmol), CuSO4 (2.483 mg, 0.02 mmol), sodium (R)-2-((S)-1,2-
dihydroxyethyl)-4-hydroxy-5-oxo-2,5-dihydrofuran-3-olate (6.16 mg, 
0.03 mmol). t-BuOH:H2O (1:1). Reaction time is 12 h. After the reaction 
was completed, the reaction mixture was extracted with DCM 3 times 
(3 X 100 mL). Dried over MgSO4 and concentrated under reduced 
pressure to afford the desired product 160d in 90 % yield (215 mg) as 
an off white solid. m.p. 123 – 124 ˚C. 1H NMR (400 MHz, CDCl3) δ 8.02 
(d, J = 8.0 Hz, 2H), 7.95 (dd, J = 13.0, 8.1 Hz, 4H), 7.81 (s, 1H), 7.56 (q, J 
= 7.5 Hz, 3H), 7.45 - 7.35 (m, 6H), 6.35 (d, J = 2.4 Hz, 1H), 6.26 – 6.22 
(m, 1H), 6.13 (t, J = 5.7 Hz, 1H), 5.54 – 5.40 (m, 2H), 4.88 (dd, J = 9.3, 
4.6 Hz, 1H), 4.77 (dd, J = 12.2, 3.2 Hz, 1H), 4.59 (dd, J = 12.2, 4.8 Hz, 
1H), 3.65 (t, J = 8.4 Hz, 1H), 2.82 (d, J = 13.2 Hz, 1H), 2.69 (d, J = 14.8 
Hz, 1H), 2.27 – 2.15 (m, 2H), 2.12 – 1.99 (m, 1H), 1.85 (d, J = 12.1 Hz, 
1H), 1.75 – 1.52 (m, 6H), 1.48 – 1.22 (m, 5H), 1.10 (t, J = 11.3 Hz, 1H), 
1.02 – 0.80 (m, 3H), 0.75 (s, 3H), 0.67 (s, 3H). 13C NMR (101 MHz, CDCl3) 
δ 166.2, 165.2, 165.1, 143.0, 134.0, 133.8, 133.5, 130.0, 129.9, 129.9, 
129.4, 128.7, 128.7, 128.6, 128.5, 122.9, 90.5, 81.9, 81.3, 77.4, 75.2, 
71.7, 63.8, 53.8, 50.9, 43.2, 43.0, 42.2, 36.8, 36.7, 36.2, 35.7, 31.2, 30.6, 
29.81, 28.8, 24.4, 23.5, 20.9, 11.8, 11.2. HRMS (ESI+): m/z calcd for 
C48H52N6O8 [M+H]+: 841.3919, found 841.3929. 
 
((2R,3S,5R)-3-((4-Chlorobenzoyl)oxy)-5-(4-((5-phenyl-1H-1,2,3-
triazol-1-yl)methyl)-1H-1,2,3-triazol-1-yl)tetrahydrofuran-2-
yl)methyl 4-chlorobenzoate (160e): 5-phenyl-1-(prop-2-yn-1-yl)-1H-
1,2,3-triazole (50 mg, 0.27 mmol), (2R,3S,5R)-5-azido-2-(((4-
chlorobenzoyl)oxy)methyl)tetrahydrofuran-3-yl 4-chlorobenzoate 
(143 mg, 0.33 mmol), CuSO4 (2.178 mg, 0.01 mmol), sodium (R)-2-((S)-
1,2-dihydroxyethyl)-4-hydroxy-5-oxo-2,5-dihydrofuran-3-olate (5.95 
mg, 0.03 mmol). t-BuOH:H2O (1:1). Reaction time is 12 h. After the 
reaction was completed, the reaction mixture was extracted with DCM 
3 times (3 X 100 mL), dried over MgSO4 and concentrated under 
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reduced pressure to afford the desired product 160e in 88% yield (148 
mg) as an off white solid. m.p. 154 – 155 ˚C. 1H NMR (300 MHz, CDCl3) 
δ 8.02 – 7.85 (m, 5H), 7.71 (s, 1H), 7.52 – 7.36 (m, 10H), 6.41 (t, J = 6.1 
Hz, 1H), 5.80 (dd, J = 6.5, 3.3 Hz, 1H), 5.61 (s, 2H), 4.68 – 4.59 (m, 1H), 
4.59 – 4.45 (m, 2H), 3.35 - 3.26 (m, 1H), 2.88 - 2.80 (m, 1H). 13C NMR 
(75 MHz, CDCl3) δ 165.3, 165.0, 143.1, 140.3, 139.9, 131.2, 129.8, 
129.3, 129.1, 129.0, 128.9, 127.8, 127.5, 126.4, 123.2, 88.8, 83.5, 75.1, 
64.2, 43.4, 37.8. HRMS (ESI+): m/z calcd for C30H24Cl2N6O5 [M+H]+: 
619.1257, found 619.1264. 
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Chapter 5 
Synthesis of polycyclic dihydroindoles by selective 
decomposition of bis(1,2,3-triazoles) mediated by 
rhodium-catalysis 
Reproduced in part with permission from [“Synthesis of polycyclic 
dihydroindoles by selective decomposition of bis(1,2,3-triazoles) mediated by 
rhodium-catalysis” Sampad Jana, Robby Vroemans and Wim Dehaen Adv. 
Synth. Catal. 2017, 359, 3085 – 3089] Copyright © [2017] John Wiley & Sons, 
Inc. 
Sampad Jana carried out the experiments, analyzed the data and wrote the 
manuscript. 
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5.1 Introduction 
Substituted indoles are encountered in a vast number of heterocyclic 
molecules with a wide range of applications ranging from medicinal to 
material chemistry1. More specifically, 3,4-fused indoles and 
hapalindole alkaloid analogues are important pharmacophores found 
in nature, such as dehydrobufotenine, chanoclavine, lysergic acid, and 
cyclavine (Figure 9).2 Generally, this type of fused indoles can be 
synthesized only via multistep procedures2d,3. Therefore, the biological 
properties of these type of fused heterocycles remain for the most 
part unexplored because of the difficulties in obtaining them in 
sufficient quantities. Hence, the development of atom economic one 
step synthetic strategies towards 3,4-fused indoles is highly desirable.  
In recent years, azavinylcarbenes derived from N-sulfonyl-1,2,3-
triazoles have drawn considerable attention in the chemical 
community as a means towards the synthesis of various heterocycles 
which are otherwise very difficult to synthesize.4,5,6 1,2,3-Triazoles are 
known to be very stable heterocycles, however they can be 
decomposed to azavinylcarbenes by using appropriate substituents on 
the 1,2,3-triazole ring and a transition metal catalyst.  In 2007, 
Gevorgyan was first to point out that 1,2,3-triazoles could be cleaved 
by transition metal catalysis to azavinylcarbene species, which was 
further used in various transformation.4,5,6 Since then, a vast number 
of synthetic strategies have been discovered including 
transannulation, cyclopropanation, dehydrogenative rearrangements, 
C-H bond insertion, ring expansion, and ylide formation, in which 1-
sulfonyl-1,2,3-triazoles have been used as a carbene precursor.4,5,6 
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Figure 9 Representative bioactive molecules with 3,4-fused indole core 
 
Scheme 35 Decomposition of triazole into azavinylcarbene 
We have been working on the development of various synthetic 
strategies towards the synthesis of functionalized 1,2,3-triazoles.7 
Recently, we have reported a novel methodology towards the 
synthesis of propargyl substituted 1,2,3-triazoles, and further 
functionalization of these triazoles via Cu(I)-catalyzed click reaction 
resulted in the formation of unique N,C-linked bis(1,2,3-triazoles).7a 
5.2 Result and discussion 
136 
 
In 2014 Murakami et al. reported an intramolecular dearomatizing 
annulation reaction of 4-(3-arylpropyl)-1,2,3-triazoles furnishing 
dihydroindole skeletons.4k Inspired by this report, we have anticipated 
that this reaction could be applied to the N,C-linked bis(1,2,3-triazoles) 
bearing the appropriate substituents (Scheme 35). The bis(1,2,3-
triazole) 161a, has been synthesized from N-propargyl-5-
phenyltriazole with tosyl azide in presence of copper(I) thiophene-2-
carboxylate (CuTc) catalyst. As we had hoped, our initial trial with 161a 
in presence of Rh(II) leads to selective decomposition of the 1,4-
disubstituted 1,2,3-triazole core, leading to a 3,4-fused dihydroindole 
162a via intramolecular [3 + 2]-annulation reactions. To the best of our 
knowledge, this is the first example of a selective decomposition of 
bis(1,2,3-triazoles) into azavinylcarbene in presence of a rhodium 
catalyst. 
 
Table 11 optimization of reaction conditionsa 
 
Entry 
 
Catalyst 
 
Temp (°C) Time (h) Solvent 
 
Yieldb 
(%) 
1 Rh2(OAc)4 80 12 DCE 43 
2 Rh2(OAc)4 80 4 DCE 46 
3 Rh2(oct)4 80 4 DCE 51 
4 Rh2(Piv)4 80 4 DCE 63 
5 Rh2(tpa)4 80 4 DCE 49 
6 Rh2(esp)2 80 4 DCE 76 
7 Rh2(esp)2 60 4 DCE 57 
8 Rh2(esp)2 100 4 DCE 66 
9 Rh2(esp)2 80 4 Toluene 69 
10 Rh2(esp)2 80 4 CHCl3 70 
11 Rh2(esp)2 80 4 Cyclohexane 63 
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 [a]All reactions were conducted on a 0.26 mmol scale in 4 mL solvent with 5 
mol% catalyst under N2 atmosphere. [b]isolated yield. Rh2(tpa)4 = 
Rh2(triphenylacetate)4, Rh2(esp)2 = bis[rhodium(α,α,α′,α′-tetramethyl-1,3- 
benzenedipropionic acid)]. 
After getting this promising result, we started to optimize this novel 
annulation reaction (Table 11). Triazole 161a was treated with a 
catalytic amount of Rh2(OAc)4 in dry DCE at 80 °C under nitrogen 
atmosphere, and the desired fused indole 162a was obtained in 43 % 
yield after 12 h. An increase in yield was observed when the reaction 
time was reduced to 4 h. Next, changing the catalyst from Rh2(OAc)4 
to Rh2(esp)2 resulted in a significant increase in yield under the same 
conditions. Other catalyst, such as Rh2(oct)4 used by Murakami et al.4k, 
Rh2(Piv)4, and Rh2(tpa)4 gave no better result. It was found that the 
yield decreased if the reaction was carried out at lower or higher 
temperature than 80 °C. While changing the solvent to toluene, CHCl3 
and cyclohexane resulted in slightly lower yield (Table 11).  
With the optimized conditions in hand, we started to investigate the 
role of the sulfonyl group substituents (Table 12). It was found that 
neither electron donating or electron withdrawing groups on the 
phenylsulfonyl ring had a significant effect on the outcome of the 
reaction (162b and 162c). Next, the substitution effect on the 5-aryl 
ring was investigated (Table 12). Electron donating groups such as –
Me (162d) and –OMe (162e) at the 4- position resulted in slightly lower 
yields, whereas an electron withdrawing group –F (162f) at the para 
position resulted in an increased yield. Similar trends were observed 
in case of the meta isomers. For instance, meta –F (162h) and –CF3 
(162i) afforded excellent yields as compared to meta –Me (162g) 
isomer. 
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Table 12 Scope of dearomatizing trans annulation reaction of bis(1,2,3-
triazoles)a 
[a]General conditions: 161 (0.23 mmol), and Rh2(esp)2 (0.012 mmol), were 
heated in DCE (4 mL) at 80 °C for 4h unless otherwise noted. 
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In order to prove the generality of this reaction, in addition to the 
transannulation reaction onto different substituted phenyl groups, the 
use of heterocyclic dibenzofuran was also investigated (Scheme 36). 
Substrate 161k underwent Rh(II)-catalyzed intramolecular cyclization 
to give the corresponding polyheterocyclic products 162k in good 
yield. 
3,4-Fused indoles alkaloid analogues are interesting pharmacophores 
which could be accessible via oxidative aromatization of 
dihydroindole. Similar to Murakami et al.4k the oxidation reaction of  
3,4-dihydroindole 162a was carried out with MnO2. This afforded the 
triazole-fused alkaloid analogue 163 in excellent yield (Scheme 4). 
 
 
Scheme 36 use of benzofuran in transannulation reaction towards 162k 
The synthetic utility of the Rh(II)-catalyzed selective 1,2,3-triazole 
decomposition and annulation reaction was further exemplified by a 
one-pot synthesis of 3,4-fused dihydroindole 162a starting from 
propargyl triazole 164 in moderate yield (Scheme 38). Thus, in this way 
the interesting 1,2,3-triazole derived (dihydro)indole alkaloid 
analogues are accessible in a few reaction steps. 
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Scheme 37. Formation of fused indole derivative 
A sequential one-pot synthesis of fused indole 163 was also carried out 
starting from bis(1,2,3-triazoles) 161a. A mixture of bis(1,2,3-triazole) 
161a and Rh2(esp)2 was heated at 80 °C in DCE for 4h to form the 
dihydroindole. Subsequently, MnO2 was added to the same reaction 
tube, which was further stirred at 80 °C for 24h to afford fused indole 
of bis(1,2,3-triazole) 163 in good yield. Thus the sequential one-pot 
reaction provides an easy access to triazole fused indole 163 in good 
yield (Scheme 39).  
 
 
Scheme 38 One-pot procedure starting from propargyl triazoles 
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Scheme 39 One-pot procedure to access triazole fused indole from 
bis(1,2,3-triazole) 
 
Scheme 40 Proposed reaction mechanism 
A reaction mechanism is postulated on the basis of the previous 
literature reports4-6 (Scheme 40). Triazole 161a is in equilibrium with 
ring-chain tautomer -diazo imine I, which subsequently reacts with 
Rh(II) affording -imino rhodium carbene complex II and releases 
molecular dinitrogen. Then, intramolecular nucleophilic attack occurs 
of the phenyl at the electrophilic carbene center in a 6-exo mode to 
generate zwitterionic species III. In a final step, the anionic rhodium of 
III undergoes elimination which drives the final cyclization step, 
leading to final product 162a and regenerating the Rh(II)-catalytic 
species.  
 
5.3 Conclusion 
In conclusion, we have disclosed an unprecedented selective 
decomposition of bis(1,2,3-triazoles) by a Rh(II)-catalyzed [3 + 2]-
intramolecular annulation reaction which leads to the formation of 
3,4-fused indoles. Extension of this protocol to heterocycles led to 
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interesting polyfused 1,2,3-triazole derivatives. This protocol presents 
a simple, one-step, and atom economic efficient method for the 
synthesis of 1,2,3-triazole fused dihydroindoles and indoles, which 
could so far not be synthesized by other means. Further applications 
of these products in medicinal chemistry are in progress and will be 
reported in due course. 
5.4 Experimental Section 
5.4.1 General procedure for preparation of bis-triazoles.  
 
 
 
A flame dried tube was charged with the appropriate propargyl 
triazole (0.66 mmol) , CuTc (0.06 mmol), and tosyl azide (0.73 mmol) 
in dry toluene(2 mL) under N2 atmosphere. The resulted mixture was 
heated at 60 °C for 3 h. After consumption of the starting product as 
apparent from TLC analysis,  the crude reaction mixture was 
concentrated in vacuo, and the product was isolated by flash column 
chromatography (EtOAc: heptane 1:1) to obtain pure product.  
 
5.4.1.1 Charactarization data 
 
5-Phenyl-1-((1-tosyl-1H-1,2,3-triazol-4-yl)methyl)-1H-1,2,3-
triazole(161a): 83% Yield, Off white solid, m.p. 90 - 91 °C, 1H NMR (400 
MHz, CDCl3) δ 8.14 (s, 1H), 7.98 (d, J = 8.4 Hz, 2H), 7.73 (s, 1H), 7.51 – 
7.42 (m, 5H), 7.39 (d, J = 8.1 Hz, 2H), 5.63 (s, 2H), 2.46 (s, 3H). 13C NMR 
(101 MHz, CDCl3) δ 147.65, 142.11, 138.31, 132.82, 132.38, 130.48, 
129.71, 129.12, 128.86, 128.67, 126.06, 123.29, 42.94, 21.73. HRMS 
(ESI+) m/z calcd for C18H16N6O2S [M + H]+ 381.1128, found 381.1162. 
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1-((4-Methoxyphenyl)sulfonyl)-4-((5-phenyl-1H-1,2,3-triazol-1-
yl)methyl)-1H-1,2,3-triazole (161b): 65% Yield, off white solid, m.p. 
260 - 261 °C, 1H NMR (600 MHz, CDCl3) δ 8.14 (s, 1H), 8.04 (d, J = 9.0 
Hz, 2H), 7.73 (s, 1H), 7.50 – 7.48 (m, 3H), 7.46 – 7.44 (m, 2H), 7.04 (d, J 
= 9.0 Hz, 2H), 5.63 (s, 2H), 3.89 (s, 3H). 13C NMR (151 MHz, CDCl3) δ 
165.75, 142.31, 138.57, 133.13, 131.59, 130.00, 129.42, 129.14, 
126.57, 126.31, 123.26, 115.34, 114.38, 56.12, 43.24. HRMS (ESI+) m/z 
calcd for C18H16N6O3S [M + H]+ 397.10772, found 397.1034. 
 
5-Phenyl-1-((1-((4-(trifluoromethyl)phenyl)sulfonyl)-1H-1,2,3-
triazol-4-yl)methyl)-1H-1,2,3-triazole (161c): 78% Yield, off white 
solid, m.p. 239 - 240 °C, 1H NMR (300 MHz, CDCl3) δ 8.27 (d, J = 8.3 Hz, 
2H), 8.22 (s, 1H), 7.89 (d, J = 8.3 Hz, 2H), 7.74 (s, 1H), 7.51 – 7.43 (m, 
5H), 5.65 (s, 2H). 13C NMR (151 MHz, CDCl3) δ 152.20, 141.32, 137.57, 
132.80, 129.41, 129.06, 128.87, 128.65, 128.45, 126.50, 126.33, 
125.07, 124.90, 124.88, 123.27, 43.14. HRMS (ESI+) m/z calcd for 
C18H13F3N6O2S [M + H]+ 435.08454, found 435.0839 
 
5-(4-Tolyl)-1-((1-tosyl-1H-1,2,3-triazol-4-yl)methyl)-1H-1,2,3-triazole 
(161d): 58% Yield, Off white solid, m.p. 135 - 136 °C, 1H NMR (300 MHz, 
CDCl3) δ 8.14 (s, 1H), 7.98 (d, J = 8.3 Hz, 2H), 7.71 (s, 1H), 7.39 (d, J = 
8.2 Hz, 2H), 7.35 – 7.29 (m, 4H), 5.62 (s, 2H), 2.46 (s, 3H), 2.42 (s, 3H). 
13C NMR (151 MHz, CDCl3) δ 147.81, 142.47, 140.24, 138.65, 132.93, 
132.72, 130.68, 130.09, 129.01, 128.97, 123.40, 123.22, 43.18, 22.00, 
21.48. HRMS (ESI+) m/z calcd for C19H18N6O2S [M + H]+ 395.1284, 
found 395.1285. 
 
5-(4-Methoxyphenyl)-1-((1-tosyl-1H-1,2,3-triazol-4-yl)methyl)-1H-
1,2,3-triazole (161e): 89% Yield, Off white solid, m.p. 146 - 150 °C, 1H 
NMR (300 MHz, CDCl3) δ 8.15 (s, 1H), 7.99 (d, J = 8.5 Hz, 2H), 7.68 (s, 
1H), 7.42 – 7.34 (m, 4H), 7.00 (d, J = 8.8 Hz, 2H), 5.61 (s, 2H), 3.86 (s, 
3H), 2.46 (s, 3H).  13C NMR (75 MHz, DMSO) δ 160.04, 145.48, 141.44, 
137.82, 137.44, 132.43, 130.13, 128.15, 125.53, 118.56, 114.56, 55.35, 
43.01, 20.82. HRMS (ESI+) m/z calcd for C19H18N6O3S [M + H]+ 
411.1233, found 411.1232. 
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5-(4-Fluorophenyl)-1-((1-tosyl-1H-1,2,3-triazol-4-yl)methyl)-1H-
1,2,3-triazole (161f): 59% Yield, Off white solid, m.p. 99 - 100 °C, 1H 
NMR (300 MHz, CDCl3) δ 8.20 (s, 1H), 7.99 (d, J = 8.5 Hz, 2H), 7.70 (s, 
1H), 7.50 – 7.44 (m, 2H), 7.40 (d, J = 8.1 Hz, 2H), 7.18 (t, J = 8.6 Hz, 2H), 
5.60 (s, 2H), 2.46 (s, 3H). 13C NMR (75 MHz, CDCl3) δ 147.92, 142.17, 
137.65, 132.60, 131.31, 131.19, 130.72, 129.04, 123.49, 122.33, 
116.79, 116.50, 43.05, 22.02. HRMS (ESI+) m/z calcd for C18H15FN6O2S 
[M + H]+ 399.1033, found 399.1033. 
 
5-(3-Tolyl)-1-((1-tosyl-1H-1,2,3-triazol-4-yl)methyl)-1H-1,2,3-triazole 
(161g): 66% Yield, Off-white semi solid, 1H NMR (300 MHz, CDCl3) δ 
8.14 (s, 1H), 7.99 (d, J = 8.5 Hz, 2H), 7.71 (s, 1H), 7.42 – 7.34 (m, 3H), 
7.30 (s, 1H), 7.23 (d, J = 6.8 Hz, 2H), 5.63 (s, 2H), 2.46 (s, 3H), 2.40 (s, 
3H). 13C NMR (75 MHz, CDCl3) δ 141.08, 140.93, 139.74, 137.88, 
131.99, 130.03, 129.56, 129.33, 129.18, 128.65, 126.48, 126.01, 
123.46, 44.41, 21.44. HRMS (ESI+) m/z calcd for C19H18N6O2S [M + H]+ 
395.1284, found 395.1283. 
 
5-(3-Fluorophenyl)-1-((1-tosyl-1H-1,2,3-triazol-4-yl)methyl)-1H-
1,2,3-triazole (161h): 72% Yield, Off white solid, m.p. 118 - 119 °C, 1H 
NMR (300 MHz, CDCl3) δ 8.19 (s, 1H), 7.99 (d, J = 8.5 Hz, 2H), 7.74 (s, 
1H), 7.48 (td, J = 7.9, 5.8 Hz, 1H), 7.40 (d, J = 8.1 Hz, 2H), 7.29 – 7.25 
(m, 1H), 5.63 (s, 2H), 2.46 (s, 3H). 13C NMR (75 MHz, CDCl3) δ 164.43, 
161.13, 141.20, 140.73, 138.24, 131.52, 131.41, 129.21, 128.87, 
126.17, 125.90, 125.35, 118.08, 117.81, 116.76, 116.45, 44.06, 21.39. 
HRMS (ESI+) m/z calcd for C18H15FN6O2S [M + H]+ 399.1033, found 
399.1030. 
 
1-Tosyl-4-((5-(3-(trifluoromethyl)phenyl)-1H-1,2,3-triazol-1-
yl)methyl)-1H-1,2,3-triazole(161i): 70% Yield, Off white solid, m.p. 83 
- 84 °C, 1H NMR (300 MHz, CDCl3) δ 8.24 (s, 1H), 8.00 (d, J = 8.5 Hz, 2H), 
7.81 – 7.72 (m, 4H), 7.70 – 7.61 (m, 1H), 7.40 (d, J = 8.1 Hz, 2H), 5.61 
(s, 2H), 2.46 (s, 3H). 13C NMR (151 MHz, CDCl3) δ 147.95, 141.90, 
137.22, 133.52, 132.64, 132.52, 130.74, 130.10, 129.07, 127.28, 
126.79, 126.13, 123.52, 43.20, 22.02. HRMS (ESI+) m/z calcd for 
C19H15F3N6O2S [M + H]+ 449.1001, found 449.0997. 
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4-Methyl-5-phenyl-1-((1-tosyl-1H-1,2,3-triazol-4-yl)methyl)-1H-
1,2,3-triazole (161j): 79% Yield, Off white solid, m.p. 131 - 132 °C, 1H 
NMR (300 MHz, CDCl3) δ 8.08 (s, 1H), 7.98 (d, J = 8.4 Hz, 2H), 7.51 – 
7.47 (m, 3H), 7.39 (d, J = 8.2 Hz, 2H), 7.35 – 7.29 (m, 2H), 5.52 (s, 2H), 
2.46 (s, 3H), 2.32 (s, 3H). 13C NMR (151 MHz, CDCl3) δ 147.77, 142.57, 
141.53, 134.91, 132.76, 130.66, 129.67, 129.34, 128.98, 126.78, 
123.21, 53.56, 43.37, 21.98, 10.79. HRMS (ESI+) m/z calcd for 
C19H18N6O2S [M + H]+ 395.12846, found 395.1269. 
 
5-(Dibenzo[b,d]furan-2-yl)-1-((1-tosyl-1H-1,2,3-triazol-4-yl)methyl)-
1H-1,2,3-triazole(161k): 72% Yield, Off white solid, m.p. 180 - 181 °C, 
1H NMR (300 MHz, CDCl3) δ 8.25 (s, 1H), 8.13 – 8.11 (m, 1H), 8.01 – 
7.96 (m, 3H), 7.80 (s, 1H), 7.69 – 7.60 (m, 2H), 7.56 – 7.50 (m, 2H), 7.40 
– 7.36 (m, 3H), 5.68 (s, 2H), 2.45 (s, 3H). 13C NMR (75 MHz, CDCl3) δ 
156.86, 156.79, 147.88, 142.44, 132.67, 130.72, 129.02, 128.31, 
128.10, 125.43, 123.62, 123.46, 121.85, 121.24, 120.76, 119.34, 
112.72, 112.07, 43.11, 22.02. HRMS (ESI+) m/z calcd for C24H18N6O3S 
[M + H]+ 471.1233, found 471.1230. 
 
5.4.2 General synthesis for Rh(II) catalyzed annulation reaction: 
 
 
 
A flame dried reaction tube, fitted with rubber septum, was charged 
with triazole 161a – 161i (0.263 mmol) and Rh2(esp)2 (0.013 mmol) at 
ambient temperature. The reaction tube was then evacuated and filled 
with argon three times before adding DCE (4 mL). The reaction mixture 
was then heated at 80 °C for 4h. After consumption of the starting 
product apparent from TLC analysis, the reaction mixture was cooled 
to room temperature. The crude reaction mixture was concentrated in 
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vacuo, and the product was isolated by flash column chromatography 
(ACN:DCM 1:20)to obtain pure product 162a - 162i.  
 
5.4.2.1 Characterization data 
(3aS,3a1R)-4-Tosyl-3a,3a1,4,6-tetrahydropyrrolo[4,3,2-
de][1,2,3]triazolo[5,1-a]isoquinoline (162a): 76% Yield, Off white 
solid, m.p. 203 - 204 °C, 1H NMR (400 MHz, CDCl3) δ 7.77 (s, 1H), 7.72 
(d, J = 8.3 Hz, 2H), 7.39 (d, J = 8.1 Hz, 2H), 6.66 (t, J = 1.7 Hz, 1H), 6.31 
– 6.24 (m, 2H), 6.21 – 6.15 (m, 1H), 5.24 (d, J = 14.7 Hz, 1H), 5.02 (d, J 
= 14.6 Hz, 1H), 4.43 (dd, J = 13.6, 5.1 Hz, 1H), 3.73 (d, J = 13.6 Hz, 1H), 
2.47 (s, 3H). 13C NMR (101 MHz, CDCl3) δ 144.83, 134.50, 132.33, 
130.19, 130.13, 129.39, 128.03, 126.08, 122.84, 120.33, 118.60, 
113.14, 56.21, 45.60, 41.81, 21.79. 
 
(3aS,3a1R)-4-((4-Methoxyphenyl)sulfonyl)-3a,3a1,4,6-
tetrahydropyrrolo[4,3,2-de][1,2,3]triazolo[5,1-a]isoquinoline (162b): 
72% Yield, Off white solid, m.p. 175 - 176 °C, 1H NMR (400 MHz, CDCl3) 
δ 7.80 – 7.75 (m, 3H), 7.05 (d, J = 8.9 Hz, 2H), 6.65 (s, 1H), 6.31 – 6.23 
(m, 2H), 6.17 (dd, J = 9.4, 5.1 Hz, 1H), 5.24 (d, J = 14.7 Hz, 1H), 5.02 (d, 
J = 14.6 Hz, 1H), 4.43 (dd, J = 13.6, 5.2 Hz, 1H), 3.90 (s, 3H), 3.74 (d, J = 
13.7 Hz, 1H). 13C NMR (101 MHz, CDCl3) δ 163.81, 134.52, 130.24, 
130.19, 129.40, 126.85, 126.06, 122.90, 120.35, 118.61, 114.73, 
113.10, 56.19, 55.87, 45.62, 41.84. HRMS (ESI+) m/z calcd for 
C18H16N4O3S [M + H]+ 369.1015, found 369.1015. 
 
(3aS,3a1R)-4-((4-(Trifluoromethyl)phenyl)sulfonyl)-3a,3a1,4,6-
tetrahydropyrrolo[4,3,2-de][1,2,3]triazolo[5,1-a]isoquinoline (162c): 
74% Yield, Off white solid, m.p. 191 - 192 °C, 1H NMR (300 MHz, CDCl3) 
δ 7.97 (d, J = 8.2 Hz, 2H), 7.87 (d, J = 8.3 Hz, 2H), 7.78 (s, 1H), 6.68 (t, J 
= 1.8 Hz, 1H), 6.33 – 6.25 (m, 2H), 6.18 (ddd, J = 8.9, 5.2, 1.8 Hz, 1H), 
5.26 (d, J = 14.7 Hz, 1H), 5.08 – 5.00 (m, 1H), 4.50 (dd, J = 13.6, 5.2 Hz, 
1H), 3.79 (d, J = 13.7 Hz, 1H). 13C NMR (151 MHz, CDCl3) δ 139.36, 
135.51, 135.29, 134.35, 129.50, 129.36, 128.44, 126.76, 126.74, 
126.62, 124.11, 122.01, 120.37, 118.54, 114.02, 56.55, 45.53, 41.89. 
HRMS (ESI+) m/z calcd for C18H13F3N4O2S [M + H]+ 407.07839, found 
407.0776. 
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(3aR,3a1R)-3-Methyl-4-tosyl-3a,3a1,4,6-tetrahydropyrrolo[4,3,2-
de][1,2,3]triazolo[5,1-a]isoquinoline (162d): 72% Yield, Off white 
semi-solid, 1H NMR (300 MHz, CDCl3) δ 7.71 (d, J = 7.6 Hz, 3H), 7.38 (d, 
J = 8.0 Hz, 2H), 6.76 (t, J = 1.7 Hz, 1H), 6.23 (dd, J = 6.0, 2.1 Hz, 1H), 6.03 
(d, J = 5.1 Hz, 1H), 5.28 – 5.20 (m, 1H), 5.06 – 4.96 (m, 1H), 4.25 (d, J = 
12.3 Hz, 1H), 3.64 (d, J = 12.3 Hz, 1H), 2.47 (s, 3H), 2.19 – 2.14 (m, 3H). 
13C NMR (75 MHz, CDCl3) δ 157.33, 144.82, 132.38, 131.76, 131.45, 
130.06, 128.20, 124.16, 119.57, 117.93, 114.50, 61.90, 45.45, 43.48, 
23.65, 21.80. HRMS (ESI+) m/z calcd for C19H18N4O2S [M + H]+ 
367.1223, found 367.1216. 
 
(3aR,3a1R)-3-Methoxy-4-tosyl-3a,3a1,4,6-tetrahydropyrrolo[4,3,2-
de][1,2,3]triazolo[5,1-a]isoquinoline (162e): 69% Yield, Off white 
solid, m.p. 195 - 196 °C, 1H NMR (300 MHz, CDCl3) δ 7.76 (d, J = 8.3 Hz, 
2H), 7.69 (s, 1H), 7.36 (d, J = 8.0 Hz, 2H), 6.84 (t, J = 1.6 Hz, 1H), 6.29 
(dd, J = 6.6, 2.4 Hz, 1H), 5.29 – 5.20 (m, 2H), 5.08 – 4.96 (m, 1H), 4.28 
(d, J = 11.9 Hz, 1H), 3.88 – 3.78 (m, 1H), 3.53 (s, 3H), 2.45 (s, 3H). 13C 
NMR (75 MHz, CDCl3) δ 13C NMR (75 MHz, CDCl3) δ 153.27, 144.38, 
134.79, 133.47, 131.48, 129.73, 128.39, 128.14, 119.43, 113.62, 
111.39, 96.12, 60.08, 55.33, 45.40, 44.65, 21.71. HRMS (ESI+) m/z 
calcd for C19H18N4O3S [M + H]+ 383.1172, found 383.1162. 
 
(3aR,3a1R)-3-Fluoro-4-tosyl-3a,3a1,4,6-tetrahydropyrrolo[4,3,2-
de][1,2,3]triazolo[5,1-a]isoquinoline (162f): 81% Yield, Off white 
solid, m.p. 76 - 77 °C, 1H NMR (400 MHz, CDCl3) δ 7.78 – 7.74 (m, 3H), 
7.39 (d, J = 8.1 Hz, 2H), 6.80 (t, J = 1.7 Hz, 1H), 6.22 (ddd, J = 6.8, 4.6, 
2.4 Hz, 1H), 5.91 (dd, J = 10.9, 6.6 Hz, 1H), 5.26 (d, J = 14.5 Hz, 1H), 5.05 
– 4.97 (m, 1H), 4.38 (dd, J = 12.7, 8.2 Hz, 1H), 3.99 (d, J = 12.7 Hz, 1H), 
2.47 (s, 3H). 13C NMR (101 MHz, CDCl3) δ 157.09, 154.39, 145.08, 
134.00, 132.25, 131.43, 130.19, 129.31, 128.32, 117.49, 117.43, 
117.21, 117.15, 116.19, 115.97, 111.69, 111.67, 105.97, 105.76, 77.16, 
57.65, 57.38, 46.06, 45.99, 45.33, 21.82. HRMS (ESI+) m/z calcd for 
C18H15FN4O2S [M + H]+ 371.0972, found 971.0982. 
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(3aS,3a1R)-2-Methyl-4-tosyl-3a,3a1,4,6-tetrahydropyrrolo[4,3,2-
de][1,2,3]triazolo[5,1-a]isoquinoline (162g): 71% Yield, Off white 
semi-solid, 1H NMR (300 MHz, CDCl3) δ 7.77 (s, 1H), 7.71 (d, J = 8.3 Hz, 
2H), 7.38 (dd, J = 8.5, 0.6 Hz, 2H), 6.64 (t, J = 1.8 Hz, 1H), 6.16 (d, J = 2.0 
Hz, 1H), 5.93 – 5.86 (m, 1H), 5.23 (d, J = 14.6 Hz, 1H), 5.05 – 4.95 (m, 
1H), 4.40 (ddd, J = 13.3, 5.5, 1.1 Hz, 1H), 3.64 (d, J = 13.2 Hz, 1H), 2.46 
(s, 3H), 1.92 (s, 3H). 13C NMR (75 MHz, CDCl3) δ 144.69, 134.47, 134.44, 
132.34, 130.10, 130.04, 129.74, 129.25, 127.96, 126.48, 122.57, 
120.53, 117.55, 113.17, 57.16, 45.61, 41.50, 22.10, 21.75. HRMS (ESI+) 
m/z calcd for C19H18N4O2S [M + H]+ 367.1223, found 367.1219. 
 
 (3aR,3a1R)-2-Fluoro-4-tosyl-3a,3a1,4,6-tetrahydropyrrolo[4,3,2-
de][1,2,3]triazolo[5,1-a]isoquinoline (162h): 88% Yield, Off white 
solid, m.p. 171 - 172 °C, 1H NMR (300 MHz, DMSO) δ 8.15 (s, 1H), 7.78 
(d, J = 8.3 Hz, 2H), 7.51 (d, J = 8.0 Hz, 2H), 6.87 (s, 1H), 6.62 – 6.55 (m, 
1H), 5.67 (dd, J = 12.6, 5.9 Hz, 1H), 5.33 (d, J = 14.3 Hz, 1H), 5.08 (d, J = 
14.2 Hz, 1H), 4.55 (dt, J = 13.1, 5.6 Hz, 1H), 4.05 (d, J = 12.9 Hz, 1H), 
2.43 (s, 3H). 13C NMR (151 MHz, CDCl3) δ 159.74, 158.06, 145.02, 
143.69, 139.28, 133.30, 133.28, 132.38, 130.60, 130.27, 130.13, 
129.83, 127.96, 126.56, 124.94, 124.87, 114.80, 114.54, 111.85, 99.11, 
98.97, 57.40, 57.32, 45.65, 42.22, 21.80. HRMS (ESI+) m/z calcd for 
C18H15FN4O2S [M + H]+ 371.097, found 371.0959. 
 
(3aS,3a1R)-4-Tosyl-2-(trifluoromethyl)-3a,3a1,4,6-
tetrahydropyrrolo[4,3,2-de][1,2,3]triazolo[5,1-a]isoquinoline (162i): 
78% Yield, Off white solid, m.p. 68 - 69 °C, 1H NMR (300 MHz, CDCl3) δ 
7.87 (s, 1H), 7.73 (d, J = 8.3 Hz, 2H), 7.40 (d, J = 8.0 Hz, 2H), 6.70 – 6.61 
(m, 2H), 6.33 (d, J = 1.9 Hz, 1H), 5.32 – 5.23 (m, 1H), 5.05 (d, J = 14.8 
Hz, 1H), 4.66 – 4.53 (m, 1H), 3.80 (d, J = 13.9 Hz, 1H), 2.48 (s, 3H). 13C 
NMR (151 MHz, CDCl3) δ 145.32, 132.03, 130.36, 130.20, 129.85, 
129.64, 129.43, 128.05, 126.58, 123.50, 123.26, 123.12, 123.08, 
121.70, 113.17, 112.50, 55.15, 45.57, 41.96, 21.81. HRMS (ESI+) m/z 
calcd for C19H15F3N4O2S [M + H]+ 421.0940, found 421.0926. 
 
(3aS,3a1R)-10-Methyl-4-tosyl-3a,3a1,4,6-tetrahydropyrrolo[4,3,2-
de][1,2,3]triazolo[5,1-a]isoquinoline (162j): 73% Yield, Off white 
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solid, m.p. 111 - 112 °C, 1H NMR (300 MHz, CDCl3) δ 7.71 (d, J = 8.3 Hz, 
2H), 7.38 (d, J = 8.0 Hz, 2H), 6.63 (t, J = 1.7 Hz, 3H), 6.29 (dd, J = 9.6, 6.0 
Hz, 1H), 6.22 – 6.12 (m, 2H), 5.18 (d, J = 14.7 Hz, 1H), 5.01 – 4.92 (m, 
1H), 4.39 (dd, J = 13.6, 5.2 Hz, 1H), 3.70 (d, J = 13.6 Hz, 1H), 2.46 (s, 3H), 
2.40 (s, 3H). 13C NMR (151 MHz, CDCl3) 144.72, 139.91, 132.13, 130.11, 
129.64, 129.60, 127.94, 126.15, 122.12, 121.31, 117.73, 113.39, 56.25, 
45.57, 42.14, 21.70, 12.05. HRMS (ESI+) m/z calcd for C19H18N4O2S [M 
+ H]+ 367.1223, found 367.1216. 
 
(2a1R,13bR)-1-Tosyl-1,2a1,3,13b-tetrahydrobenzofuro[2,3-
g]pyrrolo[4,3,2-de][1,2,3]triazolo[5,1-a]isoquinoline (162k): 63% 
Yield, Off white solid, m.p. 195 - 196 °C,  1H NMR (300 MHz, CDCl3) δ 
7.90 (s, 1H), 7.81 (dd, J = 8.3, 1.8 Hz, 2H), 7.60 (d, J = 7.4 Hz, 1H), 7.53 
(d, J = 7.8 Hz, 1H), 7.40 – 7.36 (m, 1H), 7.34 – 7.29 (m, 3H), 6.92 (d, J = 
2.4 Hz, 1H), 6.84 (d, J = 1.7 Hz, 1H), 5.35 – 5.06 (m, 3H), 4.17 (d, J = 12.7 
Hz, 1H), 2.40 (s, 3H). 13C NMR (75 MHz, CDCl3) δ 155.82, 147.01, 
144.83, 133.02, 131.01, 130.00, 129.83, 128.24, 126.57, 125.75, 
124.34, 123.63, 119.42, 118.34, 115.79, 114.30, 112.27, 111.76, 55.36, 
46.56, 45.51, 21.75. HRMS (ESI+) m/z calcd for C24H18N4O3S [M + H]+ 
443.1172, found 443.1181. 
 
5.4.3 Oxidative aromatization reaction: 
A flame dried reaction tube was charged with dihydroindole 162a (100 
mg, 0.284 mmol), MnO2 (123 mg, 1.419 mmol) in DCE (2 mL). The 
reaction mixture was then heated at 80 °C for 24 h. After the 
completion of the reaction, the solvent was evaporated in vacuo. The 
crude reaction mixture was then directly purified by flash column 
chromatography (ACN: DCM 1:20) to afford fused indole 163 as a off 
white solid (79mg, 89 %). 
 
4-Tosyl-4,6-dihydropyrrolo[4,3,2-de][1,2,3]triazolo[5,1-
a]isoquinoline (163): 89% Yield, Off white solid, m.p. 210 - 211 °C, 1H 
NMR (300 MHz, CDCl3) δ 8.01 (s, 1H), 7.87 (dd, J = 5.4, 3.5 Hz, 1H), 7.81 
(d, J = 8.4 Hz, 2H), 7.50 (t, J = 1.9 Hz, 1H), 7.40 (d, J = 2.1 Hz, 1H), 7.39 
(s, 1H), 7.26 (d, J = 8.0 Hz, 2H), 5.82 (d, J = 1.9 Hz, 2H), 2.36 (s, 3H). 13C 
NMR (151 MHz, CDCl3) δ 145.69, 135.15, 133.01, 132.27, 130.25, 
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128.49, 126.98, 126.97, 126.92, 125.62, 120.97, 117.30, 117.02, 
114.28, 112.17, 45.67, 21.73. HRMS (ESI+) m/z calcd for C18H14N4O2S 
[M + H]+ 351.0910, found 351.0911. 
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6.1 Introduction 
The human immunodeficiency virus (HIV), the causative agent of the 
acquired immunodeficiency syndrome (AIDS), has been plaguing the 
human race for more than thirty years.1 According to the global 
statistics of UNAIDS, it has been estimated that globally 36.7 million 
people were suffering from HIV/AIDS in 2015.2 Even though more than 
thirty drugs targeting different steps of the viral life cycle are either 
approved or in clinical stages to treat HIV/AIDS,2 a cure remains 
elusive. Moreover, emergence of HIV strains that are no longer 
sensitive to the drug cocktails employed leading to inability to 
completely block the viral replication.3 Thus, finding new anti-HIV 
agents that are less toxic and more effective in targeting HIV reservoirs 
in the body is still needed. Artemisinin is a naturally occurring 1,2,4-
trioxane sesquiterpene, first isolated in 1972 from a Chinese medicinal 
plant that has been used as a treatment for fever for many centuries.4  
Reduction of the carbonyl group of artemisinin leads to the synthesis 
of dihydroartemisinin in high yields without disrupting the unusual 
peroxide linkage of artemisinin which has in turn led to the 
development of a series of semi-synthetic first-generation derivatives 
including the oil soluble artemether and arteether, and water soluble 
sodium artesunate.6 Derivatives of artemisinin have shown an 
improved potency as antimalarial, anticancer and antiviral agents as 
compared to artemisinin itself.5,6,7 Furthermore, derivatives of 
dihydroartemisinin are found to have anti-proliferative, antibacterial, 
antiviral, and immunosuppressive activities.8-21 Even though it displays 
a high activity profile, dihydroartemisinin does suffer some drawbacks 
such as neurotoxicity in animal models, short pharmacological half-
life, and recrudescence of the disease.22, 23  
Artemisnin and derivatives of artemisnin are also well known for the 
anti-viral activity.23b However, the shortcomings of the current 
artemisinin derivatives and emergence of multidrug resistance for 
artemisinin based combination therapies24 are the motivation to 
search for novel artemisinin compounds for anti-viral propperties. 
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Figure 10 Structures of artemisinin and its semi -synthetic derivatives 
Although 1,2,3-triazole derivatives of artemisinin have been 
synthesized and evaluated for biological activity,25, 26 no attempt has 
been made to synthesize 1,5-disubstituted 1,2,3-triazole derivatives of 
dihydroartemisinin in a single step and metal free conditions. The 
widespread applications of 1,2,3-triazoles have triggered the demand 
for metal free and easier access to this privileged scaffold. Herein we 
disclose the implementation of our recently developed triazolization 
strategy27-29 in which dihydroartemisinin scaffold was joined with 
variety of interesting heterocyclic moieties. We presume that this 
strategy could help in synthesizing a series of compound with minimal 
effort to obtain various fused and 1,5-disubstituted triazole derivatives 
of dihydroartemisinin. 
6.2 Results and Discussion 
6.2.1 Organocatalytic synthesis of triazole functionalized 
artemisinin  
As an effective method of functionalizing dihydroartemisinin with 
a triazole heterocycle, we implemented our recently developed 
triazolization strategy.27–29 The method generally involves the reaction 
of a primary amine and an enolizable ketone 129 in the presence of 4-
nitrophenyl azide 131a as a source of dinitrogen. The mechanistic 
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study of this reaction indicated that an equilibrium exists between 
imine and enamine followed by an enamine mediated [3 + 2] 
cycloaddition reaction. This leads to the formation of a triazole 
intermediate followed by elimination of nitroaniline which gave the 
fused or 1,5-disubstituted 1,2,3-triazole derivative of 
dihydroartemisinin. It would be interesting to investigate if a delicate 
structure like dihydroartemisinin could survive the triazolization 
condition. 
 
 
Scheme 40 synthetic route towards the preparation of amine precursor 169 
Initially, the amine functionalized dihydroartemisinin 169 was 
synthesized by a previously reported procedure.31 It involves the 
conversion of dihydroartemisinin into 10-
bromoethoxydihydroartemisinin 167 by using 2-bromoethanol 166 in 
the presence of BF3·Et2O as a catalyst. Reaction of sodium azide with 
10-bromoethoxydihydroartemisinin 167 afforded 2-(10b-
dihydroartemisinoxy) ethyl azide 168 in isolated yield of 95%. The 
azido compound was then reduced to 2-(10b-dihydroartemisinoxy) 
ethyl amine 169 via Staudinger reduction in a yield of 74% (Scheme 
40). 
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Table 12 substrate scope with respect to ketones a 
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[a]Reaction conditions:  169 (1.0 equiv.), 129 (1.0 equiv.), 131a (1.2 equiv.), toluene 
(0.4 mL), 60 °C, 16 h, isolated yield. [b]24 h 
 
The amine modified dihydroartemisinin was then tested for the 
triazolization strategy with various aromatic and enolizable ketones. 
Cyclic ketones such as tetralones and their derivatives reacted 
smoothly under the modified triazolization conditions leading to the 
expected product in moderate yield. Acetophenone was also 
converted to the desired product 170f (Table 12). Next, the versatility 
of this triazolization reaction was shown by functionalizing the 
modified dihydroartemisinin 169 with the male sex hormone analogue 
dihydrotestosterone and the triterpene betulonic acid giving rise to 
the fused triazole derivatives (170k and 170l, respectively) in 
moderate yield (Table 12). 
      In the next series of experiments, we reversed the strategy by 
functionalizing dihydroatemisinin scaffold with symmetrical enolizable 
cyclic ketone. The building block 171 was obtained by classical DCC 
coupling reaction of dihydroartemisinin with cyclohexanone-4-
carboxylic acid isolated in 82 % yield (Scheme 36). 
 
Scheme 41 synthetic route towards the preparation of keto precursor 171 
The versatility of our triazolization methodology was further 
exploited by condensing with various commercial and biologically 
relevant primary amine derivatives. Ketone modified 
dihydroartemisinin 171 was treated with various benzylamines 172 
which led to the synthesis of triazole conjugate 173a – 173d in good 
yield (Table 13). Tryptamine also works fine under these reaction 
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circumstances leading to the expected product 173d in moderate yield 
(Table 13). 
 
 
Table 13 substrate scope with respect to amines a 
[a]Reaction conditions: 171 (1.0 equiv.), 172 (1.0 equiv.), 131a (1.2 equiv.), toluene 
(0.4 mL), 60 °C, 16 h, isolated yield. 
6.2.2 Anti HIV activity evaluation 
The newly synthesized dihydroartemisinin triazole derivatives 
were evaluated for their inhibitory effects (IC50) on the replication of 
wild-type HIV-1 (IIIB) and HIV-2 (ROD) in MT-4 cell cultures, in parallel 
with their cytotoxicities (CC50) using the 3-(4,5-dimethylthiazol-2-yl)-
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2,5-diphenyl tetrazolium bromide (MTT) method.31 A series of 
nucleoside reverse transcriptase inhibitors (NRTIs) i.e. 
azidothymidine (AZT), lamivudine (3TC) and didanosine (DDI), and 
non-nucleoside reverse transcriptase inhibitors (NNRTIs) i.e. 
nevirapine (NVP), efavirenz (EFV), and etravirine (ETR) were included 
as reference compounds. The biological results are represented as IC50 
and CC50 values in Table 14.  
Most of the new triazole analogues of dihydroartemisinin are 
completely devoid of anti-HIV activity.  However, the unsubstituted 
beta-2- tetralone analogue 170b exhibited moderate activity against 
wild type HIV-1 IIIB with IC50 value of 2.78 μM, whereas its alpha 
tetralone analogue 170a did not show any activity.  Both mono and di-
methoxy analogue of beta-tetralone, 170e and 170c respectively, are 
slightly less active against HIV-1 wt with IC50 values of 5.18 and 4.06 
μM respectively. The active molecules were also evaluated for their 
inhibitory activity against a double RT mutant (K103N; Y181C) HIV-1 
strain (RES056).  The derivatives 170b, 170c and 170e, just like the first 
generation NNRTI nevirapine, completely lose their inhibitory activity, 
whereas the anti-HIV of efavirenz and etravirine is only slightly 
affected.  Therefore, the active beta-tetralone most probably act via 
an NNRTI-type mode of action.   
 
Compound IC50 (µM)a CC50 
(µM)b 
HIV-1 
strain IIIB  
HIV-2 
strain ROD  
HIV-1 
strain 
RES056 
 
170a >10.3 >10.3 NT >10.3 
170b 2.78 > 31.5 > 31.5 31.5 
170c 4.06 >21.2 >21.2 21.2 
170e 5.18 >14.9 >14.9 14.9 
azidothymidine 0.0064 0.0082 0.0071 >7.50 
lamivudine 2.53 9.90 NT >87.2 
didanosine 76.0 82.1 NT >212 
nevirapine 0.075 >15.0 >15.0 >15.0 
efavirenz 0.0024 >6.3 0.18 >6.3 
etravirine 0.0034 >2.29 0.045 2.29 
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Table 14 In vitro anti HIV activity and cytotoxicity of triazole derivatives of 
dihydroartemisinin 
[a]IC50: concentration of compound required to achieve 50% protection of 
MT-4 cell cultures against HIV-1-induced cytotoxicity, as determined by the 
MTT method. 
[b] CC50: concentration required to reduce the viability of mock-infected cell 
cultures by 50%, as determined by the MTT method. 
 
6.3 Conclusions  
In conclusion, a series of newly functionalized artemisinin has 
been prepared by using a organocatalytic multicomponent reaction. 
The starting precursors 176 and 178 were used for triazolisation 
reaction resulting in formation of fused and 1,5-disubstituted 1,2,3-
triazole derivatives. All derivatives were screened against HIV wt and 
three molecules exhibited moderate activity. The beta-tetralone 
derivatives 170b, 170c, and 170e were inhibitory to HIV-1 replication 
in cell culture with a limited cytotoxicity. However, no inhibitory 
activity was observed against HIV-2 and an NNRTI-resitant double RT 
mutant (K103N; Y181C) HIV-1 strain (RES056), pointing at an NNRTI-
type mode of action for the active derivatives. Further studies on 
modification of artemisinin by triazolization reaction are under 
investigation and will be reported in due time. 
 
6.4 Experimental section 
6.4.1 General procedure for modified triazolization reaction 
A flame-dried screw-capped reaction tube equipped with magnetic 
stirring bar was charged with amine, ketone, 4-nitrophenylazide, and 
4 Å molecular sieves. The mixture was dissolved in toluene (0.4 mL) 
and stirred at 60 °C for 18-36 h. The reaction was monitored by TLC 
and after completion of reaction, the solvent was removed in vacuo. 
The crude reaction mixture was then subsequently purified by column 
chromatography (silica gel) first using DCM as eluent to remove all 4-
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nitroaniline formed during the reaction, followed by a mixture of 
heptane and ethyl acetate as the eluent to afford the title product. 
6.4.2 Characterization data 
1-(2-(((3R,6R,8aS,9R,10R,12R,12aR)-3,6,9-Trimethyldecahydro-12H-
3,12-epoxy[1,2]dioxepino[4,3-i]isochromen-10-yl)oxy)ethyl)-4,5-
dihydro-1H-naphtho[1,2-d][1,2,3]triazole (170a): 169 (60 mg, 0.18 
mmol), 1-tetralone (26.8 mg, 0.18 mmol), 4-nitrophenylazide (36.1 
mg, 0.22 mmol). Reaction time is 24 h. The product was purified by 
flash column chromatography (at first DCM followed by 
EtOAc/heptane = 3:2) afforded 170a (42 mg, 48%) as an off-white 
semisolid: 1H NMR (400 MHz, CDCl3) δ 7.94 (d, J = 7.4 Hz, 1H), 7.30 (td, 
J = 7.4, 1.8 Hz, 1H), 7.24 – 7.17 (m, 2H), 5.38 (s, 1H), 4.62 (d, J = 8.0 Hz, 
1H), 4.60 – 4.54 (m, 1H), 4.53 – 4.44 (m, 1H), 4.23 (dt, J = 10.6, 4.3 Hz, 
1H), 3.91 (ddd, J = 10.7, 8.6, 4.0 Hz, 1H), 3.09 – 2.91 (m, 4H), 1.87 – 
1.81 (m, 1H), 1.71 – 1.62 (m, 3H), 1.60 – 1.49 (m, 3H), 1.47 (s, 3H), 1.44 
– 1.35 (m, 1H), 1.29 (dt, J = 14.4, 3.2 Hz, 1H), 1.22 – 1.09 (m, 2H), 1.06 
– 0.95 (m, 1H), 0.88 (dd, J = 6.3, 3.6 Hz, 6H). 13C NMR (101 MHz, CDCl3) 
δ 143.34, 134.03, 133.69, 129.04, 128.19, 127.37, 127.35, 122.16, 
107.27, 101.43, 97.25, 82.73, 68.54, 48.50, 45.24, 44.11, 39.98, 35.27, 
34.55, 34.52, 32.81, 28.81, 23.87, 22.17, 19.41, 19.34, 18.76. 
3-(2-(((3R,6R,8aS,9R,10R,12R,12aR)-3,6,9-Trimethyldecahydro-12H-
3,12-epoxy[1,2]dioxepino[4,3-i]isochromen-10-yl)oxy)ethyl)-4,5-
dihydro-3H-naphtho[1,2-d][1,2,3]triazole (170b): 169 (60 mg, 0.18 
mmol), beta-tetralone (26.8 mg, 0.18 mmol), 4-nitrophenylazide (36.1 
mg, 0.22 mmol). Reaction time was 16 h. The product was purified by 
flash column chromatography (at first DCM followed by 
EtOAc/heptane = 3:2) afforded 170b (62 mg, 70%) as an off-white 
solid: mp 104 – 105 °C; 1H NMR (400 MHz, CDCl3) δ 7.94 (d, J = 7.4 Hz, 
1H), 7.30 (td, J = 7.4, 1.8 Hz, 1H), 7.24 – 7.17 (m, 2H), 5.38 (s, 1H), 4.62 
(d, J = 8.0 Hz, 1H), 4.60 – 4.54 (m, 1H), 4.53 – 4.44 (m, 1H), 4.23 (dt, J = 
10.6, 4.3 Hz, 1H), 3.91 (ddd, J = 10.7, 8.6, 4.0 Hz, 1H), 3.09 – 2.91 (m, 
4H), 1.87 – 1.81 (m, 1H), 1.71 – 1.62 (m, 3H), 1.60 – 1.49 (m, 3H), 1.47 
(s, 3H), 1.44 – 1.35 (m, 1H), 1.29 (dt, J = 14.4, 3.2 Hz, 1H), 1.22 – 1.09 
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(m, 2H), 1.06 – 0.95 (m, 1H), 0.88 (dd, J = 6.3, 3.6 Hz, 6H). 13C NMR (101 
MHz, CDCl3) δ 143.34, 134.03, 133.69, 129.04, 128.19, 127.37, 127.35, 
122.16, 107.27, 101.43, 97.25, 82.73, 68.54, 48.50, 45.24, 44.11, 39.98, 
35.27, 34.55, 34.52, 32.81, 28.81, 23.87, 22.17, 19.41, 19.34, 18.76.  
7,8-Dimethoxy-3-(2-(((3R,6R,8aS,9R,10R,12R,12aR)-3,6,9-
trimethyldecahydro-12H-3,12-epoxy[1,2]dioxepino[4,3-
i]isochromen-10-yl)oxy)ethyl)-4,5-dihydro-3H-naphtho[1,2-
d][1,2,3]triazole (170c): 169 (60 mg, 0.18 mmol), 6,7-dimethoxy-3,4-
dihydronaphthalen-2(1H)-one (37.8 mg, 0.18 mmol), 4-
nitrophenylazide (36.1 mg, 0.22 mmol). Reaction time was 16 h. The 
product was purified by flash column chromatography (at first DCM 
followed by EtOAc/heptane = 3:2) afforded 170c (67 mg, 67%) as an 
off-white semisolid: 1H NMR (400 MHz, CDCl3) δ 7.49 (s, 1H), 6.76 (s, 
1H), 5.38 (s, 1H), 4.62 (d, J = 7.9 Hz, 1H), 4.59 – 4.53 (m, 1H), 4.51 – 
4.44 (m, 1H), 4.26 – 4.18 (m, 1H), 3.95 (s, 3H), 3.89 (s, 4H), 3.05 – 2.84 
(m, 4H), 1.88 – 1.79 (m, 1H), 1.71 – 1.62 (m, 3H), 1.60 – 1.50 (m, 3H), 
1.47 (s, 3H), 1.44 – 1.35 (m, 1H), 1.33 – 1.23 (m, 2H), 1.21 – 1.10 (m, 
1H), 1.08 – 0.95 (m, 1H), 0.91 – 0.85 (m, 6H). 13C NMR (101 MHz, CDCl3) 
δ 148.40, 148.20, 143.46, 133.09, 125.92, 121.85, 111.89, 107.25, 
105.67, 101.41, 97.24, 82.71, 68.50, 56.26, 56.18, 48.52, 45.23, 44.12, 
39.97, 35.26, 34.55, 34.51, 32.80, 28.45, 23.85, 22.16, 19.62, 19.32, 
18.74. 
8-Nitro-3-(2-(((3R,6R,8aS,9R,10R,12R,12aR)-3,6,9-
trimethyldecahydro-12H-3,12-epoxy[1,2]dioxepino[4,3-
i]isochromen-10-yl)oxy)ethyl)-4,5-dihydro-3H-naphtho[1,2-
d][1,2,3]triazole (170d): 169 (60 mg, 0.18 mmol), 7-nitro-3,4-
dihydronaphthalen-2(1H)-one (35 mg, 0.18 mmol), 4-nitrophenylazide 
(36.1 mg, 0.22 mmol). Reaction time was 16 h. The product was 
purified by flash column chromatography (at first DCM followed by 
EtOAc/heptane = 3:2) afforded 170d (70.4 mg 73%) as an off-white 
semisolid: 1H NMR (400 MHz, CDCl3) δ 8.78 (d, J = 2.2 Hz, 1H), 8.12 (dd, 
J = 8.3, 2.3 Hz, 1H), 7.48 (d, J = 8.4 Hz, 1H), 5.38 (s, 1H), 4.91 – 4.87 (m, 
2H), 4.61 (d, J = 7.9 Hz, 1H), 4.45 – 4.39 (m, 1H), 4.15 – 4.01 (m, 1H), 
3.15 – 3.02 (m, 4H), 1.86 – 1.79 (m, 1H), 1.69 – 1.61 (m, 3H), 1.55 – 
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1.48 (m, 3H), 1.44 (s, 3H), 1.36 – 1.32 (m, 1H), 1.32 – 1.27 (m, 2H), 1.21 
– 1.11 (m, 1H), 1.02 – 0.92 (m, 1H), 0.88 – 0.76 (m, 6H). 13C NMR (101 
MHz, CDCl3) δ 147.43, 145.81, 144.66, 131.02, 129.79, 126.95, 123.16, 
118.31, 107.19, 101.28, 97.24, 82.76, 77.16, 68.37, 50.36, 45.28, 44.08, 
39.56, 35.21, 34.58, 34.51, 32.61, 30.78, 29.85, 23.85, 22.17, 20.38, 
19.18, 18.80. 
 
8-Methoxy-3-(2-(((3R,6R,8aS,9R,10R,12R,12aR)-3,6,9-
trimethyldecahydro-12H-3,12-epoxy[1,2]dioxepino[4,3-
i]isochromen-10-yl)oxy)ethyl)-4,5-dihydro-3H-naphtho[1,2-
d][1,2,3]triazole (170e): 169 (60 mg, 0.18 mmol), 7-methoxy-3,4-
dihydronaphthalen-2(1H)-one (32.3 mg, 0.18 mmol), 4-
nitrophenylazide (36.1 mg, 0.22 mmol). Reaction time is 16 h. The 
product was purified by flash column chromatography (at first DCM 
followed by EtOAc/heptane = 3:2) afforded 170e (62 mg 66%) as an 
off-white semisolid: 1H NMR (400 MHz, CDCl3) δ 7.51 (d, J = 2.7 Hz, 1H), 
7.13 (d, J = 8.3 Hz, 1H), 6.75 (dd, J = 8.3, 2.7 Hz, 1H), 5.37 (s, 1H), 4.62 
(d, J = 8.0 Hz, 1H), 4.60 – 4.54 (m, 1H), 4.53 – 4.45 (m, 1H), 4.27 – 4.19 
(m, 1H), 3.95 – 3.88 (m, 1H), 3.86 (s, 3H), 3.04 – 2.88 (m, 4H), 1.86 – 
1.80 (m, 1H), 1.71 – 1.62 (m, 3H), 1.61 – 1.49 (m, 3H), 1.47 (s, 3H), 1.43 
– 1.35 (m, 1H), 1.34 – 1.27 (m, 2H), 1.22 – 1.15 (m, 1H), 1.06 – 0.95 (m, 
1H), 0.90 – 0.86 (m, 6H). 13C NMR (101 MHz, CDCl3) δ 159.10, 143.39, 
134.39, 129.97, 129.15, 125.68, 113.95, 107.26, 106.62, 101.41, 97.23, 
82.71, 68.49, 55.62, 48.52, 45.22, 44.10, 39.95, 35.25, 34.54, 34.50, 
32.79, 27.96, 23.85, 22.15, 19.63, 19.32, 18.74. 
 
5-Phenyl-1-(2-(((3R,6R,8aS,9R,10R,12R,12aR)-3,6,9-
trimethyldecahydro-12H-3,12-epoxy[1,2]dioxepino[4,3-
i]isochromen-10-yl)oxy)ethyl)-1H-1,2,3-triazole (170f): 169 (60 mg, 
0.18 mmol), acetophenone (22 mg, 0.18 mmol), 4-nitrophenylazide 
(36.1 mg, 0.22 mmol). Reaction time is 24 h. The product was purified 
by flash column chromatography (at first DCM followed by 
EtOAc/heptane = 3:2) afforded 170f (41 mg 49 %) as an off-white 
semisolid: 1H NMR (400 MHz, CDCl3) δ 7.69 (s, 1H), 7.53 – 7.44 (m, 5H), 
5.35 (s, 1H), 4.64 – 4.46 (m, 3H), 4.32 – 4.21 (m, 1H), 4.12 – 4.00 (m, 
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1H), 1.88 – 1.79 (m, 1H), 1.70 – 1.62 (m, 3H), 1.61 – 1.49 (m, 3H), 1.47 
(s, 3H), 1.42 – 1.33 (m, 1H), 1.31 – 1.22 (m, 2H), 1.21 – 1.12 (m, 1H), 
1.06 – 0.94 (m, 1H), 0.89 – 0.81 (m, 6H). 13C NMR (101 MHz, CDCl3) δ 
138.90, 132.92, 129.45, 129.26, 129.10, 127.25, 107.23, 101.60, 97.23, 
82.71, 68.08, 48.04, 45.27, 44.12, 39.70, 35.27, 34.57, 34.53, 32.79, 
23.86, 22.17, 19.19, 18.76. 
 
5-(3,4-Dibromophenyl)-1-(2-(((3R,6R,8aS,9R,10R,12R,12aR)-3,6,9-
trimethyldecahydro-12H-3,12-epoxy[1,2]dioxepino[4,3-
i]isochromen-10-yl)oxy)ethyl)-1H-1,2,3-triazole (170g): 169 (60 mg, 
0.18 mmol), 1-(3,4-dibromophenyl)ethan-1-one (51 mg, 0.18 mmol), 
4-nitrophenylazide (36.1 mg, 0.22 mmol). Reaction time was 36 h. The 
product was purified by flash column chromatography (at first DCM 
followed by EtOAc/heptane = 3:2) afforded 170g (42 mg 37%) as an 
off-white solid: mp 105 – 106 °C; 1H NMR (400 MHz, CDCl3) δ 7.83 (d, J 
= 2.0 Hz, 1H), 7.73 – 7.69 (m, 2H), 7.32 (dd, J = 8.3, 2.1 Hz, 1H), 5.31 (s, 
1H), 4.60 – 4.52 (m, 3H), 4.28 – 4.22 (m, 1H), 4.07 – 4.00 (m, 1H), 1.86 
– 1.80 (m, 1H), 1.71 – 1.64 (m, 2H), 1.62 – 1.56 (m, 3H), 1.54 – 1.49 (m, 
1H), 1.46 (s, 3H), 1.32 – 1.22 (m, 3H), 1.19 – 1.10 (m, 2H), 1.04 – 0.95 
(m, 1H), 0.88 (d, J = 5.7 Hz, 3H), 0.84 (d, J = 7.1 Hz, 3H). 13C NMR (151 
MHz, CDCl3) δ 134.32, 134.22, 133.20, 129.19, 128.04, 126.35, 125.68, 
107.26, 101.58, 97.21, 82.71, 68.42, 48.52, 45.24, 44.09, 39.71, 35.27, 
34.56, 34.53, 32.81, 23.87, 22.17, 19.22, 18.78. 
 
5-(Naphthalen-1-yl)-1-(2-(((3R,6R,8aS,9R,10R,12R,12aR)-3,6,9-
trimethyldecahydro-12H-3,12-epoxy[1,2]dioxepino[4,3-
i]isochromen-10-yl)oxy)ethyl)-1H-1,2,3-triazole (170h): 169 (60 mg, 
0.18 mmol), 1-(naphthalen-1-yl)ethan-1-one (31.2 mg, 0.18 mmol), 4-
nitrophenylazide (36.1 mg, 0.22 mmol). Reaction time was 36 h. The 
product was purified by flash column chromatography (at first DCM 
followed by EtOAc/heptane = 3:2) afforded 170h (49 mg 53%) as an 
off-white semisolid: 1H NMR (400 MHz, CDCl3) δ 7.97 (d, J = 8.2 Hz, 1H), 
7.92 (d, J = 7.7 Hz, 1H), 7.79 (s, 1H), 7.58 – 7.46 (m, 5H), 5.24 (s, 1H), 
4.51 (d, J = 8.0 Hz, 1H), 4.42 – 4.34 (m, 2H), 4.13 – 4.04 (m, 1H), 3.92 – 
3.83 (m, 1H), 1.84 – 1.78 (m, 1H), 1.72 – 1.58 (m, 3H), 1.57 – 1.45 (m, 
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3H), 1.41 (s, 3H), 1.31 – 1.23 (m, 1H), 1.19 – 1.09 (m, 3H), 1.01 – 0.93 
(m, 1H), 0.89 – 0.80 (m, 6H). 13C NMR (101 MHz, CDCl3) δ 136.53, 
134.52, 133.76, 132.25, 130.29, 129.05, 128.66, 127.34, 126.66, 
125.27, 125.00, 124.59, 107.13, 101.35, 97.16, 82.65, 67.70, 48.24, 
45.26, 44.05, 39.52, 35.23, 34.56, 34.52, 32.70, 23.83, 22.15, 19.25, 
18.76. 
 
2-Methoxy-4-(1-(2-(((3R,6R,8aS,9R,10R,12R,12aR)-3,6,9-
trimethyldecahydro-12H-3,12-epoxy[1,2]dioxepino[4,3-
i]isochromen-10-yl)oxy)ethyl)-1H-1,2,3-triazol-5-yl)phenol (170i): 
169 (60 mg, 0.18 mmol), 1-(4-hydroxy-3-methoxyphenyl)ethan-1-one 
(30.5 mg, 0.18 mmol), 4-nitrophenylazide (36.1 mg, 0.22 mmol). 
Reaction time was 36 h. The product was purified by flash column 
chromatography (at first DCM followed by EtOAc/heptane = 3:2) 
afforded 170i (35 mg 38%) as an off-white semisolid: 1H NMR (400 
MHz, CDCl3) δ 7.64 (s, 1H), 7.01 (s, 3H), 5.86 (s, 1H), 5.34 (s, 1H), 4.59 
(d, J = 7.9 Hz, 1H), 4.57 – 4.44 (m, 2H), 4.31 – 4.21 (m, 1H), 4.11 – 4.02 
(m, 1H), 3.93 (s, 3H), 1.88 – 1.80 (m, 1H), 1.70 – 1.58 (m, 3H), 1.57 – 
1.50 (m, 3H), 1.47 (s, 3H), 1.40 – 1.31 (m, 1H), 1.30 – 1.20 (m, 2H), 1.18 
– 1.10 (m, 1H), 1.06 – 0.96 (m, 1H), 0.89 – 0.81 (m, 6H). 13C NMR (101 
MHz, CDCl3) δ 146.91, 138.98, 132.62, 122.83, 118.92, 115.07, 111.85, 
107.27, 101.57, 97.25, 82.69, 68.20, 56.29, 47.85, 45.25, 44.10, 39.83, 
35.27, 34.56, 34.53, 32.81, 29.84, 23.84, 22.17, 19.19, 18.77. 
 
5-Benzyl-1-(2-(((3R,6R,8aS,9R,10R,12R,12aR)-3,6,9-
trimethyldecahydro-12H-3,12-epoxy[1,2]dioxepino[4,3-
i]isochromen-10-yl)oxy)ethyl)-4,5,6,7-tetrahydro-1H-
[1,2,3]triazolo[4,5-c]pyridine (170j): 169 (60 mg, 0.18 mmol), 1-
benzylpiperidin-4-one (34.7 mg, 0.18 mmol), 4-nitrophenylazide (36.1 
mg, 0.22 mmol). Reaction time was 16 h. The product was purified by 
flash column chromatography (at first DCM followed by 
EtOAc/heptane = 3:2) afforded 170j (61 mg 63%) as an off-white 
semisolid: 1H NMR (400 MHz, CDCl3) δ 7.38 – 7.28 (m, 5H), 5.37 (s, 1H), 
4.60 (d, J = 7.9 Hz, 1H), 4.52 - 4,46 (m, 1H), 4.42 – 4.34 (m, 1H), 4.23 – 
4.17 (m, 1H), 3.90 – 3.82 (m, 1H), 3.75 (s, 2H), 3.72 – 3.64 (m, 2H), 2.85 
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- 2,68 (m, 4H), 1.85 – 1.81 (m, 1H), 1.70 – 1.53 (m, 6H), 1.47 (s, 3H), 
1.39 - 1.36 (m, 1H), 1.34 – 1.26 (m, 1H), 1.95 - 1.12 (m, 2H), 1.08 – 0.99 
(m, 1H), 0.92 - 0.83 (m, 6H). 13C NMR (101 MHz, CDCl3) δ 142.03, 
138.18, 131.76, 129.08, 128.52, 127.46, 107.26, 101.43, 97.23, 82.71, 
68.54, 61.64, 49.92, 49.39, 48.23, 45.25, 44.14, 39.93, 35.26, 34.55, 
34.52, 32.81, 29.82, 23.86, 22.16, 20.99, 19.28, 18.76. 
 
(1S,3aS,3bR,5aS,10aS,10bS,12aS)-10a,12a-Dimethyl-7-(2-
(((3R,6R,8aS,9R,10R,12R,12aR)-3,6,9-trimethyldecahydro-12H-3,12-
epoxy[1,2]dioxepino[4,3-i]isochromen-10-yl)oxy)ethyl)-
1,2,3,3a,3b,4,5,5a,6,7,10,10a,10b,11,12,12a-
hexadecahydrocyclopenta[7,8]phenanthro[2,3-d][1,2,3]triazol-1-ol 
(170k): 169 (60 mg, 0.18 mmol), (5S,8R,9S,10S,13S,14S,17S)-17-
hydroxy-10,13-dimethylhexadecahydro-3H-
cyclopenta[a]phenanthren-3-one (53.2 mg, 0.18 mmol), 4-
nitrophenylazide (36.1 mg, 0.22 mmol). Reaction time was 16 h. The 
product was purified by flash column chromatography (at first DCM 
followed by EtOAc/heptane = 3:2) afforded 170k (72 mg 63%) as an 
off-white solid: mp 96 – 97 °C; 1H NMR (400 MHz, CDCl3) δ 5.39 (s, 1H), 
4.61 (d, J = 7.9 Hz, 1H), 4.48 (dt, J = 14.2, 4.2 Hz, 1H), 4.40 – 4.31 (m, 
1H), 4.20 (dt, J = 8.9, 4.4 Hz, 1H), 3.91 – 3.85 (m, 1H), 3.66 (t, J = 8.5 Hz, 
1H), 2.85 (d, J = 15.3 Hz, 1H), 2.55 (dd, J = 16.2, 5.0 Hz, 1H), 2.30 (t, J = 
13.6 Hz, 2H), 2.11 – 2.03 (m, 1H), 1.89 - 1.82 (m, 2H), 1.75 – 1.51 (m, 
10H), 1.48 – 1.47 (m, 3H), 1.45 – 1.38 (m, 3H), 1.32 – 1.25 (m, 3H), 1.20 
– 1.12 (m, 3H), 1.05 – 0.96 (m, 2H), 0.91 – 0.87 (m, 6H), 0.76 (s, 3H), 
0.72 (s, 3H). 13C NMR (151 MHz, CDCl3) δ 142.96, 131.85, 107.28, 
101.25, 97.27, 82.74, 81.99, 68.40, 53.86, 50.95, 48.03, 45.26, 44.14, 
43.00, 42.39, 39.98, 36.96, 36.78, 36.31, 35.75, 35.32, 34.56, 34.54, 
32.84, 31.34, 30.60, 29.05, 25.01, 23.87, 23.58, 22.18, 20.93, 19.39, 
18.78, 11.73, 11.17. 
 
(1R,3aS,5aR,5bR,7aR,12aR,12bR,14aR,14bR)-5a,5b,8,8,12a-
Pentamethyl-1-(prop-1-en-2-yl)-9-(2-(((3R,6R,8aS,9R,10R,12R,12aR)-
3,6,9-trimethyldecahydro-12H-3,12-epoxy[1,2]dioxepino[4,3-
i]isochromen-10-yl)oxy)ethyl)-
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2,3,4,5,5a,5b,6,7,7a,8,9,12,12a,12b,13,14,14a,14b-
octadecahydrocyclopenta[7,8]chryseno[2,3-d][1,2,3]triazole-3a(1H)-
carboxylic acid (170l): 169 (60 mg, 0.18 mmol), 
(1R,3aS,5aR,5bR,7aR,11aR,11bR,13aR,13bR)-5a,5b,8,8,11a-
pentamethyl-9-oxo-1-(prop-1-en-2-yl)icosahydro-3aH-
cyclopenta[a]chrysene-3a-carboxylic acid (83  mg, 0.18 mmol), 4-
nitrophenylazide (36.1 mg, 0.22 mmol). Reaction time was 16 h. The 
product was purified by flash column chromatography (at first DCM 
followed by EtOAc/heptane = 3:2) afforded 170l (68 mg 47%) as an off-
white semisolid: 1H NMR (400 MHz, CDCl3) δ 5.39 (s, 1H), 4.76 (s, 1H), 
4.69 – 4.63 (m, 2H), 4.59 – 4.51 (m, 1H), 4.28 - 4.23 (m, 1H), 4.19 – 4.11 
(m, 1H), 3.06 - 3.00 (m, 1H), 2.91 (d, J = 15.3 Hz, 1H), 2.31 – 2.23 (m, 
2H), 2.12 (d, J = 15.3 Hz, 1H), 2.03 – 1.96 (m, 2H), 1.86 – 1.76 (m, 3H), 
1.71 (s, 3H), 1.69 – 1.63 (m, 3H), 1.60 – 1.50 (m, 8H), 1.48 (s, 5H), 1.45 
– 1.39 (m, 2H), 1.37 (d, J = 2.5 Hz, 1H), 1.32 (d, J = 7.6 Hz, 4H), 1.29 – 
1.22 (m, 9H), 1.18 – 1.10 (m, 3H), 1.00 (d, J = 4.6 Hz, 6H), 0.90 - 0.87 
(m, 6H), 0.78 (s, 3H). 13C NMR (101 MHz, CDCl3) δ 180.60, 150.37, 
141.10, 138.35, 110.01, 107.26, 101.71, 97.31, 82.75, 68.55, 56.48, 
54.86, 49.47, 49.31, 49.21, 47.00, 45.30, 44.10, 42.61, 40.75, 39.80, 
39.09, 38.59, 38.42, 37.18, 35.29, 34.60, 34.56, 33.76, 33.54, 32.82, 
32.22, 30.71, 29.94, 29.84, 28.82, 25.65, 23.90, 22.19, 21.57, 19.55, 
19.33, 19.09, 18.80, 16.17, 15.80, 14.83. 
 
(3R,6R,8aS,9R,12R,12aR)-3,6,9-Trimethyldecahydro-12H-3,12-
epoxy[1,2]dioxepino[4,3-i]isochromen-10-yl 4-oxocyclohexane-1-
carboxylate (171): dihydroartemisinin (1gm, 3.52 mmol), 
dicyclohexylmethanediimine (0.726 gm, 3.52 mmol), 4-
oxocyclohexane-1-carboxylic acid (0.600 gm, 4.22 mmol), N,N-
dimethylpyridin-4-amine (0.064 gm, 0.52 mmol). Reaction time was 18 
h. The product is purified by flash column chromatography 
(DCM/MeOH = 99/1). Afforded 178 (1.2 gm, 84%)as an off-white 
semisolid:1H NMR (400 MHz, CDCl3) δ 5.82 (d, J = 9.8 Hz, 1H), 5.45 (s, 
1H), 2.91 – 2.75 (m, 1H), 2.60 (ddd, J = 9.9, 7.2, 4.6 Hz, 1H), 2.62 - 2.58 
(m, 1H), 2.55 - 2.45 (m, 1H), 2.39 – 2.34 (m, 2H), 2.33 – 2.27 (m, 1H), 
2.25 – 2.20 (m, 1H), 2.14 – 2.00 (m, 3H), 1.95 – 1.87 (m, 1H), 1.81 - 1.75 
(m, 2H), 1.67 - 1.56 (m, 2H), 1.52 – 1.46 (m, 1H), 1.45 – 1.41 (m, 3H), 
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1.39 – 1.25 (m, 3H), 1.11 – 1.00 (m, 1H), 0.97 (d, J = 6.0 Hz, 3H), 0.86 
(d, J = 7.1 Hz, 3H). 13C NMR (101 MHz, CDCl3) δ 210.13, 173.04, 104.63, 
92.27, 91.67, 80.25, 77.48, 76.84, 51.70, 45.39, 40.70, 39.87, 39.66, 
37.41, 36.33, 34.21, 31.94, 28.78, 28.05, 26.06, 24.71, 22.13, 20.34, 
12.30. 
 
(3R,6R,8aS,9R,10S,12R,12aR)-3,6,9-Trimethyldecahydro-12H-3,12-
epoxy[1,2]dioxepino[4,3-i]isochromen-10-yl 1-(4-methylbenzyl)-
4,5,6,7-tetrahydro-1H-benzo[d][1,2,3]triazole-5-carboxylate (173a): 
171 (60 mg, 0.15 mmol), p-tolylmethanamine (18 mg, 0.15 mmol), 4-
nitrophenylazide (28.9 mg, 0.18 mmol). Reaction time was 16 h. The 
product was purified by flash column chromatography (at first DCM 
followed by EtOAc/heptane = 3:2) afforded 173a (53 mg, 67%) as an 
off-white semisolid: 1H NMR (400 MHz, CDCl3) δ 7.14 (d, J = 7.8 Hz, 2H), 
7.08 (d, J = 7.8 Hz, 2H), 5.83 – 5.69 (m, 1H), 5.48 – 5.29 (m, 3H), 3.20 – 
3.05 (m, 1H), 3.03 – 2.91 (m, 1H), 2.86 – 2.76 (m, 1H), 2.68 – 2.50 (m, 
2H), 2.44 – 2.36 (m, H), 2.33 (s, 3H), 2.29 – 2.12 (m, 1H), 2.07 – 1.99 
(m, 1H), 1.95 – 1.85 (m, 2H), 1.79 – 1.69 (m, 2H), 1.66 – 1.57 (m, 2H), 
1.54 – 1.45 (m, 1H), 1.42 (d, J = 1.6 Hz, 3H), 1.38 – 1.25 (m, 3H), 0.96 
(d, J = 5.8 Hz, 3H), 0.80 (d, J = 7.1 Hz, 3H). 13C NMR (151 MHz, CDCl3) δ 
173.24, 172.94, 141.10, 141.06, 136.27, 136.21, 132.13, 127.09, 
127.02, 122.90, 122.73, 122.40, 122.24, 119.72, 119.63, 118.14, 
118.05, 111.69, 111.62, 111.23, 104.76, 104.72, 92.59, 92.53, 91.82, 
80.38, 80.22, 51.74, 51.70, 48.99, 48.80, 45.35, 39.53, 39.38, 37.40, 
36.38, 34.18, 32.02, 31.90, 26.77, 26.68, 26.03, 25.92, 25.02, 24.80, 
24.69, 24.35, 23.84, 22.15, 20.34, 18.23, 18.04, 12.32, 12.22. 
 
(3R,6R,8aS,9R,10S,12R,12aR)-3,6,9-Trimethyldecahydro-12H-3,12-
epoxy[1,2]dioxepino[4,3-i]isochromen-10-yl 1-(3,4,5-
trimethoxybenzyl)-4,5,6,7-tetrahydro-1H-benzo[d][1,2,3]triazole-5-
carboxylate (173b): 171 (60 mg, 0.15 mmol), (3,4,5-
trimethoxyphenyl)methanamine (29 mg, 0.15 mmol), 4-nitrophenyl 
azide (28.9 mg, 0.18 mmol). Reaction time was 16 h. The product was 
purified by flash column chromatography (at first DCM followed by 
EtOAc/heptane = 3:2) afforded 173b (55 mg, 61%) as an off-white 
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solid: mp 81 – 80 °C; 1H NMR (400 MHz, CDCl3) δ 6.40 (d, J = 6.8 Hz, 
2H), 5.82 – 5.74 (m, 1H), 5.43 (t, J = 4.6 Hz, 1H), 5.39 – 5.28 (m, 2H), 
3.83 (d, J = 1.0 Hz, 3H), 3.81 (d, J = 1.5 Hz, 6H), 3.20 – 2.94 (m, 2H), 2.88 
– 2.81 (m, 1H), 2.74 – 2.54 (m, 2H), 2.52 – 2.42 (m, 1H), 2.42 – 2.33 (m, 
1H), 2.31 – 2.20 (m, 1H), 2.02 – 1.86 (m, 2H), 1.79 – 1.68 (m, 2H), 1.66 
– 1.59 (m, 1H), 1.42 (d, J = 3.5 Hz, 3H), 1.32 – 1.23 (m, 4H), 0.97 (d, J = 
5.8 Hz, 3H), 0.90 – 0.84 (m, 2H), 0.81 (d, J = 7.1 Hz, 3H). 13C NMR (101 
MHz, CDCl3) δ 173.06, 172.85, 153.77, 142.64, 142.33, 138.12, 131.47, 
131.12, 130.33, 130.30, 104.73, 104.66, 104.61, 104.57, 92.30, 91.65, 
80.22, 80.20, 60.97, 56.34, 52.31, 52.28, 51.67, 45.37, 45.33, 39.82, 
39.47, 37.39, 36.31, 34.18, 31.92, 31.87, 29.81, 26.03, 25.47, 24.99, 
24.68, 24.20, 22.09, 20.31, 19.29, 18.87, 12.24, 12.16. 
 
(3R,6R,8aS,9R,10S,12R,12aR)-3,6,9-Trimethyldecahydro-12H-3,12-
epoxy[1,2]dioxepino[4,3-i]isochromen-10-yl 1-(benzo[d][1,3]dioxol-
5-ylmethyl)-4,5,6,7-tetrahydro-1H-benzo[d][1,2,3]triazole-5-
carboxylate (173c): 171 (60 mg, 0.15 mmol), benzo[d][1,3]dioxol-5-
ylmethanamine (22.2 mg, 0.15 mmol), 4-nitrophenylazide (28.9 mg, 
0.18 mmol). Reaction time was 16 h. The product was purified by flash 
column chromatography (at first DCM followed by EtOAc/heptane = 
3:2) afforded 173c (51 mg, 61%)as an off-white semisolid: 1H NMR (400 
MHz, CDCl3) δ 6.76 (dd, J = 6.9, 1.7 Hz, 1H), 6.68 (dt, J = 3.7, 1.6 Hz, 2H), 
5.96 (s, 2H), 5.83 – 5.73 (m, 1H), 5.43 (d, J = 3.0 Hz, 1H), 5.39 – 5.25 (m, 
2H), 3.18 – 3.06 (m, 1H), 3.04 – 2.92 (m, 1H), 2.87 – 2.78 (m, 1H), 2.69 
– 2.54 (m, 2H), 2.47 – 2.33 (m, 2H), 2.28 – 2.19 (m, 1H), 2.06 – 1.86 (m, 
3H), 1.79 – 1.69 (m, 2H), 1.66 – 1.58 (m, 1H), 1.51 – 1.45 (m, 1H), 1.42 
(d, J = 1.9 Hz, 3H), 1.34 – 1.24 (m, 2H), 1.07 – 0.98 (m, 1H), 0.96 (d, J = 
5.9 Hz, 3H), 0.91 – 0.84 (m, 1H), 0.83 – 0.78 (m, 3H). 13C NMR (101 MHz, 
CDCl3) δ 173.09, 172.92, 148.40, 147.87, 142.33, 131.34, 128.43, 
121.33, 108.54, 108.21, 108.19, 104.59, 104.55, 101.45, 92.29, 91.64, 
80.22, 80.19, 51.98, 51.67, 45.38, 45.33, 39.47, 37.38, 37.36, 36.31, 
34.18, 31.92, 31.86, 26.04, 25.50, 24.99, 24.67, 24.23, 22.08, 20.31, 
19.36, 18.86, 12.15. 
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(3R,6R,8aS,9R,10S,12R,12aR)-3,6,9-Trimethyldecahydro-12H-3,12-
epoxy[1,2]dioxepino[4,3-i]isochromen-10-yl 1-(2-(1H-indol-3-
yl)ethyl)-4,5,6,7-tetrahydro-1H-benzo[d][1,2,3]triazole-5-
carboxylate (173d): 171 (60 mg, 0.15 mmol), 2-(1H-indol-3-yl)ethan-1-
amine (25.5 mg, 0.15 mmol), 4-nitrophenylazide (28.9 mg, 0.18 mmol). 
Reaction time was 16 h. The product was purified by flash column 
chromatography (at first DCM followed by EtOAc/heptane = 3:2) 
afforded 173d (39 mg, 46%) as an off-white semisolid: 1H NMR (400 
MHz, CDCl3) δ 8.42 (d, J = 7.1 Hz, 1H), 7.43 – 7.33 (m, 2H), 7.22 – 7.16 
(m, 1H), 7.11 – 7.06 (m, 1H), 6.70 (dd, J = 51.1, 2.3 Hz, 1H), 5.73 (dd, J 
= 9.9, 6.4 Hz, 1H), 5.47 (d, J = 13.4 Hz, 1H), 4.53 – 4.31 (m, 2H), 3.37 – 
3.24 (m, 2H), 3.06 – 2.87 (m, 2H), 2.70 – 2.55 (m, 2H), 2.42 – 2.32 (m, 
1H), 2.03 (ddd, J = 14.5, 7.3, 4.2 Hz, 1H), 1.93 – 1.85 (m, 3H), 1.82 – 
1.74 (m, 2H), 1.72 – 1.61 (m, 4H), 1.54 – 1.41 (m, 1H), 1.41 – 1.34 (m, 
4H), 1.34 – 1.25 (m, 2H), 0.97 (d, J = 5.6 Hz, 3H), 0.83 (d, J = 7.1 Hz, 3H). 
13C NMR (151 MHz, CDCl3) δ 173.24, 172.94, 141.10, 141.06, 136.27, 
136.21, 132.13, 127.09, 127.02, 122.90, 122.73, 122.40, 122.24, 
119.72, 119.63, 118.14, 118.05, 111.69, 111.62, 111.23, 104.76, 
104.72, 92.59, 92.53, 91.82, 80.38, 80.22, 51.74, 51.70, 48.99, 48.80, 
45.35, 39.53, 39.38, 37.40, 36.38, 34.18, 32.02, 31.90, 26.77, 26.68, 
26.03, 25.92, 25.02, 24.80, 24.69, 24.35, 23.84, 22.15, 20.34, 18.23, 
18.04, 12.32, 12.22. 
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Synthesis and anticancer activity of novel aza-artemisinin 
derivatives 
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7.1 Introduction 
Artemisinin, which is a naturaly occouring 1,2,4-trioxane 
sesquiterpene, is well known to possess antimalarial activity.1,2 
Artemisinin and its derivatives have shown an excellent safety profile. 
Recently it has been discovered that artemisinin derivatives also 
possess anticancer activity with low toxicity.3-11 Although the 
mechanism of action is still not clear, one of the believed reasons 
behind both the anticancer and antimalarial activity is the generation 
of highly cytotoxic carbon-centred free radicals by reaction of iron ions 
with the endoperoxyl moiety of artemisinin.11 In order to increase the 
therapeutic value, several derivatives of artemisinin have been 
prepared in recent years.3-10 However, biodegradation by the liver, and 
resulting short half life undermine the therapeutic value of 
artemisinin.11 Artemisinin derivatives which are devoid of these 
deficiencies will have a high chance to go into clinical trials. Thus, an 
urgent investigation is needed to improve the pharmacological 
properties of artemisinin derivatives.  
     The applications of the click reaction have grown significantly in 
various research fields in chemistry, ranging from medicinal chemistry 
to material chemistry since the discovery by Sharpless and Meldal.12 
Due to the mild reaction conditions and the high functional group 
tolerance, the click reaction has been used in diverse fields of 
chemistry for linking two partners via a triazole.13,14 Beside the click 
reaction several synthetic strategies have been discovered toward 
triazoles.15,16 Recently, the triazolization strategy developed by our 
group has drawn considerable attention. This metal-free strategy 
enables the synthesis of various previously inaccessible 1,5-
disubstituted and fused 1,2,3-triazole derivatives from commercialy 
and readily available starting materials such as unactivated enolizable 
ketones and primary amines.17-19  
Several heterocyclic derivatives of artemisinin were developed in 
order to increase the anticancer properties.3-10 Almost all the 
modifications were done at the C-10 carbon atom. In contrast, only a 
limited number of modifications at O-11 were reported.20 Among 
these, 11-aza-artemisinin and its derivatives were mostly studied and 
are known to possess various biological activities. However, the lack of 
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an efficient functional handle for further diversification of aza-
artemisinin limits its application in pharmaceutical chemistry.21 Hence 
the development of a synthetic route by which a series of diverse 
derivatives of artemisinin could be prepared is necessary. Here we 
would like to disclose the synthesis and anticancer activity of a series 
of 11-aza-artemisinin derivatives, which were prepared by the general 
click reactions, as well as dihydroartemisinin derivatives, prepared via 
triazolization strategies.22 
 
7.2 Results and discussions 
7.2.1 Chemistry 
At first 11-aza-artemisinin 175 has been prepared starting from 
artemisinin 174 by a previously reported method (Scheme 42)20. In 
accordance to that method, 11-aza-artemisinin 175 was obtained by 
immersion of artemisinin in liquid ammonia at -15 °C. The 11-aza-
artemisinin 175 was then treated with propargyl bromide in the 
presence of a base resulting in the propargyl derivative of 11-aza-
artemisinin 176 (scheme 41), which readily undergoes click reaction 
with various azides to form a library of 1,4-disubstituted triazoles 
(177a-177g) in excellent yield (Table 15).  
 
 
  Scheme 42: Synthesis of propargyl derivative of 11-aza-artemisinin 
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Table 15 List of compounds from click reaction 
 
Next, two series of compounds were prepared via triazolization 
strategy.17-19 Out of the total of three series, the second one was based 
on the variation of ketones and third one was about the variation of 
amines. In the second strategy, the amine 169 was synthesized in three 
steps starting from dihydroartemisinin.22 The amine functionalized 
dihydroartemisinin 169 was subsequently treated with various 
enolizable ketones 129 and 4-nitrophenyl azide 131a, yielding the 
desired 1,5-disubstituted or fused 1,2,3-triazoles 170a-170l (Table 16). 
Products from the third stategy were obtained by varying amines. The 
starting ketone 171 was synthesized from dihydroartemisinin in a one-
step fashion. The dihydroartemisinin functionalized ketone was then 
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treated with amine 172 and 4-nitrophenyl azide, resulting in the 
formation of fused 1,2,3-triazoles 173a-173d (Table 17). 
 
 
 
Table 16 Variations of ketones in triazolization reactions 
 
182 
 
  
 
Table 17 Variations of amines in triazolization reaction 
 
7.2.2 Biological activity 
The anti-proliferative activity of the synthesized compounds was 
evaluated in 2 tumor cell lines: human T-lymphoblastic leukemia 
(CEM) and human cervical carcinoma (HeLa) cells, and in human 
dermal microvascular endothelial HMEC-1 cells. Data are expressed as 
IC50 (50% inhibitory concentration), which is defined as the compound 
concentration that reduces cell proliferation by 50%, and are shown in 
Table 18.   
Aza-artemisinin (175) did not inhibit the growth of the cell lines tested 
(IC50 >150 µM). Also, its propargyl derivative (176) only showed a 
cytostatic effect at 100 µM. However, several 1,4-disubstituted 
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triazoles (177a-177d and 177g) displayed a marked anti-proliferative 
activity; the most active compounds being 177d and 177g, with IC50 
values in CEM cells of 0.92 and 2.6 µM, respectively. Notably, 
compounds 177a, 177b and 177d proved 8- to 50-fold less active in 
HMEC-1 endothelial cells compared to CEM leukemia cells, which may 
point to a tumor-selective effect of these compounds.  
The 1,5-disubstituted triazoles derived from dihydro-artemisinin 
(170a-170l) caused a modest inhibition of cell proliferation (IC50 ≥ 10 
µM). Only compounds 170k and 170l displayed an anti-proliferative 
activity below 10 µM in CEM cells. However, low-micromolar 
cytostatic activity was obtained in cells treated with fused 1,2,3-
triazoles (173a-173d). Interestingly, also these compounds were most 
active in CEM (IC50 of 2-4 µM), compared to HeLa (IC50 of 11-21 µM) 
and endothelial cells (IC50 of 34-40 µM). 
 
Name IC50 (µM) 
 CEM HeLa HMEC-1 
175 150 ± 15 147 ± 11 > 250 
176  104 ± 23 98 ± 51 241 ± 12 
177a  5.1 ± 0.9 36 ± 1 > 250 
177b  17 ± 1 19 ± 4 155 ± 1 
177c  18 ± 5 36 ± 21 26 ± 8 
177d  0.92 ± 0.24 1.2 ± 0.2 30 ± 0 
177e ≥ 250 > 250 > 250 
177f  > 250 ≥ 250 > 250 
177g  2.6 ± 1.0 6.1 ± 0.8 24 ± 8 
170a  21 ± 0 20 ± 0 35 ± 6 
170b  157 ± 41 > 250 > 250 
170c 128 ± 44 143 ± 40 105 ± 107 
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Table 18 In vitro anticancer activity of triazole derivatives of artemisinin  
 
7.3 Conclusion 
In summary, we have developed three synthetic strategies to access 
1,4-disubstituted, 1,5-disubstituted, and fused 1,2,3-triazoles 
analogues of artemisinin with promising anticancer activity. The click 
reaction allowed regioselective cycloaddition of alkynes and azides 
resulting in the formation of 1,4-disubstituted 1,2,3-triazoles, whereas 
the triazolization reaction allowed access to 1,5-disubstituted and 
fused 1,2,3-triazoles analogues. All the synthesized compounds were 
tested for their anticancer activity against 2 cancer cell lines and 1 
endothelial cell line. The highest activity was found for compound 
177d with IC50 values of 0.92 µM and 1.2 µM in CEM and HeLa cells, 
respectively. Moreover, compound 177d proved to be 30-fold more 
active in tumor versus endothelial cells, pointing to a potential tumor-
170d  95 ± 5 175 ± 106 160 ± 1 
170e  30 ± 7 36 ± 9 150 ± 3 
170f  25 ± 5 37 ± 5 62 ± 11 
170g  10 ± 0 11 ± 6 26 ± 0 
170h  39 ± 3 23 ± 3 62 ± 41 
170i  20 ± 2 19 ± 3 30 ± 0 
170j  11 ± 0 12 ± 1 24 ± 1 
170k  8.9 ± 3.3 16 ± 9 28 ± 0 
170l  5.0 ± 0.3 24 ± 19 121 ± 6 
173a  2.7 ± 0.2 11 ± 0 34 ± 0 
173b  4.3 ± 0.2 21 ± 4 40 ± 5 
173c  2.8 ± 0.2 11 ± 1 35 ± 4 
173d  3.9 ± 0.6 12 ± 7 40 ± 0 
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selective mechanism of action. Considering promising activity of 177d 
in cancer cell line, a new series of artemisinin derivatives should be 
prepared further for their evaluation of anticancer activity. 
 
7.4 Experimental Section 
 
 Preparation of propargyl derivative of 11-aza-artemisinin (176) 
NaOH (0.138 g, 3.13 mmol) was added to a solution of 11-
azaartemisinin (1g, 3.13 mmol) in dry THF (10 mL). The resulting 
mixture was stirred for 30 minutes at room temperature. Then a 
solution of propargyl bromide (1.86 g, 15.65 mmol) in dry THF (5 mL) 
was added dropwise at same temperature. The mixture was then 
stirred at room temperature for overnight. The completion of reaction 
was then monitored by TLC. Once the reaction was finished, the 
solvent was evaporated and the crude mixture was purified by silica 
gel flash column chromatography (heptane/ethyl acetate = 9:1) to 
afford the desired product. 1H NMR (400 MHz, CDCl3) δ 5.45 (s, 1H), 
4.81 (dd, J = 17.0, 2.3 Hz, 1H), 3.93 (dd, J = 17.0, 2.0 Hz, 1H), 3.36 – 3.25 
(m, 1H), 2.49 – 2.39 (m, 1H), 2.14 (s, 1H), 2.06 – 1.98 (m, 2H), 1.83 – 
1.72 (m, 2H), 1.71 – 1.64 (m, 1H), 1.57 – 1.43 (m, 2H), 1.40 – 1.34 (m, 
4H), 1.15 (d, J = 7.3 Hz, 3H), 1.06 – 0.97 (m, 4H), 0.97 – 0.85 (m, 1H). 
13C NMR (101 MHz, CDCl3) δ 171.72, 105.01, 80.29, 79.14, 77.40, 70.98, 
51.53, 45.88, 37.75, 36.69, 33.85, 33.25, 30.44, 25.41, 25.20, 22.73, 
19.88, 12.78. HRMS (ESI+): m/z calcd for C18H25NO4 [M+H]+: 320.1856, 
found 320.1832. 
 
7.4.1 General procedure for click reaction 
A flame-dried reaction tube equipped with magnetic stirring bar was 
charged with 176, corresponding azides, and CuTc. The mixture was 
dissolved in corresponding solvents and stirred at room temperature 
for overnight. The crude reaction mixture was then dried over vacuum 
and purified by silica gel flash column chromatography. 
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7.4.2 Charactarization data 
 
 Artemisinin derivative 177a: 176 (100 mg, 0.31 mmol), 
azidobenzene (44.8 mg, 0.38 mmol), CuTc (5.97 mg, 0.03 mmol). Dry 
DMF (0.5 mL). Reaction time was 12 h. The product was purified by 
flash column chromatography (EtOAc/heptane = 1:9) to afford 177a 
(108 mg, 79%) as an off-white semi solid. 1H NMR (400 MHz, CDCl3) δ 
8.03 (s, 1H), 7.73 (d, J = 7.9 Hz, 2H), 7.51 (t, J = 7.6 Hz, 2H), 7.41 (t, J = 
7.3 Hz, 1H), 5.58 (s, 1H), 4.91 – 4.79 (m, 2H), 3.38 – 3.30 (m, 1H), 2.46 
– 2.37 (m, 1H), 2.06 – 1.98 (m, 1H), 1.71 – 1.65 (m, 2H), 1.62 – 1.53 
(m, 2H), 1.37 – 1.31 (m, 2H), 1.25 (s, 4H), 1.13 (d, J = 7.2 Hz, 3H), 0.98 
(d, J = 6.3 Hz, 4H), 0.90 – 0.77 (m, 1H). 13C NMR (101 MHz, CDCl3) δ 
172.28, 145.74, 137.24, 129.82, 128.72, 121.49, 120.54, 105.11, 
80.51, 78.73, 51.53, 45.94, 37.51, 37.14, 36.79, 33.81, 33.31, 29.84, 
25.36, 25.16, 22.82, 19.86, 12.89. HRMS (ESI+): m/z calcd for 
C24H30N4O4 [M+H]+: 439.2339, found 439.2330. 
 
 Artemisinin derivative 177b: 176 (100 mg, 0.31 mmol), 5-azido-1,2,3-
trimethoxybenzene (79 mg, 0.38 mmol), CuTc (5.97 mg, 0.03 mmol). 
Dry THF (0.5 mL). Reaction time was 12 h. The product was purified by 
flash column chromatography (EtOAc/heptane = 1:9) to afford 177b 
(121 mg, 73%) as an off-white semi solid. 1H NMR (400 MHz, CDCl3) δ 
8.00 (s, 1H), 6.96 (s, 2H), 5.60 (s, 1H), 4.92 – 4.75 (m, 2H), 3.93 (s, 6H), 
3.88 (s, 3H), 3.39 – 3.31 (m, 1H), 2.47 – 2.37 (m, 1H), 2.07 – 1.96 (m, 
2H), 1.73 – 1.66 (m, 3H), 1.48 – 1.41 (m, 1H), 1.38 – 1.32 (m, 1H), 1.26 
(s, 3H), 1.13 (d, J = 7.3 Hz, 3H), 0.98 (d, J = 6.3 Hz, 3H), 0.90 – 0.80 (m, 
3H). 13C NMR (101 MHz, CDCl3) δ 172.29, 153.99, 145.65, 138.25, 
133.09, 121.59, 105.09, 98.25, 80.47, 78.76, 61.16, 56.61, 51.49, 45.91, 
37.50, 37.12, 36.76, 33.78, 33.28, 25.35, 25.15, 22.80, 19.83, 12.86. 
HRMS (ESI+): m/z calcd for C27H36N4O7 [M+H]+: 529.2656, found 
529.2668. 
 
Artemisinin derivative 177c: 176 (100 mg, 0.31 mmol), 4-
azidobenzonitrile (54.2 mg, 0.38 mmol), CuTc (5.97 mg, 0.03 mmol). 
Dry DMF (0.5 mL). Reaction time was 12 h. The product was purified 
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by flash column chromatography (EtOAc/heptane = 1:9) to afford 177c 
(90 mg, 62%) as an off-white semi solid. 1H NMR (400 MHz, CDCl3) δ 
8.11 (s, 1H), 7.91 (d, J = 8.8 Hz, 2H), 7.82 (d, J = 8.8 Hz, 2H), 5.56 (s, 1H), 
4.83 (q, J = 15.0 Hz, 2H), 3.35 (dd, J = 7.3, 4.6 Hz, 1H), 2.47 – 2.35 (m, 
1H), 2.06 – 1.95 (m, 2H), 1.75 – 1.66 (m, 3H), 1.63 (s, 1H), 1.57 – 1.48 
(m, 1H), 1.39 – 1.31 (m, 1H), 1.28 – 1.24 (m, 1H), 1.22 (s, 3H), 1.13 (d, 
J = 7.3 Hz, 3H), 0.99 (d, J = 6.3 Hz, 3H), 0.91 – 0.78 (m, 1H). 13C NMR 
(101 MHz, CDCl3) δ 172.38, 146.67, 140.00, 134.00, 121.37, 120.58, 
117.90, 112.36, 105.17, 80.51, 78.97, 51.49, 45.87, 37.58, 37.36, 36.76, 
33.79, 33.35, 25.34, 25.16, 22.89, 19.87, 12.85. HRMS (ESI+): m/z calcd 
for C25H29N5O4 [M+H]+: 464.2292, found 464.2249.    
 
Artemisinin derivative 177d: 176 (100 mg, 0.31 mmol), 4-
azidobenzonitrile (60.6 mg, 0.38 mmol), CuTc (5.97 mg, 0.03 mmol). 
Dry DMF (0.5 mL). Reaction time was 12 h. The product was purified 
by flash column chromatography (EtOAc/heptane = 1:9) to afford 177d 
(110 mg, 73%) as an off-white semi solid. 1H NMR (400 MHz, CDCl3) δ 
8.02 (s, 1H), 7.60 (s, 1H), 7.53 – 7.49 (m, 1H), 7.41 (t, J = 7.8 Hz, 1H), 
7.29 (s, 1H), 5.59 (s, 1H), 4.92 – 4.77 (m, 2H), 3.40 – 3.31 (m, 1H), 3.04 
– 2.95 (m, 1H), 2.41 (td, J = 14.1, 3.8 Hz, 1H), 2.07 – 1.95 (m, 2H), 1.73 
– 1.62 (m, 5H), 1.48 – 1.40 (m, 1H), 1.37 – 1.32 (m, 1H), 1.30 (d, J = 6.9 
Hz, 6H), 1.27 (s, 3H), 1.13 (d, J = 7.3 Hz, 3H), 0.97 (d, J = 6.3 Hz, 3H), 
0.90 – 0.77 (m, 1H). 13C NMR (101 MHz, CDCl3) δ 172.26, 151.10, 
145.57, 137.27, 129.69, 126.91, 121.55, 118.79, 118.01, 105.10, 80.50, 
78.70, 51.54, 45.96, 37.51, 37.07, 36.80, 34.33, 33.82, 33.30, 25.38, 
25.17, 24.00, 23.98, 22.81, 19.86, 12.90. HRMS (ESI+): m/z calcd for 
C27H36N4O4 [M+H]+: 481.2809, found 481.2817.    
 
Artemisinin derivative 177e: 176 (100 mg, 0.31 mmol), ethyl 2-
azidoacetate (40.4 mg, 0.38 mmol), CuTc (5.97 mg, 0.03 mmol). Dry 
DMF (0.5 mL). Reaction time was 12 h. The product was purified by 
flash column chromatography (EtOAc/heptane = 1:9) to afford 177e 
(68.8 mg, 49%) as an off-white semi solid. 1H NMR (400 MHz, CDCl3) δ 
7.69 (s, 1H), 5.48 (s, 1H), 5.21 – 5.04 (m, 2H), 4.89 – 4.70 (m, 2H), 3.78 
(s, 3H), 3.33 (qd, J = 7.3, 4.6 Hz, 1H), 2.46 – 2.33 (m, 1H), 2.05 – 1.94 
(m, 2H), 1.74 (s, 1H), 1.71 – 1.61 (m, 2H), 1.60 – 1.50 (m, 1H), 1.43 – 
188 
 
1.37 (m, 1H), 1.36 – 1.29 (m, 1H), 1.26 (s, 4H), 1.11 (d, J = 7.3 Hz, 3H), 
0.96 (d, J = 6.2 Hz, 3H), 0.92 – 0.84 (m, 1H). 13C NMR (101 MHz, CDCl3) 
δ 172.25, 166.73, 145.43, 124.82, 105.07, 80.41, 78.52, 53.06, 51.49, 
50.78, 45.94, 37.46, 37.10, 36.76, 33.80, 33.25, 25.32, 25.12, 22.67, 
19.84, 12.84. HRMS (ESI+): m/z calcd for C21H30N4O6 [M+H]+: 
435.2237, found 435.2234. 
 
Artemisinin derivative 177f: 176 (100 mg, 0.31 mmol), (3S,4S)-2-
azido-5-((benzoyloxy)methyl)tetrahydrofuran-3,4-diyl dibenzoate 
(183 mg, 0.38 mmol), CuTc (5.97 mg, 0.03 mmol). Dry DMF (0.5 mL). 
Reaction time was 12 h. The product was purified by flash column 
chromatography (EtOAc/heptane = 1:9) to afford 177f (119 mg, 47%) 
as an off-white semi solid. 1H NMR (400 MHz, CDCl3) δ 9.32 (s, 1H), 
8.06 – 8.01 (m, 2H), 7.99 – 7.91 (m, 4H), 7.77 (s, 1H), 7.62 – 7.52 (m, 
3H), 7.48 – 7.34 (m, 6H), 6.38 (d, J = 3.2 Hz, 1H), 6.21 (dd, J = 5.2, 3.2 
Hz, 1H), 6.13 (t, J = 5.6 Hz, 1H), 5.04 – 4.94 (m, 2H), 4.87 (dd, J = 9.5, 
4.8 Hz, 1H), 4.75 (dd, J = 12.2, 3.6 Hz, 1H), 4.60 (dd, J = 12.2, 4.9 Hz, 
1H), 3.43 (p, J = 6.9 Hz, 1H), 2.69 – 2.61 (m, 1H), 2.57 – 2.47 (m, 1H), 
2.39 – 2.29 (m, 1H), 2.12 (s, 3H), 2.08 – 2.02 (m, 1H), 1.86 – 1.72 (m, 
4H), 1.64 – 1.52 (m, 2H), 1.51 – 1.38 (m, 1H), 1.16 (d, J = 6.9 Hz, 3H), 
1.06 (d, J = 6.3 Hz, 3H). 13C NMR (101 MHz, CDCl3) δ 212.30, 209.03, 
177.55, 171.26, 166.21, 165.19, 165.11, 162.25, 143.84, 133.97, 
133.79, 133.48, 129.97, 129.90, 129.39, 128.74, 128.69, 128.68, 
128.61, 128.59, 122.66, 90.39, 81.17, 75.33, 71.80, 63.90, 60.50, 56.90, 
55.09, 41.31, 40.52, 37.19, 35.28, 34.60, 30.53, 30.01, 21.16, 20.58, 
20.19, 16.66, 14.31. HRMS (ESI+): m/z calcd for C44H46N4O11 [M+H]+: 
807.3235, found 807.3228. 
 
Artemisinin derivative 177g: 176 (100 mg, 0.31 mmol), 5-azido-2-(((4-
chlorobenzoyl)oxy)methyl)tetrahydrofuran-3-yl 4-chlorobenzoate 
(137 mg, 0.38 mmol), CuTc (5.97 mg, 0.03 mmol). Dry DMF (0.5 mL). 
Reaction time was 12 h. The product was purified by flash column 
chromatography (EtOAc/heptane = 1:9) to afford 177g (102 mg, 43%) 
as a white solid m.p. 99.3 – 100.3 ˚C.  1H NMR (400 MHz, CDCl3) δ 9.35 
(s, 1H), 8.01 – 7.90 (m, 4H), 7.73 (s, 1H), 7.46 – 7.40 (m, 4H), 6.40 (t, J 
= 6.2 Hz, 1H), 5.78 (dt, J = 6.6, 3.4 Hz, 1H), 5.07 – 4.94 (m, 2H), 4.65 – 
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4.59 (m, 1H), 4.58 – 4.45 (m, 2H), 3.45 (p, J = 6.9 Hz, 1H), 3.33 – 3.23 
(m, 1H), 2.86 – 2.77 (m, 1H), 2.70 – 2.61 (m, 1H), 2.56 – 2.46 (m, 1H), 
2.38 – 2.26 (m, 1H), 2.12 (s, 3H), 2.11 – 2.02 (m, 2H), 1.87 – 1.73 (m, 
3H), 1.68 – 1.53 (m, 2H), 1.51 – 1.43 (m, 1H), 1.17 (d, J = 6.9 Hz, 3H), 
1.07 (d, J = 6.3 Hz, 3H). 13C NMR (101 MHz, CDCl3) δ 212.27, 208.97, 
165.33, 165.05, 162.30, 143.90, 140.36, 139.95, 131.26, 131.24, 
129.08, 129.02, 127.96, 127.64, 122.38, 88.64, 83.43, 75.29, 64.30, 
56.84, 55.08, 41.30, 40.39, 37.80, 37.11, 34.63, 30.31, 30.02, 20.61, 
20.18, 16.58. HRMS (ESI+): m/z calcd for C37H40Cl2N4O9 [M+H]+: 
755.2244, found 755.2245. 
 
7.4.3 Synthesis of 1,5-disubstituted and fused 1,2,3-triazoles 
The compounds 177a to 177l and 173a to 173d were prepared using 
the method of the previous report and the spectroscopic data were 
consistent with the previous report20.  
 
7.4.4 Biological assays 
 
Cell proliferation 
Human cervical carcinoma (HeLa) cells were seeded in 96-well plates 
at 15,000 cells/well in the presence of 5-fold dilutions of the 
compounds. After 3 days of incubation, the cells were trypsinized and 
counted by means of a Coulter counter (Analis, Belgium). Human 
dermal microvascular endothelial (HMEC-1) cells were seeded on 
gelatin-coated 48-well plates at 20,000 cells/well. After overnight 
incubation, 5-fold dilutions of the compounds were added. Three days 
later, the cells were trypsinized and counted. Human T-cell leukemia 
(CEM) cells were seeded in 96-well plates at 60,000 cells/well in the 
presence of the compounds, allowed to proliferate for 4 days and then 
counted. The 50% inhibitory concentration (IC50) was defined as the 
compound concentration required to reduce cell proliferation by 
50%.23  
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General Conclusion and Outlook 
 
 
 
In this PhD research, various methodologies towards functionalized 
1,2,3-triazoles as well as their biological evaluation against viral and 
cancer cell lines have been presented. A brief summary of previously 
discovered organocatalyzed methodologies towards functionalized 
1,2,3-triazoles as well as their biological study and the synthesis of 
biological active molecules containing triazole as a core unit has been 
presented concisely. 
Organocatalytic multicomponent reactions towards the synthesis of 
trisubstituted 1,2,3-triazoles have not been discovered broadly. In this 
thesis we have described a universal approach to access 1,2,3-triazole 
derivatives in a single step from simple and readily available enolizable 
carbonyl compounds and amines which could be considered not as the 
end point, but as the initial point for the rapid generation of complex 
triazole derivatives that are inaccessible by other means. We 
successfully illustrated the utility of this reaction in natural products 
by systematically transforming them into diverse triazole derivatives. 
After successful investigation of the tri-substituted 1,2,3-triazoles 
synthesis we have focused on synthesizing NH-triazole derivatives by 
replacing primary amines with ammonium acetate salt in previously 
discovered methodology. The combination of enolizable ketones, 4-
nitrophenyl azide and NH4OAc has shown to be a powerful method to 
achieve various mono-, di- or fused NH-triazole derivatives. Extension 
of the protocol to the direct conversion of compounds containing 
multiple keto groups to the corresponding triazole heterocycles in a 
safe manner is especially notable. Importantly, this new reaction 
provides an operationally simple pathway for the triazolization of 
natural products containing enolizable ketone functionalities.  
Although there are many organo- and metal-catalytic methodologies 
reported towards functionalized 1,2,3-triazoles, but there have been 
no reports describing the synthesis of propargyl substituted triazoles 
in single step. In this thesis we have described a synthetic methodology 
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towards propargyl triazoles in a single step from readily available 
substrates. We have developed a highly efficient and regiospecific 
Zn(OAc)2 mediated synthesis of propargyl functionalized triazole 
derivatives in a single step from ketones and propargyl amine. 
Subsequently, Cu(I) reactions of these propargyl triazoles with various 
organic azides having supramolecular and medicinal interest lead to 
novel N-C linked bis-triazole moieties in a regioselective manner with 
excellent yield. This newly developed method has following 
advantages: (1) it gives access in a single step to propargyl triazoles, 
which is not possible by any other reported methods (2) it uses cheap 
and readily available building blocks, (3) it can be extended to natural 
products containing enolizable ketone groups. 
The bis triazoles formed via click reaction of propargyl triazoles can be 
decomposed to corresponding azavinyl carbenes which undergo 
various transformation leading to interesting heterocyclic moieties. In 
this thesis, we have disclosed an unprecedented selective 
decomposition of bis(1,2,3-triazoles) by a Rh(II)-catalyzed [3 + 2]-
intramolecular annulation reaction which leads to the formation of 
3,4-fused indoles. Extension of this protocol to heterocycles led to 
interesting polyfused 1,2,3-triazole derivatives. This protocol presents 
a simple, one-step, and atom economic efficient method for the 
synthesis of 1,2,3-triazole fused dihydroindoles and indoles, which 
could so far not be synthesized by other means. 
At the last stage of this PhD thesis, a series of newly functionalized 
artemisinin derivatives has been prepared by using a organocatalytic 
multicomponent reaction. The starting precursors 169 and 171 were 
used for triazolisation reaction resulting in formation of fused and 1,5-
disubstituted 1,2,3-triazole derivatives. All derivatives were screened 
against HIV I and three molecules exhibited moderate activity. The 
beta-tetralone derivatives 170b, 170c, and 170e were inhibitory to 
HIV-1 replication in cell culture with a limited cytotoxicity. However, 
no inhibitory activity was observed against HIV-2 and an NNRTI-
resitant double RT mutant (K103N; Y181C) HIV-1 strain (RES056), 
pointing at an NNRTI-type mode of action for the active derivatives. 
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Furthermore we have developed the synthetic methodology to access 
the propargyl substituted aza-artemisinin, further functionalization 
with azide via click reaction resulted in formation of various 1,4-
disubstituted 1,2,3-triazoles. All the synthesized compounds were 
tested for their anticancer activity against 2 cancer cell lines and 1 
endothelial cell line. The highest activity was found for compound 
170d with IC50 values of 0.92 µM and 1.2 µM in CEM and HeLa cells, 
respectively. Moreover, compound 170d proved to be 30-fold more 
active in tumor versus endothelial cells, pointing to a potential tumor-
selective mechanism of action. 
Aldehydes are well known building blocks for various heterocyclic 
molecules. In addition, aldehydes are used as starting materials for the 
preparation of various coordination polymers in the study of metal 
organic frameworks. By considering the utility of aldehyde 
functionalities, in the future, we will investigate the synthesis of 
various aldehyde substituted triazoles 178. The aldehyde substituted 
triazoles can be prepared via Cornforth type rearrangement of acyl 
triazoles 174 and primary amines.  
 
195 
 
 
Scheme 43 synthesis of aldehyde triazoles 
 
These novel aldehyde substituted triazoles can be used to synthesize 
various materials such as BODIPY and porphyrins. We will also 
investigate the application of this type of molecule in material and 
supramolecular chemistry. 
The novel triazolization reaction can also be used to develop triazole 
based fluorescent molecules. We will utilize triazolization reaction 
with suitable substrate followed by cyclization leading to formation of 
triazapentalene derivatives 181, the triazapentalene derivatives upon 
hydrolysis will deliver triazapentalene bearing carboxylic acid 
derivatives (182) amenable to further derivatization (Scheme 44). 
 
196 
 
Scheme 44 synthesis of triazapentalene bearing carboxylic 
 
The carboxylic acid bearing triazapentalene can be used in a four-
componant Ugi reaction followed by complexation with boron to 
produce a large variety of multichromophoric hybrid molecules (187). 
(Scheme 45) 
 
Scheme 45 Ugi reaction followed by boron complexation 
 
Furthermore, the carboxylic acid bearing triazapentalene (182) is 
subjected to amide coupling reaction to produce triazapentalene 
containing bromoaryl functionality (184). The fluorescent molecule 
184 can undergo various Pd catalyzed reactions for later stage 
modification with other fluorescent molecules to produce hybrid 
chromophoric molecules (186). 
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List of Abbreviations 
 
 
 
 
DCM dichloromethane 
DMF N,N-dimethylformamide 
DMSO dimethylsulfoxide 
EI Electron Impact 
ESI-MS Electron spray ionization-mass spectrometry 
EtOAc Ethyl acetate 
EtOH Ethanol 
1H NMR Proton nuclear magnetic resonance 
HRMS High resolution mass spectomery 
TLC Thin layer chromatography 
DBU 1,8-Diazabicycloundec-7-ene 
DCM Dichloromethane 
DMAP 4-Dimethylaminopyridine 
DMF Dimethylformamide 
DMSO Dimethyl sulfoxide 
HeLa Cell line derived from cervical cancer cells taken from      
Henrietta Lacks 
HIV Human Immunodeficiency Virus 
HMEC-1 Human dermal microvascular endothelial cell line 
IC50 Half maximal inhibitory concentration 
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MCR Multicomponent reaction 
MeI Methyl Iodide 
MeOH Methanol 
PE Petroleum Ether 
4NPA 4-Nitrophenyl azide 
rt Room temperature 
RuAAC Ruthenium(II)-catalysed azide-alkyne cycloaddition 
CuAAC Copper(I)-catalysed azide-alkyne cycloaddition 
SPAAC Strain-Promoted  azide-alkyne cycloaddition 
THF Tetrahydrofuran 
TLC Thin Layer Chromatography 
MS Molecular sieve 
Cp* 1,2,3,4,5-Pentamethylcyclopentadiene 
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Safety Aspects 
 
 
 
The laboratory work was performed in this thesis while following the 
safety guidelines from the departmental safety brochure. The specific 
information and precautions can be found at the website of the HSE 
service. 
https://admin.kuleuven.be/sab/vgm/algemeen/EN 
The general risk assessment is RA_MDS4_2014_0020_Synthesis of 
1,5-disubstituted 1,2,3-triazoles 
It is recommended to look the MSDS for all chemicals and catalysis 
before setting up the experiments. In this thesis work various 
ketones, amines were used as starting materials which can be found 
in the KU Leuven database for Hazardous compounds.  
 
Sodium azide (NaN3) 
NaN3 is a highly toxic compound. In order to avoid the formation of 
hazardous and toxic HN3, acids should not be used in a reaction with 
NaN3. Also chlorinated solvents should be avoided. At the end of the 
reaction solvents should be removed carefully due to possibility of 
explosive decomposition. 
 
Organic azides 
Organic azides such as 4-nitrophenyl azide and tosyl azide are 
potentially explosive in nature and should be kept in a cool place, 
therefore they should not be heated unless they are diluted with 
solvents. 
 
Solvents 
Halogenated solvents: DCM, CHCl3, and DCE are very toxic and 
carcinogenic solvents 
THF: highly flammable and irritating to respirotary system. 
DMF: DMF is highly toxic by inhalation and it is also a flammable 
solvent. 
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DMSO: DMSO can cause headaches and itching and burning on 
contact with the skin  
Methanol: Methanol is a highly flammable solvent.  
Reagents 
Before repeating any reaction in this thesis, it is highly recomended 
to check the risk assessments for a particular reagent. 
Acetic Acid: Acetic acid can cause severe burning marks and corrosive 
as well. 
Boron trifluoride diethyl etherate: It can cause severe eye damage 
and skin burns. It is highly flammable. Always keep in a cool place. 
Rh-catalyst: It may cause digestive tract irritation. 
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